CN1067893A - 杂环衍生物 - Google Patents
杂环衍生物 Download PDFInfo
- Publication number
- CN1067893A CN1067893A CN92104790A CN92104790A CN1067893A CN 1067893 A CN1067893 A CN 1067893A CN 92104790 A CN92104790 A CN 92104790A CN 92104790 A CN92104790 A CN 92104790A CN 1067893 A CN1067893 A CN 1067893A
- Authority
- CN
- China
- Prior art keywords
- group
- compound
- rudimentary
- alkyl
- isobutyl phenenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 title claims description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 157
- 150000003839 salts Chemical class 0.000 claims abstract description 117
- 238000002360 preparation method Methods 0.000 claims abstract description 107
- -1 phenyl amino formyl Chemical group 0.000 claims description 184
- 125000000217 alkyl group Chemical group 0.000 claims description 131
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 128
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 124
- 239000000203 mixture Substances 0.000 claims description 119
- 238000000034 method Methods 0.000 claims description 105
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 77
- 238000006243 chemical reaction Methods 0.000 claims description 57
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 47
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 46
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 36
- 239000001257 hydrogen Substances 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 35
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 30
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 30
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 27
- 125000001118 alkylidene group Chemical group 0.000 claims description 26
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 20
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 19
- 229960003604 testosterone Drugs 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- 239000001301 oxygen Substances 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 125000006239 protecting group Chemical group 0.000 claims description 15
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 14
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 14
- 150000002431 hydrogen Chemical class 0.000 claims description 14
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 14
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 13
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 11
- 239000011737 fluorine Substances 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 239000000376 reactant Substances 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 238000003379 elimination reaction Methods 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 125000004450 alkenylene group Chemical group 0.000 claims description 8
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 7
- 125000004423 acyloxy group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 6
- 230000032050 esterification Effects 0.000 claims description 6
- 238000005886 esterification reaction Methods 0.000 claims description 6
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 4
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 3
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 claims description 3
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 claims description 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- 235000010290 biphenyl Nutrition 0.000 claims 2
- OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical group [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 claims 2
- 150000001538 azepines Chemical class 0.000 claims 1
- 230000021523 carboxylation Effects 0.000 claims 1
- 238000006473 carboxylation reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 163
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 105
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 104
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 94
- 239000000243 solution Substances 0.000 description 73
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 65
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 63
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 58
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 55
- 235000019439 ethyl acetate Nutrition 0.000 description 55
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
- 238000005406 washing Methods 0.000 description 40
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- 239000002585 base Substances 0.000 description 38
- 239000012044 organic layer Substances 0.000 description 37
- 239000002904 solvent Substances 0.000 description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 32
- 238000010898 silica gel chromatography Methods 0.000 description 32
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 29
- 239000002253 acid Substances 0.000 description 28
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 26
- 229920002554 vinyl polymer Polymers 0.000 description 26
- 238000001704 evaporation Methods 0.000 description 24
- 230000008020 evaporation Effects 0.000 description 24
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 20
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 19
- 239000012141 concentrate Substances 0.000 description 19
- 235000008504 concentrate Nutrition 0.000 description 19
- 239000011541 reaction mixture Substances 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 16
- 239000007864 aqueous solution Substances 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- 239000003513 alkali Substances 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 150000002148 esters Chemical class 0.000 description 12
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 12
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 235000017557 sodium bicarbonate Nutrition 0.000 description 12
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 12
- 238000000605 extraction Methods 0.000 description 10
- 229940095102 methyl benzoate Drugs 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 238000003810 ethyl acetate extraction Methods 0.000 description 9
- 125000004494 ethyl ester group Chemical group 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 229910052801 chlorine Inorganic materials 0.000 description 8
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- 239000011707 mineral Substances 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 6
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 229910052783 alkali metal Inorganic materials 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 150000007530 organic bases Chemical class 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 235000015320 potassium carbonate Nutrition 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 6
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical group C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 5
- 239000002841 Lewis acid Substances 0.000 description 5
- 125000005907 alkyl ester group Chemical group 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 229910000085 borane Inorganic materials 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 5
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 150000007517 lewis acids Chemical class 0.000 description 5
- 150000004702 methyl esters Chemical class 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 5
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 5
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 4
- FPZWZCWUIYYYBU-UHFFFAOYSA-N 2-(2-ethoxyethoxy)ethyl acetate Chemical group CCOCCOCCOC(C)=O FPZWZCWUIYYYBU-UHFFFAOYSA-N 0.000 description 4
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 206010067482 No adverse event Diseases 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 150000001340 alkali metals Chemical class 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 229940050176 methyl chloride Drugs 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 238000007738 vacuum evaporation Methods 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 3
- 150000003973 alkyl amines Chemical class 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 229960003328 benzoyl peroxide Drugs 0.000 description 3
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- KXUHSQYYJYAXGZ-UHFFFAOYSA-N isobutylbenzene Chemical compound CC(C)CC1=CC=CC=C1 KXUHSQYYJYAXGZ-UHFFFAOYSA-N 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 238000012805 post-processing Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229960001866 silicon dioxide Drugs 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 238000000935 solvent evaporation Methods 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 229940005605 valeric acid Drugs 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 2
- AVZBOAGCVKEESJ-UHFFFAOYSA-O 2-ethyl-1,2-benzoxazol-2-ium-7-ol Chemical class C1=CC(O)=C2O[N+](CC)=CC2=C1 AVZBOAGCVKEESJ-UHFFFAOYSA-O 0.000 description 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 2
- 108010029908 3-oxo-5-alpha-steroid 4-dehydrogenase Proteins 0.000 description 2
- 102000001779 3-oxo-5-alpha-steroid 4-dehydrogenase Human genes 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- IGIJSFNBEUBMGB-UHFFFAOYSA-N 4-(cyclohexyliminomethylideneamino)-n,n-diethylcyclohexan-1-amine Chemical compound C1CC(N(CC)CC)CCC1N=C=NC1CCCCC1 IGIJSFNBEUBMGB-UHFFFAOYSA-N 0.000 description 2
- UPCARQPLANFGQJ-UHFFFAOYSA-N 4-bromo-2-fluorobenzaldehyde Chemical compound FC1=CC(Br)=CC=C1C=O UPCARQPLANFGQJ-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- DELPSTRBSBMRBI-UHFFFAOYSA-N CC(CCC)=O.C1=CC=CC=C1 Chemical compound CC(CCC)=O.C1=CC=CC=C1 DELPSTRBSBMRBI-UHFFFAOYSA-N 0.000 description 2
- XQCKXOKBWVXUJH-UHFFFAOYSA-N CCOC([O])=O Chemical compound CCOC([O])=O XQCKXOKBWVXUJH-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- OJHYCVSSMDJYAK-UHFFFAOYSA-N O(O)O.O1N=CC=C1 Chemical compound O(O)O.O1N=CC=C1 OJHYCVSSMDJYAK-UHFFFAOYSA-N 0.000 description 2
- NBJIBSAUQOMIRS-UHFFFAOYSA-N O.C(CCC)[K] Chemical group O.C(CCC)[K] NBJIBSAUQOMIRS-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- VAKKJWXZRREDEX-UHFFFAOYSA-N [O].CC#CC Chemical compound [O].CC#CC VAKKJWXZRREDEX-UHFFFAOYSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 2
- 150000008046 alkali metal hydrides Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- VQFAIAKCILWQPZ-UHFFFAOYSA-N bromoacetone Chemical compound CC(=O)CBr VQFAIAKCILWQPZ-UHFFFAOYSA-N 0.000 description 2
- 125000006309 butyl amino group Chemical group 0.000 description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Substances ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- QQVDYSUDFZZPSU-UHFFFAOYSA-M chloromethylidene(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CCl QQVDYSUDFZZPSU-UHFFFAOYSA-M 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- PQLFROTZSIMBKR-UHFFFAOYSA-N ethenyl carbonochloridate Chemical compound ClC(=O)OC=C PQLFROTZSIMBKR-UHFFFAOYSA-N 0.000 description 2
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- UHAAFJWANJYDIS-UHFFFAOYSA-N n,n'-diethylmethanediimine Chemical compound CCN=C=NCC UHAAFJWANJYDIS-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- RFPMGSKVEAUNMZ-UHFFFAOYSA-N pentylidene Chemical group [CH2+]CCC[CH-] RFPMGSKVEAUNMZ-UHFFFAOYSA-N 0.000 description 2
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 2
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 2
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 2
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 2
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- PVFOMCVHYWHZJE-UHFFFAOYSA-N trichloroacetyl chloride Chemical compound ClC(=O)C(Cl)(Cl)Cl PVFOMCVHYWHZJE-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- RFDOTTUPKXBZMV-UHFFFAOYSA-N 1-(4-bromo-2-fluorophenyl)pentan-1-ol Chemical compound CCCCC(O)C1=CC=C(Br)C=C1F RFDOTTUPKXBZMV-UHFFFAOYSA-N 0.000 description 1
- ZHZJQLFPBLCILI-UHFFFAOYSA-N 1-(methoxymethoxy)pentane Chemical compound CCCCCOCOC ZHZJQLFPBLCILI-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- ORLCYMQZIPSODD-UHFFFAOYSA-N 1-chloro-2-[chloro(2,2,2-trichloroethoxy)phosphoryl]oxybenzene Chemical compound ClC1=CC=CC=C1OP(Cl)(=O)OCC(Cl)(Cl)Cl ORLCYMQZIPSODD-UHFFFAOYSA-N 0.000 description 1
- RZAMXGLIMOFSBN-UHFFFAOYSA-N 1-ethynoxyhexane Chemical group CCCCCCOC#C RZAMXGLIMOFSBN-UHFFFAOYSA-N 0.000 description 1
- SNUSZUYTMHKCPM-UHFFFAOYSA-N 1-hydroxypyridin-2-one Chemical compound ON1C=CC=CC1=O SNUSZUYTMHKCPM-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- SODQFLRLAOALCF-UHFFFAOYSA-N 1lambda3-bromacyclohexa-1,3,5-triene Chemical compound Br1=CC=CC=C1 SODQFLRLAOALCF-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- AMOYMEBHYUTMKJ-UHFFFAOYSA-N 2-(2-phenylethoxy)ethylbenzene Chemical compound C=1C=CC=CC=1CCOCCC1=CC=CC=C1 AMOYMEBHYUTMKJ-UHFFFAOYSA-N 0.000 description 1
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- FGLBSLMDCBOPQK-UHFFFAOYSA-N 2-nitropropane Chemical compound CC(C)[N+]([O-])=O FGLBSLMDCBOPQK-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- SDXAWLJRERMRKF-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazole Chemical compound CC=1C=C(C)NN=1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- NXTNASSYJUXJDV-UHFFFAOYSA-N 3-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(C(Cl)=O)=C1 NXTNASSYJUXJDV-UHFFFAOYSA-N 0.000 description 1
- ROSPTOARLKNIPP-UHFFFAOYSA-N 4,4,4-trifluoro-1-[4-(2-methylpropyl)phenyl]butan-1-one Chemical compound CC(C)CC1=CC=C(C(=O)CCC(F)(F)F)C=C1 ROSPTOARLKNIPP-UHFFFAOYSA-N 0.000 description 1
- GDBUZIKSJGRBJP-UHFFFAOYSA-N 4-acetoxy benzoic acid Chemical compound CC(=O)OC1=CC=C(C(O)=O)C=C1 GDBUZIKSJGRBJP-UHFFFAOYSA-N 0.000 description 1
- XLWQUESMILVIPR-UHFFFAOYSA-N 4-ethoxybenzoyl chloride Chemical compound CCOC1=CC=C(C(Cl)=O)C=C1 XLWQUESMILVIPR-UHFFFAOYSA-N 0.000 description 1
- NJESAXZANHETJV-UHFFFAOYSA-N 4-methylsalicylic acid Chemical compound CC1=CC=C(C(O)=O)C(O)=C1 NJESAXZANHETJV-UHFFFAOYSA-N 0.000 description 1
- 125000002173 5α-dihydrotestosterone group Chemical group 0.000 description 1
- ZSMRRZONCYIFNB-UHFFFAOYSA-N 6,11-dihydro-5h-benzo[b][1]benzazepine Chemical class C1CC2=CC=CC=C2NC2=CC=CC=C12 ZSMRRZONCYIFNB-UHFFFAOYSA-N 0.000 description 1
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229910000497 Amalgam Inorganic materials 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 description 1
- DGFQXXDHYHWWSP-UHFFFAOYSA-N CC(C)OC([O])=O Chemical compound CC(C)OC([O])=O DGFQXXDHYHWWSP-UHFFFAOYSA-N 0.000 description 1
- PSEJBIODJNSJNT-UHFFFAOYSA-N CCCCC([O])=O Chemical compound CCCCC([O])=O PSEJBIODJNSJNT-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 229910021554 Chromium(II) chloride Inorganic materials 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- HDFFVHSMHLDSLO-UHFFFAOYSA-N Dibenzyl phosphate Chemical compound C=1C=CC=CC=1COP(=O)(O)OCC1=CC=CC=C1 HDFFVHSMHLDSLO-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- ASMQGLCHMVWBQR-UHFFFAOYSA-N Diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)(O)OC1=CC=CC=C1 ASMQGLCHMVWBQR-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- ICMAFTSLXCXHRK-UHFFFAOYSA-N Ethyl pentanoate Chemical compound CCCCC(=O)OCC ICMAFTSLXCXHRK-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010036976 Prostatism Diseases 0.000 description 1
- 206010051482 Prostatomegaly Diseases 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229910021623 Tin(IV) bromide Inorganic materials 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 206010047486 Virilism Diseases 0.000 description 1
- UOHUDFHWFDUDID-UHFFFAOYSA-N [Cl].C[SiH](C)C Chemical compound [Cl].C[SiH](C)C UOHUDFHWFDUDID-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- CGIHPACLZJDCBQ-UHFFFAOYSA-N acibenzolar Chemical compound SC(=O)C1=CC=CC2=C1SN=N2 CGIHPACLZJDCBQ-UHFFFAOYSA-N 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 125000001243 alanino group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 229910052728 basic metal Inorganic materials 0.000 description 1
- 150000003818 basic metals Chemical class 0.000 description 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229940117975 chromium trioxide Drugs 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- LRCIYVMVWAMTKX-UHFFFAOYSA-L chromium(ii) acetate Chemical compound [Cr+2].CC([O-])=O.CC([O-])=O LRCIYVMVWAMTKX-UHFFFAOYSA-L 0.000 description 1
- XBWRJSSJWDOUSJ-UHFFFAOYSA-L chromium(ii) chloride Chemical compound Cl[Cr]Cl XBWRJSSJWDOUSJ-UHFFFAOYSA-L 0.000 description 1
- 229940109126 chromous chloride Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- GUGXBRGATQTAFP-UHFFFAOYSA-N cyclopropylmethylbenzene Chemical compound C=1C=CC=CC=1CC1CC1 GUGXBRGATQTAFP-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- GRTGGSXWHGKRSB-UHFFFAOYSA-N dichloromethyl methyl ether Chemical compound COC(Cl)Cl GRTGGSXWHGKRSB-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HBGGXOJOCNVPFY-UHFFFAOYSA-N diisononyl phthalate Chemical compound CC(C)CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC(C)C HBGGXOJOCNVPFY-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- DVOPEILSPUBYLM-UHFFFAOYSA-N ethyl 5-pyridin-2-ylpentanoate Chemical compound CCOC(=O)CCCCC1=CC=CC=N1 DVOPEILSPUBYLM-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- UOYBLOSINLFZLV-UHFFFAOYSA-N formaldehyde 2-methylpropylbenzene Chemical compound C=O.C(C(C)C)C1=CC=CC=C1 UOYBLOSINLFZLV-UHFFFAOYSA-N 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- YWGHUJQYGPDNKT-UHFFFAOYSA-N hexanoyl chloride Chemical compound CCCCCC(Cl)=O YWGHUJQYGPDNKT-UHFFFAOYSA-N 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- JYJVVHFRSFVEJM-UHFFFAOYSA-N iodosobenzene Chemical compound O=IC1=CC=CC=C1 JYJVVHFRSFVEJM-UHFFFAOYSA-N 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- RWGFKTVRMDUZSP-UHFFFAOYSA-N isopropyl-benzene Natural products CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 235000015122 lemonade Nutrition 0.000 description 1
- 235000012204 lemonade/lime carbonate Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 229910000400 magnesium phosphate tribasic Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- LWLPYZUDBNFNAH-UHFFFAOYSA-M magnesium;butane;bromide Chemical compound [Mg+2].[Br-].CCC[CH2-] LWLPYZUDBNFNAH-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- JHZWMBRFGLKQSH-UHFFFAOYSA-N methyl $l^{1}-oxidanylformate Chemical compound COC([O])=O JHZWMBRFGLKQSH-UHFFFAOYSA-N 0.000 description 1
- 125000006178 methyl benzyl group Chemical group 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 1
- SWVGZFQJXVPIKM-UHFFFAOYSA-N n,n-bis(methylamino)propan-1-amine Chemical compound CCCN(NC)NC SWVGZFQJXVPIKM-UHFFFAOYSA-N 0.000 description 1
- PNUJBVDTPXKNDZ-UHFFFAOYSA-N n-methyl-2h-pyridin-1-amine Chemical compound CNN1CC=CC=C1 PNUJBVDTPXKNDZ-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- MCSAJNNLRCFZED-UHFFFAOYSA-N nitroethane Chemical compound CC[N+]([O-])=O MCSAJNNLRCFZED-UHFFFAOYSA-N 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical compound CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005934 tert-pentyloxycarbonyl group Chemical group 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- LTSUHJWLSNQKIP-UHFFFAOYSA-J tin(iv) bromide Chemical compound Br[Sn](Br)(Br)Br LTSUHJWLSNQKIP-UHFFFAOYSA-J 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- UBZYKBZMAMTNKW-UHFFFAOYSA-J titanium tetrabromide Chemical compound Br[Ti](Br)(Br)Br UBZYKBZMAMTNKW-UHFFFAOYSA-J 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- RXJKFRMDXUJTEX-UHFFFAOYSA-N triethylphosphine Chemical compound CCP(CC)CC RXJKFRMDXUJTEX-UHFFFAOYSA-N 0.000 description 1
- CMSYDJVRTHCWFP-UHFFFAOYSA-N triphenylphosphane;hydrobromide Chemical compound Br.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 CMSYDJVRTHCWFP-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了具有药理学活性的上式化合物及
其药学上可接受的盐,公开了它们的制备方法。
式中R′、R2、R3、R″、A、Q、X、Y和Z的定义同
说明书。
Description
本发明涉及新杂环衍生物及其药学上可接受的盐。更具体地说,本发明涉及新杂环衍生物及其药学上可接受的盐、制备方法、药用组合物以及药用用途,所述新杂环衍生物及其药学上可接受的盐具有药理活性,例如可以揣制睾酮5α-还原酶的活性。
因此,本发明的目的提供新杂环衍生物及其药学上可接受的盐,它们不用作睾酮5α还原酶揣制剂。
本发明的第二个目的是提供制备所述杂环衍生物或其盐的制备方法。
本发明的第三个目的是提供含所述杂环衍生物或其药学上可接受的盐作为活性成分的药用组合物。
本发明第四个目的是提供所述杂环衍生物或其药学上可接受的盐的药用用途,例如作为睾酮5α-还原酶抑制剂,用于治疗或预防睾酮5α-还原酶媒介疾病如人或动物的脱发、痤疮、前列腺病等。
本发明杂环衍生物是新的,可以用式(Ⅰ)表示:
式中R1是羧基或保护的羧基,
R2是氢、低级烷基或囟素,
R11是氢或低级烷基,
A是低级亚烷基,它不以被氧或低级亚烯基取代,
Q是羰基或低级亚烷基,
其中R4是氢或低级烷基、R5是氢氢、低级烷基或Y-Z-R3,
Y是单键或低级亚烷基
按照本发明,目的化合物(Ⅰ)及其盐可以按下述方法制备。
方法1
方法4
方法6
方法8
方法10
其中R1、R2、R3、R4、R5、R11、A、Q、X、Y和Z各自的定义同上,
R1 a是保护的羧基,
R6 b是氨基保护基,
R6 c是低级烷基、可含适宜取代基的芳(低级)烷基或氨基保护基,
R7是可含有适当取低基的芳基,
R8是羧基保护基,
R9是可含适宜取代基的氨基,
W1是离去基团,
W1、W2、W3和W10各自是酸根,
Y1是低级亚烷基,
基中R6 a是氢、低级烷基或氨基保护基,且
基中R6的定义同上。
化合物(Ⅰ)的适宜的盐是常用的无毒、药学上可接受的盐,可以包括与碱生成的盐或酸加成盐,例如与无机碱生成的盐,例如碱金属盐(例如钠盐、钾盐、铯盐等)、碱土金属盐(例如钙盐、镁盐等);铵盐;与有机碱生成的盐,例如有机胺盐(例如三乙胺盐、吡啶盐、甲基吡啶盐、乙醇胺盐、三乙醇胺盐、二环己胺盐、N,N′-二苄基乙二胺盐等);无机酸加成盐(例如盐酸盐、氢溴酸盐、硫酸盐、磷酸盐等);有机羧酸或磺酸加成盐(例如甲酸盐、乙酸盐、三氟乙酸盐、马来酸盐、酒石酸盐、甲磺酸盐、苯磺酸盐、对甲苯磺酸盐等);与碱性的或酸性的氨基酸(例如精氨酸、天冬氨酸、谷氨酸等)生成的盐;等等,它们的优选实例是酸加成盐。
在方法1-10中,关于化合物(Ⅰ-a)_(Ⅰ-R)、(Ⅱ)、(Ⅲ)、(Ⅲa)、(Ⅳ)、(Ⅴ)、(Ⅵ)、(Ⅶ)、(Ⅷ)、(Ⅻ)和(ⅩⅪ)的盐,这些化合物的盐的适宜的例子归为目标化合物(Ⅰ)的实例。
在本说明书的前后文叙述中,包括在本发明范围内的适宜的例子和各种定义的说明详细说明如下。
除有特别说明外,“低级”一词是指1-6个碳原子,优选的是1-4个碳原子。
适宜的“低级烷基”可以包括含1-10个碳原子的直链或支链烷基,例如甲基、乙基、丙基、异丙基、丁基、异丁基、特丁基、戊基、己基、庚基、辛基、壬基、癸基等,优选的是含1-6个碳原子的烷基,更优选的是含1-4个碳原子的烷基。
“囟素”是指氟、氯、溴和碘。
适宜的“低级亚烷基”是指二价的直链或支链低级烷基例如亚烷基、亚乙基、亚丙基、亚丁基、亚戊基、亚己基、1,2-亚丙基等,它们可以被氧取代。
适宜的“离去基团”可以包括羟基、由羟基衍生的反应性基团等。
适宜的“由羟基衍生的反应性基团“包括酸根等。”
适宜的“酸根”包括囟素(例如氟、氯、溴、碘)、酰氧基(例如乙酰氧基、甲苯磺酰氧基、甲磺酰基等)。
适宜的“低级亚链烯基”包括含2-6个碳原子的亚链烯基,例如亚乙烯基、亚丙烯基等。
适宜的“可含适宜取代基的芳基”包括常见的基团例如芳基(例如苯基、萘基等)、取代的芳基例如低级烷芳基(例如甲苯基、二甲苯基、三甲苯基、异丙苯基、异丁苯基等)、囟代芳基(例如氯苯基等)。
“可含适宜取代基的芳(低级)烷基”中的“芳(低级)烷基”是指芳基取代的直链或支链C1-C10烷基,适宜的“可含适宜取代基的芳(低级)烷基”包括常见基团如芳(低级)烷基(例如三苯甲基、二苯甲基、苄基、苯乙基、萘甲基、1-苯基乙基、苯丙基、苯丁基、苯戊基、苯己基、苯庚基、苯辛基、苯基、2,2-二乙基-1-苯基丙基等),取代的[芳(低级)烷基],例如,被一个或多个取代基取代的芳(低级)烷基,所述取代基如上述的低级烷基、上述的囟素、氰基、羧基、下述的保护羧基、上述的可含适宜取代基的芳基、下述的酰胺化的羧基、低级烷氧基(如甲氧基、乙氧基、丙氧基等)、羟基(低级)烷基(如羟基异丁基等)、保护的羟基(低级)烷基如低级烷酰氧基(低级)烷基(如乙酰氧基异丁基等)、环(低级)烷基(低级)烷基(如环丙基甲基、环丁基甲基等)、低级链烯基(如乙烯基、丙烯基、丁烯基等)和低级链炔基(如乙炔基、丙炔基、丁炔基等)。“可含适宜取代基的芳(低级)烷基“的具体例子有甲基苄基、异丁基苄基、(甲基苯基)乙基、(异丁基苯基)乙基、(甲基苯基)丙基、(异丁基苯基)丙基、(异丁基苯基)丁基、(甲基苯基)戊基、(异丁基苯基)戊基、(异丁基苯基)己基、(异丁基苯基)庚基、(异丁基苯基)辛基、双(甲基苯基)甲基、双(丙基苯基)甲基、双(丁基苯基)甲基、双(异丁基苯基)甲基、双(氯苯基)甲基、氰基)(异丁基苯基)甲基、(羧基)(异丁基苯基)甲基、(苄氧基羰基)(异丁基苯基)甲基、(N,N-乙基氨基甲酰基)(异丁基苯基)甲基、(叔丁基氨基甲酰基)(异丁基苯基)甲基、(苯基氨基甲酰基)异丁基苯基)甲基、(异丁基苯基氨基甲酰基)(异丁基苯基)甲基、(丁基氨基甲酰基)异丁基苯基)甲基、(庚基氨基甲酰基)(异丁基苯基)甲基、(乙氧基)(异丁基苯基)乙基、(异丁基苯基)三氟丁基、(苯基)(异丁基苯基)甲基、[(异丁基)(甲氧基)苯基]戊基、[(氟)(异丁基)苯基]戊基、[(氟)(羟基异丁基)苯基]戊基、[(氟)(乙酰氧基异丁基)苯基]戊基、(环丙基甲基苯基)丁烯基、(异丁基苯基)丁炔基、(异丁基苯基)丁炔基、(异丁基苯基)戊烯基等]等。
适宜的“氨基保护基”可以是用于有机化学领域的常见保护基,即包括酰基,例如低级烷酰基(如甲酰基、乙酰基、丙酰基、丁酰基、异丁酰基、戊酰基、异戊酰基、特戊酰基、己酰基等)、低级烷氧基羰基(如甲氧基羰基、乙氧基羰基、丙氧基羰基、丁氧基羰基、叔丁氧基羰基等)等。
适宜的“保护的羧基”包括酯化的羧基。
“酯化的羧基”中酯的部分的适宜例子例如低级烷酯(如甲酯、乙酯、丙酯、异丙酯、丁酯、异丁酯、叔丁酯、戊酯、己酯、1-环丙基乙酯等),所述低级烷酯可含至少一个取代基,例如,低级烷酰氧基(低级)烷基酯[如乙酰氧甲基酯、丙酰氧基甲基酯、丁酰氧基甲基酯、戊酰氧基甲基酯、特戊氧基甲基酯、己酰氧基甲基酯、1(或2)-乙酯氧基乙酯、1(或2或3)-乙酰氧基丙酯、1(或2或3或4)-乙酰氧基丁酯、1(或2)-丁酰氧基乙酯、1(或2)-异丁酰氧基乙酯、1(或2)-特戊酰氧乙酯、1(或2)-己酰氧基乙酯、异丁酰氧基甲酯、2-乙基丁酰氧基甲酯、3,3-二甲基丁酰氧基甲酯、1(或2)-戊酰氧基乙酯等),低级烷碘酰基(低级)烷酯(如2-甲磺酰基乙酯等),-(或二或三)-囟代(低级)烷酯(如2-碘乙酯、2,2,2-三氯乙酯等)、低级烷氧基羰基氧基(低级)烷酯(如甲氧基羰基氧基甲酯、乙氧基羰基氧基甲酯、2-甲氧基羰基氧基乙酯、1-乙氧基羰基氧基乙酯、1-异丙氧基羰基氧基乙酯等)、酞叉基(低级)烷酯、或(5-低级烷基-2-氧-1,3-二噁唑-4-基)(低级)烷酯[如(5-甲基-2-氧-1,3-二噁唑-4-基)甲酯、(5-乙基-2-氧-1,3-二噁唑-4-基)甲酯、(5-丙基-2-氧-1,3-二噁唑-4-基)乙酯等];低级烯酯(如乙烯酯、烯丙酯等);低级炔酯(如乙炔酯、丙炔酯等)可含至少一个适宜取代基的芳(低级)烷酯(如苄酯、4-甲氧基苄酯、4-硝基苄酯、苯乙酯、三苯甲酯、二苯甲酯、双(甲氧基苯基)甲酯、3,4-二甲氧基苄酯、4-羟基-3,5-二叔丁基苄酯等);可含至少一个适宜取代基的芳酯(如苯酯、4-氯苯酯、甲苯酯、叔丁基苯酯、二甲苯酯、三甲苯酯、异丙苯酯等);酞酯;等等。
上述酯化的羧基的优选实例可包括低级烷氧基羰基(如甲氧基羰基、乙氧基羰基、丙氧基羰基、异丙氧基羰基、丁氧基羰基、异丁氧基羰基、叔丁氧基羰基、戊氧基羰基、叔戊氧基羰基、己氧基羰基、1-环丙基乙氧基羰基等)。
适宜的“羧基保护基”可以是上面定义的“保护的羧基”中的酯的部分,包括低级烷基(如甲基、乙基等)、芳(低级)烷基(如苄基等)。
适宜的“可含适宜取代基的氨基”是指药学领域常见的基团,包括氨基、一或二(低级)烷基氨基(如甲基氨基、二甲基氨基、乙基氨基、二乙基氨基、丁基氨基、叔丁基氨基、庚基氨基等)、芳基氨基(如苯基氨基等)、低级烷基芳基氨基(如异丁基苯基氨基等)。
适宜“含氮杂环基”包括含至少一个氮子的饱和或不饱和单环或多环杂环基。具体的优选杂环基可以是5-或6-员脂族杂单环基团(如吗啉基、吡咯烷基、咪唑烷基、哌啶基、哌嗪基等)、不饱和稠杂环基如二苯并[6或7元不饱和]杂单环基(如吩噁嗪基、吩噻嗪基、10,11-二氢-5H-二苯并叮庚因基等)等。
适宜的“酰胺化的羧基”指可含适宜取代基的氨基酰基,包括氨基甲酰基、一或二(低级)烷基氨基甲酰基(如甲基氨基甲酰基、二甲基氨基甲酰基、乙基氨基甲酰基、二乙基氨基甲酰基、丁基氨基甲酰基、叔丁基氨基甲酰基、庚基氨基甲酰基等)、低级烷基芳基氨基甲酰基(如异丁基苯基氨基甲酰基等)等。
适宜的“[取代的氨基甲酰基](低级)烷基”指氨基甲酰基(低级)烷基,其中氨基甲酰基被一个或两个取代基取,适宜的取代基包括常见的基团如上述的低级烷基、可含上述适宜取代基的芳基。这样定义的“[取代的氨基甲酰基](低级)烷基”的具体例子有丁基氨基甲酰基甲基、1-(庚基氨基甲酰基)乙基、异丁基苯基氨基甲酰基甲基、1-(异丁基苯基氨基甲酰基)乙基等。
具体地说,R1、R2、R3、R11、A、Q、X、Y和Z的优选实例如下。
R1是羧基;
酯化的羧基如低级烷氧基羰基,更优选的是C1-C4烷氧基羰基(如甲氧基羰基、乙氧基羰基等);或
芳(低级)烷氧基羰基,更优选的是一或二或三苯基(C1-C4)烷氧基羰基(如苄氧基羰基等),
R2是氢;
低级烷基,更优选的是C1-C4烷基(如甲基等);或
囟素(如氯),
R3是可被低级烷基取代的芳基,更优选的是C1-C4烷基取代的苯基(如异丁基苯基);可被一个或多个取代基取代的芳(低级)烷基,所述取代基包括低级烷基、囟素、氰基、羧基、保护的羧基、酰胺化的羧基、低级烷氧基、羟基(低级)烷基、保护的羟基(低级)烷基、环(低级)烷基、低级链烯和低级链炔基,更优选的是可被一至四个基团取代的一或二或三苯基(低级烷基,所述取代基选自低级烷基、囟素、氰基、羧基、苯基(低级)烷氧基羰基、一或二(低级)烷氧基氨基甲酰基、苯基氨基甲酰基、低级烷基苯基氨基甲酰基、低级烷氧基、羟基(低级)烷基、低级烷酰氧基(低级)烷基、环(低级)烷基(低级)烷基、低级链烯基和低级链炔基,更优选的是可被一至四个基团取代的一或二或三苯基(C1-C10)烷基,所述取代基选自(C1-C10)烷基、囟素、氰基、羧基、苯基(C1-C4)烷氧基羰基、一或二(C1-C10)烷基氨基甲甲酰基、苯基氨基甲酰基、(C1-C4)烷基苯基氨基甲酰基、(C1-C4)烷氧基、羟基(C1-C4)烷基、(C1-C4)烷酰氧基(C1-C4)烷基、环(C3-C6)烷基(C1-C4)烷基、(C2-C4)链烯基和(C2-C4)链炔基,[如苄基、异丁基苄基、(异丁基苯基)乙基、(异丁基苯基)丙基、(异丁基苯基)丁基(异丁基苯基)戊基、(异丁基苯基)己基、(异丁基苯基)庚基、(异丁基苯基)辛基、双(异丁基苯基)甲基、双(氯苯基)甲基、(氰基)(异丁基苯基)甲基、(羧基)(异丁基苯基)甲基、(苄氧基羰基)(异丁基苯基)甲基、(苄氧基羰基)(异丁基苯基)甲基、(N,N-二乙基氨基甲酰基)(异丁基苯基)甲基、(叔丁基氨基甲酰基)(异丁基苯基)甲基、(苯基氨基甲酰基)(异丁基苯基)甲基、(异丁基苯基氨基甲酰基)(异丁基苯基)甲基、(丁基氨基甲酰基)(异丁基苯基)甲基、(庚基氨基甲酰基)(异丁基苯基)甲基、(乙氧基)(异丁基苯基)乙基、(异丁基苯基)(三氟)丁基、(苯基)(异丁基苯基)甲基、(异丁基)(甲氧基)苯基]戊基、[(氟)(异丁基)苯基]戊基、[(氟)(羟基异丁基)苯基]戊基、[(氟)(乙酰氧基异丁基)苯基]戊基、(环丙基甲基苯基)丁烯基、(异丁基苯基)丁炔基、(异丁基苯基)丁烯基、(异丁基苯基)戊烯基等];
氨基甲酰基(低级)烷基,基中氨基甲酰基部分被一个或二个取代基取代,所述取代基包括低级烷基和低级烷基苯基,更优选的是(C1-C10)烷基氨基甲酰基(C1-C4)烷基或(C1-C4)烷基苯基氨基甲酰基(C1-C4)烷基(如庚基氨基甲酰基乙基、异丁基苯基氨基甲酰基甲基、异丁基苯基氨基甲酰基乙基等);
5或6员脂族杂单环羰基(如哌啶基羰基等);或
不饱和稠杂环基(如吩噁嗪基、吩噻嗪基、10,11-二氢-5H-二苯并[b,f]吖庚因基等),
R11是氢;或低级烷基,更优选的是C1-C4烷基(如甲基等),
A 是可被氧取代的低级亚烷基、更优选的是可被氧取代的C1-C4亚烷基(如亚乙基、三亚甲基、氧三亚甲基等);或
低级亚链烯基、更优选的是C2-C4亚链烯基(如亚丙烯基等),
Q 是羰基;或
低级亚烷基,更优选的是C1-C4亚烷基(如亚甲基等),
X 是
其中R4是氢;或低级烷基,更优选的是C1-C4烷基(如甲基等),
R5是氢;低级烷基,更优选的是C1-C4烷基(如甲基等);或可被低级烷基或低级烷氧基羰基等基团取代的芳(低级)烷基氨基,更优选的是C1-C4烷基苄基氨基,或N-C1-C4烷氧基羰基-N-C1-C4烷基苄基氨基(如异丁基苄基氨基,N-叔丁氧基羰基-N-异丁基苄基氨基等),
Y是键;或
低级亚烷基,更优选的是C1-C4亚烷基(如亚甲基等),
和
其中R6是氢;低级烷基,优选的是C1-C4烷基(如甲基、乙基等);
低级烷氧基羰基,优选的是C-C烷氧基羰基(如叔丁氧基羰基等);
可被低级烷基取代的芳(低级)烷基,更优选的是可被低级烷基取代的一或二或三苯基(低级)烷基,更优选的是可被C1-C4烷基取代的一或二或三苯基(C1-C6)烷基(如苄基、异丁基苄基等)
方法1-10用于制备本发明目标化合物(Ⅰ),下面将作详细介绍。
方法1
将化合物(Ⅱ)或其盐与化合物(Ⅲ)或其盐反应,制得目标化合物(Ⅰ-a)。
注反应通常在溶剂中进行,所述溶剂如醇[如甲醇、乙醇等]、二氯甲烷、苯、N,N-二甲基甲酰胺、四氢呋喃、二乙醚、甲苯或其它任何对反应无不良影响的溶剂。
在该反应中,当化合物(Ⅲ)中的W1是酸根时,反应可以在无机碱或有机碱存在下进行,如碱金属氢氧化物[如氢氧化钠、氢氧化钾等]、碱金属碳酸盐[如碳酸钠、碳酸钾等]、碱金属碳酸氢盐[如碳酸氢钠、碳酸氢钾等]、碱金属氢化物(如氢化钠、氢化钾等)、三(低级)烷基胺[如三甲胺、三乙胺、二异丙基乙胺等]、吡啶或其衍生物[如甲基吡啶、二甲基吡啶、4-二甲基氨基吡啶等]等。如果使用的碱是液态,则也可以用作溶剂。
当化合物(Ⅲ)中的W1是羟基时,该反应通常在常见缩合剂存在下进行,所述缩合剂如N,N′-二环己基碳化二亚胺;N-环己基-N′-吗啉代乙基碳化二亚胺;N-环己基-N′-(4-二乙基氨基环己基)碳化二亚胺;N,N′-二乙基碳化二亚胺,N,N′-二异丙基碳化二亚胺;N-乙基-N′-(3-二甲基氨基丙基)碳化二亚胺,N,N′-羰基-双(2-甲基咪唑);亚戊基乙烯酮-N-环己基亚胺、二苯基乙烯酮-N-环己基亚胺;乙氧基乙炔;1-烷氧基-1-氯乙烯;三烷基亚磷酸酯;多磷酸乙酯;多磷酸异丙酯;三氯氧化磷(磷酰氯);三氯化磷;亚硫酰氯;草酰氯;囟代甲酸低级烷酯(如氯甲酸乙酯、氯甲酸异丙酯等];三芳基膦[如三苯膦等]或三(低级)烷基膦[如三乙基膦等]和二(低级)烷基偶氮二甲酸酯[如偶氮二甲酸二乙酯等]的组合物;2-乙基-7-羟基苯并异噁唑鎓盐,2-乙基-5-(间磺苯基)异噁唑鎓氢氧化物分子内盐;1-(对氯苯磺酰氧基)-6-氯-1H-苯并三唑;N,N-二甲基甲酰胺与亚硫酰氯、光气、氯甲酸三氯甲酯、三氯氧化磷等反应制备的所谓Vilsmeier试剂;或类似物。
该反应对温度要求不严,反应可以在冷却、室温或加热条件下进行。
方法2
将化合物(Ⅳ)或其盐与化合物(Ⅴ)或其盐反应,可以制备目标化合物(Ⅰ-b)或其盐。
该反应通常在溶剂中进行,所述溶剂如醇[如甲醇、乙醇等]、二氯甲烷、苯、N,N-二甲基甲酰胺、四氢呋喃、二乙醚或任何其它对反应无不良影响的溶剂。
该反应可以在无机碱或有机碱存在下进行,所述碱例如碱金属氢氧化物[如氢氧化钠、氢氧化钾等]、碱金属碳酸盐[如碳酸钠、碳酸钾等]、碱金属碳酸氢盐[如碳酸氢钠、碳酸氢钾等]、碱金属氢化物(如氢化钠、氢化钾等)、三(低级)烷基胺[如三甲胺、三乙胺、二异丙基乙胺等]、吡啶或其衍生物[如甲基吡啶、二甲基吡啶、4-二甲基氨基吡啶等]如果使用的碱是液态,则也可以用作溶剂。
该反应对温度要求不严,反应可以在冷却、室温或加热条件下进行。
方法3
将化合物(Ⅵ)或共盐与化合物(Ⅲa)或其盐反应,可以制得目标化合物(Ⅰ-c)。
该反应可以按与方法2基本相同的方法进行,因而该反应的反应方式和反应条件[如溶剂、反应温度等]参见方法2。
本反应包括当R1是羧基时,在反应过程中或在本方法的后处理步骤,将羧基保护起来。
方法4
将化合物(Ⅰ-a)或其盐消去羧基保护基可以制得目标化合物(Ⅰ-e)或其盐。
在本消去反应中,所有常见的消去羧基保护基的方法均可使用,例如,水解、还原、用路易氏酸消去,等等。当羧基保护基是酯时,可以水解消去或用路易氏酸消去。水解最好在碱或酸存在下进行。
适宜的碱包括无机碱和有机碱,所述无机碱例如碱金属氢氧化物(如氢氧化钠、氢氧化钾等)、碱土金属氢氧化物(如氢氧化镁、氢氧化钙等)、碱金属碳酸盐(如碳酸钠、碳酸钾等)、碱土金属碳酸盐(如碳酸镁、碳酸钙等)、碱金属碳酸氢盐(如碳酸氢钠、碳酸氢钾等)、碱金属金属乙酸盐(如乙酸钠、乙酸钾等)、碱土金属磷酸盐(如磷酸镁、磷酸钙等)、碱金属磷酸氢盐(如磷酸氢二钠、磷酸氢二钾等)或类似物,所述有机碱例如三烷基胺(如三甲胺、三乙胺等)、甲基吡啶、N-甲基吡咯烷、N-甲基吗啉、1,5-二氮杂二环[4.3.0]壬-5-酮、1,4-二氮杂二环[2.2.2]辛烷、1,5-二氮杂二环[5.4.0]十-碳烯-5或类似物。用碱水解时,反应通常在水中或在亲水机溶剂中或其混合溶剂中进行。
适宜的酸包括有机酸(如甲酸、乙酸、丙酸等)和无机酸(如盐酸、氢溴酸、硫酸等)。
本水解通常在有机溶剂、水或其混合溶剂中进行。
该反应对温度要求不严,可以根据羧基保护基的类型和消去方法选择适宜的温度。
要消去取代的或未取代的芳(低级)烷基酯用路易氏酸消去较好,即将化合物(Ⅰg)或其盐与路易氏酸反应,所述路易氏酸例如三囟化硼(如三氯化硼、三氟化硼等)、四囟化钛(如四氯化钛、四溴化钛等)、四囟化锡(如四氯化锡、四溴化锡等)、囟化铝(如三氯化铝、三溴化铝等)、三囟代乙酸(如三氯乙酸、三氟乙酸等)或类似物。该消去反应在有阳离子捕捉剂(如苯甲醚、苯酚等)存在下进行较好,并通常在下述溶剂中进行,例如硝基烷烃(如硝基甲烷、硝基乙烷等)、囟化亚烷烃(如二氯甲烷、二氯乙烷等)、水、醇(如甲醇、乙醇等)、二氧六环、二乙醚、二硫化碳或其它任何对本反应无不良影响的溶剂。这些溶剂可以混合使用。
对于消去例如囟代(低级)烷基(如2-碘乙基、2,2,2-三氯乙基等)酯、芳(低级)烷基(如苄基等)酯或类似的保护基,使用还原消去较好。
用于消去反应的还原方法包括例如用金属(如锌、锌汞齐等)或铬化合物(如氯化亚铬、乙酸亚铬等)和有机酸或无机酸(如乙酸、丙酸、盐酸等)的复合物进行还原;在常用金属催化剂(如钯碳、阮内镍等)存在下的常见的催化还原。
反应温度求要不严,反应通常在冷却、室温或加热条件下进行。
方法5
将化合物(Ⅰ-p)或其盐消去羧基保护基可以制得目标化合物(Ⅰ-g)或其盐。
该反应可以按与方法4基本相同的方法进行,因而反应方式和反应条件[如碱、酸、还原剂、催化剂、溶剂、反应温度等]参见方法4。
方法6
化合物(Ⅰ-g)或其羧基活性衍生物或其盐与化合物(Ⅶ)或其氨基活性衍生物或其盐反应可以制得目标化合物(Ⅰ-h)或其盐。
适宜的化合物(Ⅶ)的氨基活性衍生物包括席夫碱型亚胺或它的互变烯胺型异构体,所述异构体由化合物(Ⅶ)与羰基化合物如醛、酮或类似物反应而得;化合物(Ⅶ)与甲硅烷基化合物[如双(三甲基甲硅烷基)乙酰胺、-(三甲基甲硅烷基)乙酰胺、双(三甲基甲硅烷基)脲或类似物]反应生成的甲硅烷衍生物;化合物(Ⅸ)与三氯化磷或光气或类似物反应生成的衍生物。
适宜的化合物(Ⅰ-g)的羧基活性衍生物包括酰基囟、酸酐、活化酰胺、活性酯等,所述活性衍生物的适宜例子可以是酰氯;酰基叠氮;与酸形成的混酐,所述酸例如取代的磷酸[如二烷基磷酸、苯基磷酸、二苯基磷酸、二苄基磷酸、囟代磷酸等]、二烷基亚磷酸、亚硫酸、硫代硫酸、硫酸、磺酸[如甲磺酸等]脂族羧酸[如乙酸、丙酸、丁酸、异丁酸、特戊酸、戊酸、异戊酸、2-乙基丁酸、三氯乙酸等]或芳羧酸[如苯甲酸等];对称酸酐;与咪唑、4位取代的咪唑、二甲基吡唑、三唑或甲唑生成的活化酰胺;或活化酯[如氰基甲酯、甲氧基甲酯、二甲基亚胺基甲[(CH3)2N=
-]酯、乙烯酯、炔丙基酯、对硝基苯酯、2,4-二硝基苯酯、三氯苯酯、五氯代苯酯、甲磺酰苯酯、苯偶氮基苯酯、苯基硫酯、对硝基苯基硫酯、对甲苯基硫酯、羧甲基硫酯、吡喃酯、吡啶酯、8-喹啉硫酯等],或与N-羟基化合物[如N,N-二甲羟胺、1-羟基-2-(1H)-吡啶酮、N-羟基琥珀酰亚胺、N-羟基酞酰亚胺、1-羟基-1H-苯并三唑等]形成的酯等,这些活性衍生物可以根据所使用的化合物(Ⅰ-g)的种类进行选择。
该反应通常在常见溶剂中进行,所述溶剂例如水、醇[如甲醇、乙醇等]、丙酮、二氧六环、乙腈、氯仿、二氯甲烷、二氯乙烷、四氢呋喃、乙酸乙酯、N,N-二甲基甲酰胺、吡啶或其它任何对本反应无不良影响的有机溶剂,这些常见溶剂也可以与水混合使用。
在该反应中,当化合物(Ⅰ-g)以游离酸或其盐的形式使用时,反应在有常见缩合剂存在下进行较好,所述合剂如N,N′-二环己基碳化二亚胺;N-环己基-N′-吗啉代乙基碳化二亚胺;N-环己基-N′-(4-二乙基氨基环己基)碳化二亚胺;N,N′-二乙基碳化二亚胺,N,N′-二异丙基碳化二亚胺;N-乙基-N′-(3-二甲基氨基丙基)碳化二亚胺;N,N′-羰基双-(2-甲基咪);亚戊基乙烯酮-N-环己亚胺;二苯基乙烯酮-N-环己基亚胺;己氧基乙炔;1-烷氧基-1-氯乙烯;三烷基亚磷酸酯;多磷酸乙酯;多磷酸异丙酯;三氯氧化磷(磷酰氯);二苯基磷酰叠氮;亚硫酰氯;草酰氯;低级烷基囟代甲酸酯[如氯甲酸乙酯、氯甲酸异丙酯等];三苯膦;2-乙基-7-羟基苯并异噁唑鎓盐;2-乙基-5-(间磺苯基)异噁唑鎓氢氧化物分子内盐;1-(对氯苯磺酰氧基)-6-氯-1H-苯并三唑;N,N-二甲基甲酰胺与亚硫酰氯、光气、氯甲酸三氯甲酯、三氯氧化磷等反应制备的所谓Vilsmeier试剂等;或类似物。
该反应也可以在无机碱或有机碱存在下进行,所述碱例如碱金属碳酸氢盐、三(低级)烷基胺、吡啶、N-(低级)烷基吗啉、N,N-二(低级)烷基苄胺或类似物。
反应温度要求不严,反应通常在冷却至加热条件下进行。
方法7
将化合物(Ⅰ-i)或其盐消去氨基保护基可以制得目标化合物(Ⅰ-d)或其盐。
该反应可以按与方法4基本相同的方法进行,因而反应方式和反应条件[如碱、酸、还原剂、催化剂、溶剂、反应温度等]参见方法4。
方法8
化合物(Ⅰ-j)或其盐与化合物(Ⅷ)或其盐反应可以制得目标化合物(Ⅰ-k)。
该反应可以按与方法2基本相同的方法进行,因而反应方式样反应条件[如溶剂、反应温度等]参见方法2。
本反应包括:当R1是羧基时,在反应过程中或在本方法的后处理步骤,将羧基保护起来。
方法9
化合物(Ⅰ-e)或其盐经引入羧基保护基反应后,可制得目标化合物(Ⅰ-d)或其盐。
该反应可以按与方法2基本相同的方法进行,因而反应方式和反应条件[如溶剂、反应温度等]参见方法2。
方法10
化合物(Ⅻ)或其盐与化合物(ⅩⅪ)或其盐反应可以制得目标化合物(Ⅰ)或其盐。
该反应可以按与方法2基本相同的方法进行,因而反应方式和反应条件[如溶剂、反应温度等]能见方法2。
本反应包括当R1是保护的羧基时,在反应过程中或在本方法的后处理步骤中,将它消去。
原料化合物(Ⅱ)和(Ⅳ)可按下述方法(详见下述的制备)或常规方法制备。
方法A
其中R1、R1 a、R2、R6 d、R11、A、Q、X、Y、Y1、Z1和W2的定义同前文,
R6 d是低级烷基或氨基保护基,
R10是保护的羟基,
W4、W5、W6、W7、W8和W9各自是酸根,
A1是合氧低级亚烷基,和
A2是低级亚烷基。
方法A~D可以按常规方法进行。
本发明目标化合物(Ⅰ)可以按常规方法进行分离和提纯,例如,提取、沉淀、分步结晶、重结晶、色谱法和类似的方法。
这样获得的目标化合物(Ⅰ)可以按常方法将其转化为盐的形式。
本发明目标化合物(Ⅰ)可用作睾酮5α-还原酶抑制剂,并且对下述睾酮5α还原酶中介的疾病有效,例如前列腺病态,前列腺肥大、前列腺癌、脱发、多毛(如女性多毛等)、男性征秃发(或男性型秃发)、痤疮(如寻常痤疮、小脓胞等)、或其它的过男性化疾病等。
为了说明目标化合物(Ⅰ)的有效性,下面给出本发明有代表性的化合物的药理活性。
[Ⅰ]试验化合物:
(1)4-[3-[3-[双(4-异丁基苯基)甲基氨基]苯甲酰基]中氮茚-1-基]丁酸
(2)4[1-4-[双(4-异丁基苯基)甲基氨基]苯甲酰基]中氮茚-3-基]丁酸
(3)4[3-[3[双(4-异丁基苯基)甲氧基]苯甲酰基]中氮茚-1-基]丁酸
(4)4-[1-4-[1-(4-异丁基苯基)丙氧基]苯甲酰基]中氮茚-3-基]丁酸
(5)4-[1-[4-[1-[4-异丁基苯基)戊氧基]苯甲酰基]中氮茚-3-基]丁酸
[2]对大鼠睾酮5α-还原酶的抑制活性
试验方法:
ⅰ)材料
1,2,6,7-3H-睾酮(85-105 Ci/mmol):
1,2,6,7-3H-睾酮(85-105 Ci/mmol)是1,2,6,7-H-睾酮和睾酮的混合物,它包括85-105C;1,2,6,7-3H-睾酮/每毫摩尔睾酮,从New England Nuclear,Boston,Mass,U.S.A.购得。
Aquazol-2(Aquazol-2 Universal LSC Cocktail):
商品名,购自New England Nuclear,Boston,Mass,U.S.A.
ⅱ)前列腺睾5α-还原酶的制备
将成年的Spraque-Dawley 雄鼠(7-8周大)用乙醚处死。将前侧前列腺切成碎片(不含其囊),并分散于几毫升冰冷却的介质A(0.32M蔗糖,0.1mM二硫苏糖醇和20mM磷酸钠,PH6.5)中,测量合并后的体积。除另有说明外,均在0-4℃进行下述程序。将前列腺弄干,切碎,于组织体积3-4倍量的介质A中用Pyrex-玻璃匀质器匀质。匀质液在3000g离心15分钟,得到的沉淀混悬于介质A中,该混悬液(20-30mg 蛋白/ml)贮存于-80℃。
ⅲ)睾酮5α-还原酶的测定
反应溶液含有1mM二硫苏糖醇、40mM、磷酸钠(PH6.5)、50μM NADPH、1,2,6,7-3H-睾酮/睾酮(2.2x 10-9M)和上述制备的混悬液(0.8mg蛋白),总体积565μl。将溶于10μl 10%乙醇中的试验化合物加入,而对照试管中加入等体积的10%乙醇。加入酶混悬液使反应开始。在37℃孵化30分钟后用1ml乙酸乙酯提取反应液。取50μl乙酸乙酯液于Merck silica Plastic sheet Kieselgel 60 F254极上层析,用乙酸乙酯:环己烷(1∶1)作为展开剂。该塑料板用空气干燥,切下含有睾酮和5α-二氢睾酮部分,溶于5ml Aquazol-2中于Packard闪烁计数器(PACKARD TRI-CARB 4530)中测定放射活性,并计算出抑制率。
[3]试验结果:
就治疗或预防给药而言,本发明目标化合物以常规的药物制剂形式应用。所述药物制剂形式含有所述的本发明化合物作为活性成分,并混有适合于口服、非肠道给药和外用的药学上可接受载体(例如:有机或无机固体或液体赋形剂)。药物制剂可以是固体形式(如片剂,粒剂,粉剂,胶囊)或液体形式(如溶液,混悬液,糖浆,乳化液,柠檬水,洗液等)。
必要时,上述制剂中还可包括辅剂、稳定剂、润湿剂和其它常用的添加剂例如乳糖、柠檬酸、酒石酸、硬脂酸、硬脂酸镁、白土、蔗糖、玉米淀粉、滑石、明胶、琼脂、果胶、花生油、橄榄油、可可脂、乙二醇等。
尽管化合物(Ⅰ)的剂量取决于病人的年令、病情、应用的化合物种类等,并随之而变化,但通常每天可给予病人的量为0.01mg-500mg或更多。在治疗疾病中,可用本发明目标化合物的平均单剂量分别是约0.05mg,0.1mg,0.25mg,05mg,1mg,20mg,50mg和100mg。
给出下述制剂和实施例以解释本发明目的。
制备1
室温下向3-氯甲酰基丙酸乙酯(1.65g)和三氯化铝(1.78g)的二氯甲烷(20ml)溶液中加入中氮茚(977mg)的二氯甲烷(5ml)溶液。搅拌1小时后,加入冰,然后用氯仿提取。有机层用饱和碳酸氢钠和盐水洗涤,然后用硫酸钠干燥。蒸去溶剂后,剩余物用硅胶色谱分离,用己烷-乙酸乙酯(3∶2)洗脱,得到下述化合物。
4-(3-中氮茚基)-4-氧丁酸乙酯(0.74g)
NMR(CDCl3,δ):1.28(3H,t,J=7Hz),2.79(2H,t,J=7Hz),3.29(2H,t,J=7Hz),4.18(2H,q,J=7Hz),6.51(1H,d,J=5Hz),6.84(1H,dt,J=1Hz,6Hz),7.12(1H,m),7.52(1H,m),7.58(1H,d,J=5Hz),9.83(1H,dd,J=1Hz,6Hz)
4-(1-中氮茚基)-4-氮丁酸乙酯(0.26g)
NMR(CDCl3,δ):1.28(3H,t,J=7Hz),2.78(2H,t,J=7Hz),3.25(2H,t,J=7Hz),4.17(2H,q,J=7Hz),6.77(1H,dt,J=1Hz,7Hz),7.12(1H,m),7.22(2H,m),8.03(1H,dt,J=7Hz,1Hz),8.44(1H,dt,J=9Hz,1Hz)
制备2
在0℃下,向4(3-中氮茚基)-4-氧丁酸乙酯(556mg)的四氢呋喃(5ml)溶液中加入甲硼烷的四氢呋喃溶液(1M溶液,3.6ml)。室温下搅拌10分钟后,用0℃的磷酸二氢钾骤冷,得到的混合物用乙醚提取。有机层用水、碳酸氢钠水溶液和盐水洗涤,用硫酸钠干燥。将溶剂蒸发后,剩余物用氧化铝色谱分离(己烷-二氯甲烷=1∶1),得4-(3-中氮茚基)丁酸乙酯(294mg)。
NMR(CDCl3,δ):1.26(3H,t,J=7Hz),2.08(2H,m),2.43(2H,t,J=7Hz),2.89(2H,t,J=7Hz),4.14(2H,q,J=7Hz),6.3-6.7(4H,m),7.37(1H,dt,J=9Hz,1Hz),7.78(1H,dt,J=6Hz,1Hz)
制备3
按类似于制备2的方法,制备3下述化合物。
4-(1-中氮茚基)丁烯酸乙酯
NMR(CDCl3,δ):1.23(3H,t,J=7Hz),1.98(2H,m),2.34(2H,t,J=7Hz),2.79(2H,t,J=7Hz),4.12(2H,q,J=7Hz),6.37(1H,dt,J=1Hz,7Hz),6.56(1H,m),6.62(1H,d,J=3Hz),7.21(1H,d,J=3Hz),7.29(1H,d,J=9Hz),7.84(1H,d,J=7Hz)
制备4
室温下,向3-硝基苯甲酰氯(314mg)的二氯甲烷(20ml)溶液中加入三氯化铝(305mg)。搅拌10分钟后,加入4-(3-中氮茚基)丁酸乙酯(297mg)的二氯甲烷(3ml)溶液。1小时后,加入冰,得到的混合物用氯仿提取。有机层机用水、碳酸氢钠水溶液和盐水洗涤,用硫酸钠干燥。蒸去溶剂后,剩余物用硅胶色谱分离(己烷∶乙酸乙酯=2∶3),得到4-[1-(3-硝基苯甲酰基)中氮茚-3-基]丁酸乙酯(353mg)。
NMR(CDCl3,δ):1.23(3H,t,J=7Hz),2.08(2H,m),2.46(2H,t,J=7Hz),2.93(2H,t,J=7Hz),4.13(2H,q,J=7Hz),6.80(1H,s),6.98(1H,dt,J=1Hz,7Hz),7.30(1H,m),7.69(1H,t,J=8Hz),8.10(1H,d,J=7Hz),8.16(1H,m),8.39(1H,m),8.53(1H,dt,J=9Hz,1Hz),8.57(1H,m)
制备5
按类似于制备4的方法,制得了下述化合物。
(1)4[1-(4-硝基苯甲酰基)中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):1.25(3H,t,J=7Hz),2.04(2H,m),2.46(2H,t,J=7Hz),2.90(2H,t,J=7Hz),4.13(2H,q,J=7Hz),6.76(1H,s),6.99(1H,dt,J=1Hz,7Hz),7.32(1H,m),7.95(2H,d,J=9Hz),8.10(1H,d,J=7Hz),8.35(2H,d,J=9Hz),8.54(1H,d,J=8Hz)
(2)4-[3-(3-硝基苯甲酰基)中氮茚-1-基]丁酸乙酯
NMR(CDCl3,δ):1.23(3H,t,J=7Hz),2.01(2H,m),2.37(2H,t,J=7Hz),2.81(2H,t,J=7Hz),4.12(2H,q,J=7Hz),7.02(1H,dt,J=1Hz,7Hz),7.11(1H,s),7.28(1H,dt,J=1Hz,8Hz),7.62(1H,dt,J=8Hz,1Hz),7.69(1H,t,J=7Hz),8.12(1H,m),8.38(1H,m),8.63(1H,m),9.98(1H,d,J=7Hz)
(3)4-[3-(4-硝基苯甲酰基)中氮茚-1-基]丁酸乙酯
NMR(CDCl3,δ):1.23(3H,t,J=7Hz),2.00(2H,m),2.36(2H,t,J=7Hz),2.79(2H,t,J=7Hz),4.12(2H,q,J=7Hz),7.02(1H,dt,J=1Hz,7Hz),7.07(1H,s),7.28(1H,m),7.61(1H,dt,J=9Hz,1Hz),7.93(2H,d,J=9Hz),8.36(2H,d,J=9Hz),9.98(1H,d,J=7Hz)
(4)4-[1-(4-甲氧基苯甲酰基)中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):1.25(3H,t,J=7Hz),1.98-2.17(2H,m),2.45(2H,t,J=7Hz),2.90(2H,t,J=7Hz),3.89(3H,s),4.14(2H,q,J=7Hz),6.84-7.04(4H,m),7.12-7.22(1H,m),7.80-7.90(2H,m),8.01(1H,d,J=7Hz),8.48(1H,d,J=9Hz)
(5)4-[1-(3-甲氧基苯甲酰基)中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):1.26(3H,t,J=7Hz),1.97-2.15(2H,m),2.44(2H,t,J=7Hz),2.89(2H,t,J=7Hz),3.88(3H,s),4.13(2H,q,J=7Hz),6.87-6.97(2H,m),7.03-7.12(1H,m),7.16-7.26(1H,m),7.32-7.43(3H,m),8.03(1H,d,J=7Hz),8.51(1H,d,J=9Hz)
(6)4-[3-(4-甲氧基苯甲酰基)中氮茚-1-基]丁酸乙酯
NMR(CDCl3,δ):1.23(3H,t,J=7Hz),1.92-2.10(2H,m),2.35(2H,t,J=7Hz),2.79(2H,t,J=7Hz),3.90(3H,s),4.12(2H,q,J=7Hz),6.85-7.23(5H,m),7.54(1H,d,J=9Hz),7.77-7.88(2H,m)
(7)4-[3-(3-甲氧基苯甲酰)中氮茚-1-基]丁酸乙酯
NMR(CDCl3,δ):1.24(3H,t,J=7Hz),1.90-2.08(2H,m),2.36(2H,t,J=7Hz),2.78(2H,t,J=7Hz),3.88(3H,s),4.12(2H,q,J=7Hz),6.87-7.07(3H,m),7.13-7.40(5H,m),7.44(1H,d,J=9Hz)
制备6
向4-[1-(3-硝基苯甲酰基)中氮茚-3-基]丁酸乙酯(350mg)的二氧六环-乙醇溶液(1∶1∶10ml)中加入10%钯/碳(210mg),然后在4个大气压的氢气氛下加氢4小时,然后用硅藻土过滤。除去溶剂后得4-[1-(3-氨基苯甲酰基)中氮茚-3-基]丁酸乙酯(325mg)。
NMR(CDCl3,δ):1.23(3H,t,J=7Hz),2.05(2H,m),2.43(2H,t,J=7Hz),2.88(2H,t,J=7Hz),4.12(2H,q,J=7Hz),6.90(1H,m),6.91(1H,s),7.1-7.4(5H,m),8.01(1H,d,J=7Hz),8.48(1H,dt,J=8Hz,1Hz)
制备7
按类似于制备6的方法,制得了下述化合物。
(1)4-[1-(4-氨基苯甲酰基)中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):1.25(3H,t,J=7Hz),2.07(2H,m),2.44(2H,t,J=7Hz),2.89(2H,t,J=7Hz),4.14(2H,q,J=7Hz),6.78(2H,d,J=9Hz),6.86(1H,dt,J=1Hz,7Hz),6.92(1H,s),7.12(1H,m),7.76(2H,d,J=9Hz),7.99(1H,d,J=7Hz),8.43(1H,d,J=8Hz)
(2)4-[3-(3-氨基苯甲酰基)中氮茚-1-基]丁酸乙酯
NMR(CDCl3,δ):1.23(3H,t,J=7Hz),1.98(2H,m),2.33(2H,t,J=7Hz),2.78(2H,t,J=7Hz),6.8-7.0(2H,m),7.1-7.3(6H,m),7.54(1H,dt,J=8Hz,1Hz),9.94(1H,d,J=7Hz)
(3)4-[3-(4-氨基苯甲酰基)中氮茚-1-基]丁酸乙酯
NMR(CDCl3,δ):1.24(3H,t,J=7Hz),2.00(2H,m),2.35(2H,t,J=7Hz),2.80(2H,t,J=7Hz),4.11(2H,q,J=7Hz),6.73(2H,d,J=9Hz),6.87(1H,dt,J=1Hz,7Hz),7.02(1H,m),7.20(1H,s),7.51(1H,dt,J=9Hz,1Hz),7.72(2H,d,J=9Hz),9.86(1H,d,J=7Hz)
制备8
0℃下,向4-[1-(4-甲氧基苯甲酰基)中氮茚-3-基]丁酸乙酯(640mg)、乙硫醇(2.5ml)和二氯甲烷(8ml)的混合物中加入三氯化铝(700mg)。在0℃下搅拌10分钟后,蒸去溶剂后,将剩余物倒入乙酸乙酯和冰-水的混合物中。分出有机层,用碳酸氢钠水溶液和盐酸洗涤,用硫酸镁干燥,蒸发。剩余物用硅胶柱色谱分离,用氯仿和乙酸乙酯(4∶1)的混合物洗脱,得到4-[1-(4-羟基苯甲酰基)中氮茚-3-基]丁酸乙酯(344mg),黄色固体。
NMR(DMSO-d6,δ):1.14(3H,t,J=7Hz),1.85-2.03(2H,m),2.41(2H,t,J=7Hz),2.93(2H,t,J=7Hz),4.01(2H,q,J=7Hz),6.84-7.06(4H,m),7.19-7.30(1H,m),7.67(2H,d,J=8Hz),8.25-8.40(2H,m)
制备9
按类似于制备8的方法,制得下述化合物
(1)4-[1-(3-羟基苯甲酰基)中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):1.25(3H,t,J=7Hz),1.97-2.15(2H,m),2.43(2H,t,J=7Hz),2.88(2H,t,J=7Hz),4.13(2H,q,J=7Hz),6.86-6.97(2H,m),6.99-7.09(1H,m),7.16-7.37(3H,m),7.48(1H,s),8.01(1H,d,J=7Hz),8.50(2H,m,J=9Hz)
(2)4-[3-(4-羟基苯甲酰基)中氮茚-1-基]丁酸乙酯
NMR(CDCl3,δ):1.24(3H,t,J=7Hz),1.92-2.10(2H,m),2.38(2H,t,J=7Hz),2.79(2H,t,J=7Hz),4.13(2H,q,J=7Hz),6.86-6.98(3H,m),7.12-7.25(2H,m),7.55(1H,d,J=9Hz),7.67-7.78(2H,m)
(3)4-[3-(3-羟基苯甲酰基)中氮茚-1-基]丁酸乙酯
NMR(CDCl3,δ):1.23(3H,t,J=7Hz),1.90-2.08(2H,m),2.34(2H,t,J=7Hz),2.76(2H,t,J=7Hz),4.12(2H,q,J=7Hz),6.87-7.07(3H,m),7.13-7.40(5H,m),7.55(1H,d,J=9Hz)
制备10
0℃下,向三氯化铝(6.67g)在二氯甲烷(70ml)的悬浮液中加入己酰氯(7.0ml)。混合物在0℃下搅拌15分钟后,将异丁基苯(7.9ml)加入混合物中。混合物在0℃下搅拌30分钟后倒入冰水中。有机层用水、碳酸氢钠水溶液和盐水洗涤。溶液用硫酸镁干燥,蒸发,得4′-异丁基己酰苯酮(10.52g),无色油状物。
NMR(CDCl3,δ):0.84-0.98(9H,m),1.30-1.43(4H,m),1.60-2.01(3H,m),2.53(2H,d,J=8.5Hz),2.94(2H,t,J=7Hz),7.22(2H,d,J=8.5Hz),7.88(2H,d,J=8.5Hz)
制备11
向4′-异丁基己酰苯酮(10.5g)的2-丙醇(60ml)溶液中加入硼氢化钠(2.05g),混合物在50℃下搅拌6小时。将混合物倒入冰水中,用6N盐酸酸化。水溶液用乙酸乙酯取提,有机层用水和盐水洗涤,用硫酸镁干燥,蒸发,得到1-(4-异丁基苯基)己-1-醇(9.32g),无色油状物。
NMR(CDCl3,δ):0.83-0.96(9H,m),1.16-1.40(6H,m),1.60-1.96(3H,m),2.48(2H,d,J=7Hz),4.64(1H,t,J=7Hz),7.11(2H,d,J=8.5Hz),7.25(2H,d,J=8.5Hz)
制备12
向1-(4-异丁基苯基)己-1-醇(9.15g)和四溴化碳(25.9g)的四氢呋喃(250ml)溶液中加入三苯膦(20.5g)。混合物在室温下搅拌6小时。滤出白色固体后,将滤液蒸发。将正己烷(300ml)加入剩余物中,滤出沉淀,将滤液蒸发,剩余的油进行减压蒸发,得到1-(1-溴己基)-4-异丁基苯(3.52g),无色油状物。
NMR(CDCl3,δ):0.82-0.97(9H,m),1.20-1.60(8H,m),1.74-1.97(1H,m),2.00-2.38(2H,m),2.46(2H,d,J=7Hz),4.96(1H,t,J=7.5Hz),7.10(2H,d,J=8.5Hz),7.29(2H,d,J=8.5Hz)
制备13
将搅拌着的氢化钠(3.04g;60%,在矿物油中)的三甲亚矾(100ml)悬浮液在80℃下加热40分钟。然后将溶液冷却。然后室温下分批加入(3-羧基丙基)三苯鏻氯化物(15.9g)。30分钟后。30分钟后,室温下加入2-吡啶甲醛(3.96g),然后混合物搅拌2小时。将水加混合物中,并用1N盐酸酸化至PH等于5。混合物用乙醚提取,合并有机层,用盐水洗涤,干燥,浓缩。剩余物用硅胶色谱分离(乙酸乙酯∶甲醇=10∶1),得(4E)-5-(2-吡啶基)-4-戊酸(1.6g)。
NMR(CDCl3,δ):2.5-2.8(4H,m),6.6-6.9(2H,m),7.19(1H,m),7.37(1H,d,J=8Hz),7.70(1H,dt,J=1Hz,8Hz),8.59(1H,d,J=5Hz)
制备14
向(4E)-5-(2-吡啶基)-4-戊酸(1.6g)的乙醇(50ml)溶液中加入d-樟脑-10-磺酸(2.3g),混合物用含3A分子筛的回流冷凝管加热回流。2小时后,将混合物蒸发,用饱和碳酸氢钠水溶液稀释,然后用乙酸乙酯提取。有机层用盐水洗涤,用硫酸钠干燥,真空蒸发,得到(4E)-5-(2-吡啶基)-4-戊酸乙酯(1.84g)。
NMR(CDCl3,δ):1.26(3H,t,J=7Hz),2.45-2.7(4H,m),4.16(2H,q,J=7Hz),6.53(1H,d,J=16Hz),6.75(1H,dt,J=16Hz,7Hz),7.11(1H,m),7.25(1H,d,J=8Hz),7.63(1H,dt,J=1Hz,8Hz),8.55(1H,d,J=4Hz)
制备15
向(4E)-5-(2-吡啶基)-4-戊酸乙酯(1.84g)的乙醇(15ml)溶液中加入10%钯/碳(145mg),混合物在氢气气氛(4atm)搅拌3小时,然后用硅藻土垫子过滤。真空除去溶剂,得到5-(2-吡啶基)戊酸乙酯(1.84g)。
NMR(CDCl3,δ):1.23(3H,t,J=7Hz),1.6-1.9(4H,m),2.34(2H,t,J=7Hz),2.82(2H,t,J=7Hz),4.12(2H,q,J=7Hz),7.05-7.2(2H,m),7.62(1H,dt,J=1Hz,8Hz),8.52(1H,d,J=4Hz)
制备16
向5-(2-吡啶基)戊酸乙酯(1.07g)的溴丙酮(5ml)溶液中加入溴丙酮(0.51ml),混合物回流2小时。除去溶剂后,将剩余物溶于碳酸氢钠(1g碳酸氢钠/20ml水)水溶液中,然后回流30分钟。混合物用乙酸乙酯提取。合并有机层,用盐水洗涤,用硫酸钠干燥真空蒸发,用硅胶色谱分离(二氯甲烷)得4-(2-甲基中氮茚-1-基)丁酸乙酯(778mg)。
NMR(CDCl3,δ):1.24(3H,t,J=7Hz),1.91(2H,m),2.23(3H,s),2.32(2H,t,J=7Hz),2.74(2H,t,J=7Hz),4.11(2H,q,J=7Hz),6.32(1H,dt,J=1Hz,7Hz),6.53(1H,m),7.08(1H,s),7.21(1H,d,J=9Hz),7.76(1H,dt,J=7Hz,1Hz)
制备17
按类似于制备1的方法,制得了下述化合物。
4-(2-甲基中氮茚-3-基)-4-氧丁酸乙酯
NMR(CDCl3,δ):1.28(3H,t,J=7Hz),2.65(3H,s),2.79(2H,t,J=7Hz),3.19(2H,t,J=7Hz),4.18(2H,q,J=7Hz),6.34(1H,s),6.78(1H,dt,J=1Hz,7Hz),7.10(1H,m),7.40(1H,d,J=8Hz),9.98(1H,d,J=7Hz)
制备18
按类似于制备2的方法,制得了下述化合物。
4-(2-甲基中氮茚-3-基)丁酸乙酯
NMR(CDCl3,δ):1.24(3H,t,J=7Hz),1.90(2H,m),2.28(3H,s),2.35(2H,d,J=7Hz),2.91(2H,d,J=7Hz),4.12(2H,q,J=7Hz),6.25(1H,m),6.47(1H,m),6.60(1H,m),7.28(1H,d,J=8Hz),7.79(1H,m)
制备19
按类似于制备4的方法制得了下述化合物。
(1)4-[2-甲基-3-(4-硝基苯甲酰基)中氮茚-1-基]丁酸乙酯
NMR(CDCl3,δ):1.23(3H,t,J=7Hz),1.79(3H,s),1.86(2H,m),2.34(2H,t,J=7Hz),2.72(2H,t,J=7Hz),4.11(2H,q,J=7Hz),6.92(1H,dt,J=1Hz,7Hz),7.24(1H,m),7.52(1H,d,J=9Hz),7.74(2H,d,J=9Hz),8.34(2H,d,J=9Hz),9.87(1H,d,J=8Hz)
(2)4-[2-甲基-3-(3-硝基苯甲酰基)中氮茚-1-基]丁酸乙酯
NMR(CDCl3,δ):1.24(3H,t,J=7Hz),1.84(3H,s),1.88(2H,m),2.35(2H,t,J=7Hz),2.73(2H,t,J=7Hz),4.13(2H,q,J=7Hz),6.90(1H,dt,J=1Hz,7Hz),7.22(1H,m),7.52(1H,d,J=9Hz),7.68(1H,t,J=8Hz),7.93(1H,m),8.37(1H,m),8.46(1H,m),9.83(1H,d,J=7Hz)
(3)4-[2-甲基-1-(4-硝基苯甲酰基)中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):1.27(3H,t,J=7Hz),1.91(2H,m),2.19(3H,s),2.41(2H,t,J=7Hz),2.93(2H,t,J=7Hz),4.15(2H,q,J=7Hz),6.84(1H,dt,J=1Hz,7Hz),7.02(1H,m),7.51(1H,dt,J=9Hz,1Hz),7.80(2H,d,J=8Hz),8.09(1H,d,J=7Hz),8.32(2H,d,J=8Hz)
(4)4-[2-甲基-1-(3-硝基苯甲酰基)中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):1.26(3H,t,J=7Hz),1.92(2H,m),2.20(3H,s),2.42(2H,t,J=7Hz),2.94(2H,t,J=7Hz),4.17(2H,q,J=7Hz),6.84(1H,dt,J=1Hz,7Hz),7.02(1H,m),7.53(1H,dt,J=8Hz,1Hz),7.68(1H,t,J=8Hz),8.0-8.15(2H,m),8.38(1H,m),8.50(1H,m)
制备20
按类似于制备6的方法,制得了下述化合物。
(1)4-[3-(4-氨基苯甲酰基)-2-甲基中氮茚-1-基]丁酸乙酯
NMR(CDCl3,δ):1.24(3H,t,J=7Hz),1.88(2H,m),1.99(3H,s),2.34(2H,t,J=7Hz),2.73(2H,t,J=7Hz),4.11(2H,q,J=7Hz),6.64-6.75(1H,m),6.68(2H,d,J=8Hz),7.00(1H,m),7.42(1H,dt,J=9Hz,1Hz),7.53(2H,d,J=8Hz),9.88(1H,d,J=7Hz)
(2)4-[3-(3-氨基苯甲酰基)-2-甲基中氮茚-1-基]丁酸乙酯
NMR(CDCl3,δ):1.22(3H,t,J=7Hz),1.75-1.95(2H,m),1.89(3H,s),2.32(2H,t,J=7Hz),2.72(2H,t,J=7Hz),4.11(2H,q,J=7Hz),6.78(1H,dt,J=1Hz,7Hz),6.85-7.3(5H,m),7.44(1H,d,J=9Hz),9.69(1H,d,J=7Hz)
(3)4-[1-(4-氨基苯甲酰基)-2-甲基中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):1.25(3H,t,J=7Hz),1.91(2H,m),2.29(3H,s),2.39(2H,t,J=7Hz),2.93(2H,t,J=7Hz),4.15(2H,q,J=7Hz),6.69(1H,dt,J=7Hz),6.7-6.9(3H,m),7.46(1H,d,J=9Hz),7.64(2H,d,J=8Hz),7.96(1H,d,J=7Hz)
(4)4-[1-(3-氨基苯甲酰基)-2-甲基中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):1.27(3H,t,J=7Hz),1.92(2H,m),2.28(3H,s),2.39(2H,t,J=7Hz),2.93(2H,t,J=7Hz),4.14(2H,q,J=7Hz),6.72(1H,dt,J=1Hz,7Hz),6.8-6.95(2H,m),7.0-7.1(2H,m),7.21(1H,t,J=8Hz),7.46(1H,dt,J=8Hz,1Hz),7.99(1H,d,J=7Hz)
制备21
将N,N′-二甲基甲酰胺(0.5ml)加入4-乙酰氧基苯甲酸(50g)和草酰氯(27ml)的二氯甲烷(500ml)溶液中。混合物在室温下搅拌2小时。蒸去溶剂,将剩余物溶于正己浣(200ml)中。过滤后,将溶液蒸发,得到4-乙氧基苯甲酰氯,黄色油状物(55.1g)。
NMR(CDCl3,δ):2.35(3H,s),7.27(2H,d,J=9Hz),8.16(2H,d,J=9Hz)
制备22
将4-乙酰氧基苯甲酰氯(53.6g)加入三氯化铝(3.65g)的二氯甲烷(500ml)分散体系中。混合物在室温下搅拌20分钟后,将4-(中氮茚-3-基)丁酸乙酯(57.8g)的二氯甲烷(500ml)溶液加入其中。混合物在室温下搅拌2小时后,将溶剂蒸发。将剩余物溶于乙酸乙酯(50ml)中,然后用盐水洗涤。将N,N-二甲基氨基丙胺(20ml)加入溶液中。混合物用稀盐酸、水、碳酸氢钠水溶液和水洗涤。溶液用硫酸镁干燥,真空除去溶剂。剩余物用二异丙醚洗涤,得到4-[1-(4-乙酰氧基苯甲酰基)中氮茚-3-基]丁酸乙酯,黄色粉末(36.5g)。
NMR(CDCl3,δ):1.25(3H,t,J=7Hz),2.0-2.2(2H,m),2.35(3H,s),2.43(2H,t,J=7Hz),2.90(2H,t,J=7Hz),4.12(2H,q,J=7Hz),6.85-7.0(2H,m),7.15-7.3(1H,m),7.25(2H,d,J=8Hz),7.88(2H,d,J=8Hz),8.03(1H,d,J=7Hz),8.52(1H,d,J=9Hz)
制备23
将氢化钠(60%,分散在矿物油中)(4.38g)加入冰冻的4-[1-(4-乙酰氧基苯甲酰基)中氮茚-3-基]丁酸乙酯(36.1g)在乙醇(200ml)和四氢呋喃(200ml)的混合物中的溶液。混合物在0℃下搅拌20分钟,蒸发。将剩余溶液倒入稀盐酸和冰的混合物中,用氯仿和甲醇(10∶1)的混合物提取。有机层用碳酸氢钠水溶液和盐水洗涤,用硫酸镁干燥,蒸发。剩余物用乙酸乙酯和二乙醚洗涤,得到4-[1-(4-羟基苯甲酰基)中氮茚-3-基]丁酸乙酯,黄色粉末(29.3g)。
NMR(CDCl3,δ):1.25(3H,t,J=7Hz),2.0-2.2(2H,m),2.45(2H,t,J=7Hz),2.89(2H,t,J=7Hz),4.15(2H,q,J=7Hz),6.8-7.0(4H,m),7.18(1H,t,J=9Hz),7.78(2H,d,J=8.5Hz),8.00(1H,d,J=5.5Hz),8.50(1H,d,J=9Hz)
制备24
在25℃下,将4′-异丁基苯丁酮(1.2g)加入(+)-B-氯二异松蒎基硼烷(2.10g)的四氢呋喃(4ml)溶液中。5小时后,除去溶剂,剩余物溶于乙醚(20ml)中。将二乙醇胺(1.4ml)加入混合物中,将混合物搅拌2小时。滤出固体,用乙醚洗涤。将合并的滤液浓缩,剩余物用硅胶色谱分离(洗脱液∶己烷∶CHCl=1∶2),得到(R)-1-(4-异丁基苯基)丁-1-醇(937mg)。
NMR(CDCl3,δ):0.89(6H,d,J=7Hz),0.92(3H,t,J=7Hz),1.2-1.5(4H,m),1.6-2.0(3H,m),2.47(2H,d,J=7Hz),4.63(1H,t,J=7Hz),7.11(2H,d,J=8Hz),7.25(2H,d,J=8Hz)
制备25
按类似于制备24的方法,用(-)-B-氯二异松蒎基硼烷处理4′-异丁基苯丁酮,得到下化合物。
(S)-1-(4-异丁基苯基)丁-1-醇
NMR(CDCl3,δ):0.85-1.0(9H,m),1.15-1.95(5H,m),2.47(2H,d,J=7Hz),4.66(1H,t,J=7Hz),7.12(2H,d,J=8Hz),7.25(2H,d,J=8Hz)
制备26
向氯三甲基硅烷(16.3g)和三乙胺(30.3g)的N,N-二甲基甲酰胺(50ml)溶液中加入4′-异丁基乙酰基苯(22.0g)。立刻滤出黄色固体,将滤液回流20小时。将混合物冷却,用己烷稀释,用冷的碳酸氢钠水溶液洗涤。有机层用硫酸镁干燥,浓缩。剩余物减压蒸馏,得到4-异丁基-2-三甲基甲硅烷氧基苯乙烯(9.0g),油状物。
NMR(CDCl3,δ):0.16(9H,s),1.65-1.85(1H,m),2.35(2H,d,J=7Hz),4.27(1H,d,J=1.5Hz),4.76(1H,d,J=1.5Hz),6.98(2H,d,J=8.5Hz),7.38(2H,d,J=8.5Hz)
制备27
将亚碘酰苯(2.18g)溶于乙醇(45ml),然后将三氟化硼乙醚化物(2.55g)加入其中。混合物在-70℃下搅拌,然后加入4-异丁基-2-三甲基甲硅烷氧基苯乙烯(2.24g)加入其中。混合物在-70℃下搅拌30分钟,然后将温度缓慢升至室温。蒸掉乙醇,然后加入水。混合物用碳酸氢钠水溶液中和。混合物用二氯甲烷提取,有机相用硫酸镁干燥,浓缩。剩余物用硅胶柱色谱分离,用己烷-乙酸乙酯(94∶6)洗脱,得到4′-异丁基-2-乙氧基乙酰苯(1.90g),油状物。
NMR(CDCl3,δ):0.91(6H,d,J=7Hz),1.30(3H,t,J=7Hz),1.80-2.0(1H,m),2.53(2H,d,J=7Hz),3.65(2H,q,J=7Hz),4.74(2H,s),7.24(2H,d,J=8Hz),7.87(2H,d,J=8Hz)
制备28
按类似于制备24的方法,用(-)-B-氯二异松蒎基硼烷处理4′-异丁基-2-乙氧基乙酰苯,制得下述化合物。
(R)-1-(4-异丁基苯基)-2-乙氧基乙醇
NMR(CDCl3,δ):0.89(6H,d,J=7Hz),1.25(3H,t,J=7Hz),1.75-1.95(1H,m),2.47(2H,d,J=7Hz),3.35-3.7(4H,m),4.87(1H,dd,J=5.5Hz,6.5Hz),7.13(2H,d,J=8.5Hz),7.29(2H,d,J=8.5Hz)
制备29
按类似于制备24的方法,用(+)-B-氯二异松蒎基硼烷处理4′-异丁基-2-乙氧基乙酰苯,制得了下述化合物。
(S)-1-(4-异丁基苯基)-2-乙氧基乙醇
NMR(CDCl3,δ):0.89(6H,d,J=7Hz),1.25(3H,t,J=7Hz),1.75-1.95(1H,m),2.47(2H,d,J=7Hz),2.79(1H,s),3.35-3.7(4H,m),4.87(1H,dd,J=5.5Hz,6.5Hz),7.13(2H,d,J=8.5Hz),7.29(2H,d,J=8.5Hz)
制备30
按类似于实施例1的方法,制得了下述化合物。
(1)4-[1-[3-(苄氧基羰基甲基氨基)苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):1.23(3H,t,J=7Hz),2.05(2H,m),2.42(2H,t,J=7Hz),2.86(2H,t,J=7Hz),4.07(2H,s),4.11(2H,q,J=7Hz),5.21(2H,s),6.8-7.0(3H,m),7.1-7.4(9H,m),8.01(1H,d,J=8Hz),8.48(1H,d,J=9Hz)
(2)4-[1-[3-(1-苄氧基羰基羰基乙基)氨基苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):1.24(3H,t,J=7Hz),1.52(3H,d,J=7Hz),2.05(2H,m),2.42(2H,t,J=7Hz),2.85(2H,t,J=7Hz),4.12(2H,q,J=7Hz),4.27(1H,q,J=7Hz),5.16(2H,s),6.7-7.0(3H,m),7.1-7.4(9H,m),8.00(1H,d,J=7Hz),8.48(1H,d,J=9Hz)
制备31
向4-[1-[3-[(1-苄氧基羰基乙基)氨基]苯甲酰基]中氮茚-3-基]丁酸乙酯(0.20g)的乙醇(10ml)溶液中,加入10%钯/碳(0.1g)。混合物在室温、氢气气氛下搅拌2小时。除去催化剂,蒸去溶剂,得到4-[1-[3-(1-羧基乙基氨基)苯甲酰基]中氮茚-3-基]丁酸乙酯(0.15g),黄色粉末。
NMR(CDCl3,δ):1.25(3H,t,J=7Hz),1.57(3H,d,J=7Hz),2.0-2.3(2H,m),2.50(2H,t,J=7Hz),2.83(2H,t,J=7Hz),4.16(3H,q,J=7Hz),6.8-7.0(3H,m),7.1-7.4(4H,m),7.96(1H,d,J=7Hz),8.55(1H,d,J=9Hz)
制备32
按类似于制备31的方法,制得了下述化合物。
4-[1-(3-羧甲基氨基苯酰基)中氮茚-3-基)丁酸乙酯
NMR(CDCl3,δ):1.28(3H,t,J=7Hz),2.15(2H,m),2.50(2H,t,J=7Hz),2.83(2H,t,J=7Hz),4.00(2H,s),4.17(2H,q,J=7Hz),6.8-7.1(3H,m),7.2-7.4(4H,m),7.96(1H,d,J=7Hz),8.55(1H,d,J=9Hz)
制备33
0℃下,氮气气氛中,向(环丙基甲基)苯(1.32g)、二氯甲基甲基醚(1.25ml)与二氯甲烷(20ml)的混合物中,加入1.0M四氯化钛(Ⅳ)的二氯甲烷(15ml)溶液。混合物在0℃下搅拌10分钟,然后倒入冰水中。分出有机层,用水洗涤,用硫酸镁干燥,浓缩。剩余物用硅胶柱色层分离,用己烷和乙酸乙酯(9∶1)的混合物洗脱,得到4-(环丙基甲基)苯甲醛(580mg),油状物。
NMR(CDCl3,δ):0.5-0.65(2H,m),0.9-1.2(1H,m),2.63(2H,d,J=7Hz),7.43(2H,d,J=8.5Hz),7.82(2H,d,J=8.5Hz),9.99(1H,s)
制备34
0℃下,向溴化烯丙基镁(1.0M,在二乙醚中,3ml)的二乙醚(5ml)溶液中滴加4-(环丙基甲基)苯甲醛(240mg)的二乙醚(2ml)溶液。15分钟后,反应混合物用氯化铵水溶液骤冷,得到的混合物用乙酸乙酯提取。有机层用水洗涤,用硫酸镁干燥,浓缩。剩余物硅胶柱色谱分离,用己烷和乙酸乙酯(85∶15)混合物洗脱,得到1-[4-(环丙基甲基)苯基]-3-丁-1-醇(229mg),油状物。
NMR(CDCl3,δ):0.45-0.6(2H,m),0.85-1.2(1H,m),2.55(2H,d,J=6.5Hz),4.72(1H,t,J=6.5Hz),5.1-5.25(2H,m),5.7-5.95(1H,m),7.15-7.35(4H,m)
制备35
按类似于制备34的方法,制得了下述化合物。
1-(4-异丁基苯基)-3-丁-1-醇
NMR(CDCl3,δ):0.89(6H,d,J=7Hz),1.85(1H,m),2.47(2H,d,J=7Hz),2.52(2H,m),4.72(1H,m),5.1-5.25(2H,m),5.83(1H,m),7.13(2H,d,J=8Hz),7.27(2H,d,J=8Hz)
制备36
0℃下,向吡啶(1.98ml)的二氯甲烷(15ml)溶液中加入三氧化铬(Ⅵ)(1.23g)。30分钟后,加入1-(4-异丁基苯基)-3-丁-1-醇(525mg)的二氯甲烷(2ml)溶液,然后室温下搅拌20分钟。反应混合物用Florisil过滤,用乙醚洗涤。滤液真空浓缩,用硅胶色谱分离(己烷∶二氯甲烷=1∶1),得到1-(4-异丁基苯基)-3-丁烯-1-酮
NMR(CDCl3,δ):0.92(6H,d,J=7Hz),1.90(1H,m),2.53(2H,d,J=7Hz),3.75(2H,dt,J=7.1Hz),5.18(1H,m),5.25(1H,m),6.10(1H,m),7.23(2H,d,J=8Hz),7.89(2H,d,J=8Hz)
制备37
将2-羟基-4-甲基苯甲酸(7.61g)、碘甲烷(15.6ml)、碳酸钾(17.3g)与N,N-二甲基甲酰胺(100ml)的混合物在室温下搅拌5小小。过滤,将滤液倒入乙酸乙酯和水的混合物中。分出有机层,用水和盐水洗涤,用硫酸镁干燥,浓缩。剩余物用硅胶柱色谱分离,用正己烷和乙酸乙酯(4∶1)的混合物洗脱,得到2-甲氧基-4-甲基苯甲酸乙酯(7.99g),油状物。
NMR(CDCl3,δ):2.39(3H,s),3.88(3H,s),3.90(3H,s),6.75-6.85(2H,m),7.73(1H,d,J=8.5Hz)
制备38
按与制备37类似的方法,制得下述化合物。
3-甲氧基-4-甲基苯甲酸甲酯
NMR(CDCl3,δ):2.27(3H,s),3.88(3H,s),3.91(3H,s),7.18(1H,d,J=8Hz),7.45-7.6(2H,m)
制备39
将2-甲氧基-4-甲基苯甲酸甲酯(6.95g)、N-溴琥珀酰亚胺(8.24g)和催化量的过氧化苯甲酰(20mg)的四氯化碳(100ml)溶液的混合物加热回流2小时。反应混合物冷至室温,然后过滤。将滤液浓缩,剩余物用硅胶柱色谱分离,用正己烷和乙酸乙酯(85∶15)的混合物洗脱,得到4-溴甲基-2-甲氧基苯甲酸甲酯(2.92g),油状物。
NMR(CDCl3,δ):3.89(3H,s),3.93(3H,s),4.47(2H,s),6.95-7.05(2H,m),7.77(1H,d,J=8.5Hz)
制备40
按类似于制备39的方法,制得了下述化合物。
4-溴甲基-3-甲氧基苯甲酸甲酯
NMR(CDCl3,δ):3.93(3H,s),3.97(3H,s),4.56(2H,s),7.40(1H,d,J=8Hz),7.5-7.65(2H,m)
制备41
在氮气气氛下,将4-溴甲基-3-甲氧基苯甲酸酯(1.55g)和三乙基亚磷酸酯(1.54ml)的混合物在50℃下加热30分钟。然后将温度升至200℃保持2小时。将得到的亮黄色液体冷却,用硅胶柱色谱分离,和乙酸乙酯洗脱,得到(3-甲氧基-4-甲氧基羰基苄基)膦酸二乙酯(1.28g),油状物。
NMR(CDCl3,δ):1.2-1.4(6H,m),3.18(2H,d,J=22Hz),3.88(3H,s),3.92(3H,s),3.95-4.2(4H,m),6.85-7.0(2H,m),7.77(1H,d,J=8Hz)
制备42
按类似于制备41的方法制得了下述化合物。
(2-甲氧基-4-甲氧基羰基苄基)膦酸二乙酯
NMR(CDCl3,δ):1.24(6H,t,J=7Hz),3.29(2H,d,J=22Hz),3.89(3H,s),3.91(3H,s),3.95-4.1(4H,m),7.38(1H,dd,J=8Hz,3Hz),7.5-7.65(2H,m)
制备43
向(3-甲氧基-4-甲氧基羰基苄基)膦酸二乙酯(1.28g)、丙酮(1.5ml)与N,N-二甲基甲酰胺(5ml)的混合物中加入60%氢化钠-油分散体(162mg)。反应混合物在室温下搅拌14小时,然后将其倒入冰冻的10%柠檬酸中。混合物用乙醚提取,有机层用水和盐水洗涤,用硫酸镁干燥,浓缩。剩余物用硅胶柱色谱分离,用正己烷和乙酸乙酯(85∶15)的混合物洗脱,得到2-甲氧基-4-(2-甲基-1-丙烯基)苯甲酸甲酯(184mg),油状物。
NMR(CDCl3,δ):1.89(3H,d,J=1.5Hz),1.93(3H,d,J=1.5Hz),3.8(3H,s),3.91(3H,s),6.27(1H,s),6.8-6.9(2H,m),7.78(1H,d,J=8Hz)
制备44
按类似于制备43的方法,制得了下述化合物。
3-甲氧基-4-(2-甲基-1-丙烯基)苯甲酸甲酯
NMR(CDCl3,δ):1.83(3H,d,J=1.5Hz),1.97(3H,d,J=1.5Hz),3.89(3H,s),3.92(3H,s),6.33(1H,s),7.25(1H,d,J=8Hz),7.52(1H,d,J=1.5Hz),7.62(1H,dd,J=8Hz,1.5Hz)
制备45
向2-甲氧基-4-(2-甲基-1-丙烯基)苯甲酸甲酯(178mg)的甲醇(3ml)和1,4-二噁烷(3ml)溶液中,加入1N氢氧化钠水溶液(2ml)。混合物在50℃下搅拌3小时,然后倒入乙酸乙酯与0.5N盐酸的混合物中。分出有机层,用水和盐水洗涤。用硫酸镁干燥。蒸去溶剂,得到2-甲氧基-4-(2-甲基-1-丙烯基)苯甲酸(142mg),固体。
NMR(CDCl3,δ):1.91(3H,d,J=1.5Hz),1.95(3H,d,J=1.5Hz),4.08(3H,s),6.27(1H,s),6.87(1H,s),7.01(1H,dd,J=1.5Hz,8Hz),8.12(1H,d,J=8Hz)
制备46
按类似于制备45的方法,制得了下述化合物。
3-甲氧基-4-(2-甲基-1-丙烯基)苯甲酸
NMR(CDCl3,δ):1.85(3H,s),1.97(3H,s),3.90(3H,s),6.34(1H,s),7.28(1H,d,J=8Hz),7.58(1H,s),7.70(1H,d,J=8Hz)
制备47
将1-碘丁烷(185mg)、在苯(3ml)中的锌-铜偶合体(101mg)和N,N-二甲基甲酰胺(0.2ml)的混合物在60℃下搅拌2小时。将四(三苯膦)钯(31mg)、2-甲氧基-4-(2-甲基-1-丙烯基)苯甲酰氯[由138mg 2-甲氧基-4-(2-甲基-1-丙烯基)苯甲酸和0.07ml草酰氯制得]的苯(2ml)溶液加入上述混合物中,反应混合物在室温下搅拌30分钟。将混合物过滤,滤液浓缩。剩余物溶于乙酸乙酯中,有机溶液用水和盐水洗涤,用硫酸镁干燥,浓缩。剩余物用硅胶柱色谱分离,用己烷和乙酸乙酯(9∶1)混合物洗脱,得到2′-甲氧基-4′-(2-甲基-1-丙烯基)苯戊酮(91mg),油状物。
NMR(CDCl3,δ):0.93(3H,t,J=7.5Hz),1.25-1.5(2H,m),1.55-1.75(2H,m),1.90(3H,d,J=1.5Hz),1.93(3H,d,J=1.5Hz),2.97(2H,t,J=7.5Hz),3.89(3H,s),6.27(1H,s),6.78(1H,s),6.87(1H,d,J=8Hz),7.66(1H,d,J=8Hz)
制备48
按类似于制备47的方法制得了下述化合物。
3′-甲氧基-4′-(2-甲基-7-丙烯基)苯戊酮。
NMR(CDCl3,δ):0.97(3H,t,J=7.5Hz),1.3-1.55(2H,m),1.6-1.8(2H,m),1.84(3H,d,J=1.5Hz),1.97(3H,d,J=1.5Hz),2.97(2H,t,J=7.5Hz),3.90(3H,s),6.33(1H,s),7.26(1H,d,J=8Hz),7.45-7.6(2H,m)
制备49
将2′-甲氧基-4′-(2-甲基-1-丙烯基)苯戊酮(88mg)和10%钯/碳(30mg)的混合物在氢气气氛中搅拌30分钟。滤去催化剂,滤液浓缩。将剩余物溶于甲醇(5ml)中,然后加入氢硼化钠(16mg)。反应混合物在室温下搅拌30分钟。将混合物倒入冰水中,用6N盐酸酸化,用乙酸乙酯提取。有机层用水、盐水洗涤,用硫酸镁干燥,浓缩,得到1-(4-异丁基-2-甲氧基苯基)戊醇(88mg),油状物。
NMR(CDCl3,δ):0.8-0.95(9H,m),1.2-1.55(4H,m),1.65-2.0(3H,m),2.46(2H,d,J=7Hz),2.54(1H,d,J=6.5Hz),3.85(3H,s),4.81(1H,dd,J=6Hz,13Hz),6.65(1H,s),6.73(1H,d,J=8Hz),7.17(1H,d,J=8Hz)
制备50
按类似于制备49的方法,制得了下述化合物。
1-(4-异丁基-3-甲氧基苯基)戊醇
NMR(CDCl3,δ):0.8-0.95(9H,m),1.2-1.5(4H,m),1.65-2.0(4H,m),2.47(2H,d,J=7Hz),3.82(3H,s),4.55-4.7(1H,m),6.75-6.9(2H,m),7.04(1H,d,J=7Hz)
制备51
将(4-溴-2-氟苄基)三苯基鏻溴化物(3.82g)和叔丁基氧化钾(78mg)混合物在室温下搅拌30分钟。然后加入丙酮(1.0ml),反应混合物加热回流40小时。过滤,将滤液浓缩。将剩余物溶于乙酸乙酸中,用水、盐水洗涤,用硫酸镁干燥,蒸去溶剂。剩余物用硅胶柱色谱分离,用己烷洗脱,得到1-(4-溴-2-氟苯基)-2-甲基-1-丙烯(0.70g),油状物。
NMR(CDCl3,δ):1.77(3H,s),1.92(3H,s),6.12(1H,s),7.0-7.3(3H,m)
制备52
按常规方法,用乙醚(10ml)、镁(82mg)和1-(2-氟-4-溴苯基)-2-甲基-1-丙烯(0.70g)制得3-氟-4-(2-甲基-1-丙烯基)苯基镁溴化物的溶液。将戊醛(526mg)的乙醚(5ml)溶液滴加到格利雅溶液中。混合物在室温下搅拌30分钟。将氯化铵水溶液加入反应混合物中,分出有机层,用水、盐水洗涤,硫酸镁干燥,浓缩。剩余物用硅胶柱色谱分离,用己烷和乙酸乙酯(85∶15)的混合物洗脱,得到1-[3-氟-4-(2-甲基-1-丙烯基)苯基]戊醇(369mg),油状物。
NMR(CDCl3,δ):0.88(3H,t,J=6.5Hz),1.15-1.5(4H,m),1.6-1.85(5H,m),1.92(3H,s)
制备53
在室温、氢气气氛下,将1-[3-氟-4-(2-甲基-1-丙烯基)苯基]戊醇(300mg)、10%钯/碳(90mg)与甲醇10ml的混合物搅拌30分钟。过滤除去催化剂,蒸去溶剂。剩余物用硅胶柱色谱分离,用己烷和乙酸乙酯(85∶15)的混合物洗脱,得到1-(3-氟-4-异丁基苯基)戊醇(167mg),油状物。
NMR(CDCl3,δ):0.8-0.95(9H,m),1.15-1.5(4H,m),1.6-2.0(4H,m),2.49(2H,dd,J=1Hz,7.5Hz),4.55-4.7(1H,m),6.95-7.2(3H,m)
制备54
将钠(317mg)溶于乙醇(30ml)中,然后加入2-硝基丙烷(1.24ml)。将4-溴-2-氟苄基溴化物(3.55g)与乙醇(10ml)的混合物加入其中,反应混合物在室温下搅拌3小时,滤去不溶物。将滤液浓缩,剩余物溶于二乙醚和水中。有机层用1N氢氧化钠和水洗涤,用硫酸镁干燥,浓缩。剩余物用硅胶柱色谱分离,用己烷和乙酸乙酯(20∶1)的混合物洗脱,得到4-溴-2-氟苯甲醛(2.28g),固体。
NMR(CDCl3,δ):7.35-7.55(2H,m),7.7-7.85(1H,m)
制备55
按常用方法,用二乙醚(5ml)、镁(111mg)和1-溴丁烷(624mg)制得溴化丁基镁溶液。将4-溴-2-氟苯甲醛(925mg)的二乙醚(5ml)溶液滴加到格利雅溶液中。加完后,反应混合物在室温下搅拌30分钟。反应混合物用氯化铵水溶液骤冷,分出有机层,用水、盐水洗涤,用硫酸镁干燥,浓缩。剩余物用硅胶柱色谱分离,用己烷和乙酸乙酯(85∶15)的混合物洗脱,得到1-(4-溴-2-氟苯基)戊醇(635mg),油状物。
NMR(CDCl3,δ):0.90(3H,t,J=7Hz),1.2-1.5(4H,m),1.65-1.9(3H,m),4.9-5.05(1H,m),7.15-7.45(3H,m)
制备56
1-(4-溴-2-氟苯基)戊醇(630mg)、氯甲基甲基醚(196mg)和三乙胺(246mg)的混合物在室温下搅拌3小时。将混合物倒入冰水中,用乙酸乙酯提取。有机层用0.5N盐酸、水和盐水洗涤,用硫酸镁干燥,浓缩。剩余物用硅胶柱色谱分离,用己烷和乙酸乙酯(19∶1)混合物洗脱,得1-(4-溴-2-氟苯基)-1-(甲氧基甲氧基)戊烷(558mg),油状物。
NMR(CDCl3,δ):0.89(3H,t,J=7Hz),1.2-1.5(4H,m),1.6-1.9(2H,m),3.36(3H,s),4.5-4.6(2H,m),4.88(1H,dd,J=5.5Hz,8Hz),7.15-7.35(3H,m)
制备57
向1-(4-溴-2-氟苯基)-1-(甲氧基甲氧基)戊烷(368mg)的二乙醚(5ml)溶液中,加入1.6M正丁基锂(1.4)的己烷溶液。反应混合物在-60℃下搅拌1小时,然后将异丁醛(161mg)的二乙醚(1ml)溶液加入其中。30分钟后,将氯化铵水溶液加入反应混合物中。分出有机层,用水和盐水洗涤,用硫酸鲜干燥,浓缩。剩余物用硅胶柱色谱分离,用己烷和乙酸乙酯(4∶1)混合物洗脱,得到1-[3-氟-4-[1-(甲氧基甲氧基)戊基]苯基]-2-甲基丙醇(108mg),油状物。
NMR(CDCl3,δ):0.8-1.05(9H,m),1.15-2.05(8H,m),3.37(3H,s),4.38(1H,d,J=6.5Hz),4.5-4.6(2H,m),4.92(1H,dd,J=5.5Hz,8Hz),6.95-7.15(2H,m),7.3-7.4(1H,t,J=8Hz)
制备58
1-[3-氟-4-[1-(甲氧基甲氧基)戊基]苯基]-2-甲基丙醇(104mg)、乙酸酐(66mg)和N,N-甲基氨基吡啶(2mg)的混合物在室温下搅拌1小时。混合物倒入冰水中,用乙酸乙酯提取。有机层用水和盐水洗涤,用硫酸镁干燥,浓缩。剩余物用硅胶柱色谱分离,用己烷和乙酸乙酯(85∶15)的混合物洗脱,得到1-[3-氟-4-[1-(甲氧基甲氧基)戊基]-2-甲基丙基乙酸酯(113mg),油状物。
NMR(CDCl3,δ):0.75-1.0(9H,m),1.2-1.5(4H,m),1.6-1.9(2H,m),1.95-2.15(4H,m),3.36(3H,s),4.5-4.6(2H,m),4.90(1H,dd,J=5.5Hz,8Hz),5.44(1H,d,J=6.5Hz),6.95(1H,dd,J=1Hz,10.5Hz),7.05(1H,dd,J=1Hz,8Hz),7.35(1H,t,J=8Hz)
制备59
1-[3-氟-4-[1-(甲氧基甲氧基)戊基]苯基]-2-甲基丙基乙酸酯(110mg)、1N盐酸(0.3ml)与乙酸(3ml)的混合物在室温下搅拌1小时。减压蒸去溶剂,剩余物溶于乙酸乙酯中。有机溶液用碳酸氢钠水溶液、水和盐水洗涤,用硫酸镁干燥,浓缩。剩余物用硅胶柱色谱分离,用己烷和乙酸乙酯的混合物洗脱,得1-[3-氟-4-(1-羟基戊基)苯基]-2-甲基丙基乙酸酯(70mg),油状物。
NMR(CDCl3,δ):0.75-1.0(9H,m),1.2-1.5(4H,m),1.6-1.9(2H,m),1.95-2.15(4H,m),2.0-2.15(4H,m),4.97(1H,t,J=7Hz),5.43(1H,d,J=7.5Hz),6.96(1H,d,J=10.5Hz),7.06(1H,d,J=8Hz),7.41(1H,t,J=8Hz)
制备60
0℃下,向(3-甲氧基羰基苄基)三苯基*氯化物(6.0g)的四氢呋喃(120ml)溶液加入叔丁基氧化钾(2.0g)的四氢呋喃(50ml)溶液,混合物搅拌30分钟后,将4-异丁基苯甲醛(2.2g)加入其中。混合物搅拌2小时,然后倒入冰和稀盐酸中。有机层用乙醚提取,用水洗涤,用硫酸镁干燥,蒸发。剩余物用硅胶(300g)色谱纯化,用乙酸乙酯和正己烷(1∶50)的混合物洗脱,得3-反-[2-(4-异丁基苯基)乙烯基]苯甲酸甲酯(2.23g,白色粉末)和3-顺-[2-(4-异丁基苯基)乙烯基]苯甲酸甲酯(1.25g),无色油状物。
3-反-[2-(4-异丁基)乙烯基]苯甲酸甲酯
NMR(CDCl3,δ):0.92(6H,d,J=7Hz),1.88(1H,m),2.50(2H,d,J=7Hz),3.95(3H,s),7.08(1H,d,J=16Hz),7.15(2H,d,J=9Hz),7.20(1H,d,J=16Hz),7.43(1H,m),7.45(2H,d,J=9Hz),7.68(1H,d,J=7Hz),7.92(1H,d,J=8Hz),8.20(1H,s)
3-顺-[2-(4-异丁基)乙烯基]苯甲酸甲酯
NMR(CDCl3,δ):0.90(6H,d,J=7Hz),1.85(1H,m),2.43(2H,d,J=7Hz),3.87(3H,s),6.55(1H,d,J=11Hz),6.65(1H,d,J=11Hz),7.00(2H,d,J=8Hz),7.12(2H,d,J=8Hz),7.28(1H,t,J=8Hz),7.45(1H,d,J=8Hz),7.85(1H,d,J=8Hz),7.92(1H,s)
制备61
按类似于制备60的方法,制得得了下述化合物。
4-反-[2-(4-异丁基苯基)乙烯基]苯甲酸乙酯
NMR(CDCl3,δ):0.90(6H,d,J=7Hz),1.88(1H,m),2.50(2H,d,J=7Hz),3.93(3H,s),7.08(1H,d,J=16Hz),7.15(2H,d,J=9Hz),7.20(1H,d,J=16Hz),7.45(2H,d,J=9Hz),7.55(2H,d,J=9Hz),8.03(2H,d,J=9Hz)
4-顺-[2-(4-异丁基苯基)乙烯基]苯甲酸甲酯
NMR(CDCl3,δ):0.90(6H,d,J=7Hz),1.83(1H,m),2.43(2H,d,J=7Hz),3.90(3H,s),6.55(1H,d,J=11Hz),6.68(1H,d,J=11Hz),7.00(2H,d,J=9Hz),7.13(2H,d,J=9Hz),7.32(2H,d,J=9Hz),7.89(2H,d,J=9Hz)
制备62
向3-反-[2-(4-异丁基苯基)乙烯基]苯甲酸甲酯(2.23g)的二!烷(20ml)溶液中加入1N氢氧化钠水溶液(10ml)。混合物在100℃下搅拌45分钟,然后倒入冰和稀盐酸中。有机层用乙酸乙酯提取,水洗,用硫酸镁干燥、蒸发。剩余物用正己烷洗涤,得到3-反-[2-(4-异丁基苯基)乙烯基]苯甲酸,白色粉末(1.74g)。
NMR(CDCl3+CD3OD,δ):0.92(6H,d,J=7Hz),1.89(1H,m),2.50(2H,d,J=7Hz),7.08(1H,d,J=16Hz),7.21(1H,d,J=16Hz),7.15(2H,d,J=8Hz),7.45(2H,d,J=8Hz),7.43(1H,m),7.69(1H,d,J=8Hz),7.95(1H,d,J=8Hz),8.22(1H,s)
制备63
按类似于制备62的方法,制得了下述化合物。
(1)4-反-[2-(4-异丁基苯基)乙烯基]苯甲酸
NMR(CDCl3+CD3OD,δ):0.90(6H,d,J=7Hz),1.88(1H,m),2.50(2H,d,J=7Hz),7.08(1H,d,J=16Hz),7.15(2H,d,J=9Hz),7.22(1H,d,J=16Hz),7.45(2H,d,J=9Hz),7.56(2H,d,J=9Hz),8.02(2H,d,J=9Hz)
(2)3-顺-[2-(4-异丁基苯基)乙烯基]苯甲酸
NMR(CDCl3,δ):0.90(6H,d,J=7Hz),1.85(1H,m),2.45(2H,d,J=7Hz),6.58(1H,d,J=12Hz),6.70(1H,d,J=12Hz),7.00(2H,d,J=9Hz),7.13(2H,d,J=9Hz),7.31(1H,t,J=8Hz),7.50(1H,d,J=8Hz),7.93(1H,d,J=8Hz),8.00(1H,s)
(3)4-顺-[2-(4-异丁基苯基)乙烯基]苯甲酸
NMR(CDCl3,δ):0.90(6H,d,J=7Hz),1.87(1H,m),2.45(2H,d,J=7Hz),6.55(1H,d,J=11Hz),6.70(1H,d,J=11Hz),7.02(2H,d,J=9Hz),7.14(2H,d,J=9Hz),7.36(2H,d,J=9Hz),7.97(2H,d,J=9Hz)
制备64
向3-反-[2-(4-异丁基苯基)乙烯基]苯甲酸(0.56g)的氯甲烷(10ml)悬浮体中加入草酰氯(0.5ml)和N,N-二甲基甲酰胺(0.05ml)。混合物在室温下搅拌30分钟,蒸发。剩余物溶于正己烷(10ml)中,过滤。蒸发滤液,得3-反-[2-(4-异丁基苯基)乙烯基]苯甲酰氯(0.54g),白色粉末。
NMR(CDCl3,δ):0.93(6H,d,J=7Hz),1.90(1H,m),2.50(2H,d,J=7Hz),7.08(1H,d,J=16Hz),7.18(2H,d,J=9Hz),7.21(1H,d,J=16Hz),7.45(2H,d,J=9Hz),7.5(1H,m),7.81(1H,d,J=7Hz),8.00(1H,d,J=9Hz),8.22(1H,s)
制备65
按类似于制备65的方法,制得了下述化合物。
(1)4-顺-[2-(4-异丁基苯基)乙烯基]苯甲酰氯
NMR(CDCl3,δ):0.90(6H,d,J=7Hz),1.83(1H,m),2.45(2H,d,J=7Hz),6.55(1H,d,J=11Hz),6.77(1H,d,J=11Hz),7.02(2H,d,J=9Hz),7.13(2H,d,J=9Hz),7.38(2H,d,J=9Hz),7.97(2H,d,J=9Hz)
(2)4-反-[2-(4-异丁基苯基)乙烯基]苯甲酰氯
NMR(CDCl3,δ):0.92(6H,d,J=7Hz),1.38(1H,m),2.50(2H,d,J=7Hz),7.08(1H,d,J=16Hz),7.18(2H,d,J=9Hz),7.30(1H,d,J=16Hz),7.48(2H,d,J=9Hz),7.60(2H,d,J=9Hz),8.10(2H,d,J=9Hz)
(3)3-顺-[2-(4-异丁基苯基)乙烯基]苯甲酰氯
NMR(CDCl3,δ):0.90(6H,d,J=7Hz),1.85(1H,m),2.43(2H,d,J=7Hz),6.55(1H,d,J=12Hz),6.72(1H,d,J=12Hz),7.02(2H,d,J=9Hz),7.12(2H,d,J=9Hz),7.34(1H,t,J=8Hz),7.55(1H,d,J=8Hz),7.92(1H,d,J=8Hz),8.02(1H,s)
制备66
按类似于制备24的方法,用(+)-B-氯二异松蒎基硼烷处理1-(4-异丁基苯基)-3-丁烯-1-酮,制得下述化合物。
(R)-1-(4-异丁基苯基)-3-丁烯-1醇
NMR(CDCl3,δ):0.90(6H,d,J=7Hz),1.86(1H,m),2.46(2H,d,J=7Hz),2.52(2H,m),4.71(1H,t,J=7Hz),5.12(1H,m),5.18(1H,m),5.83(1H,m),7.13(2H,d,J=8Hz),7.27(2H,d,J=7Hz)
制备67
按类似于制备10的方法,制得下述化合物。4-异丁基苯甲酰苯
NMR(CDCl3,δ):0.94(6H,d,J=7Hz),1.75-2.05(1H,m),2.57(2H,d,J=7Hz),7.27(2H,d,J=9Hz),7.35-7.85(7H,m)
制备68
向4,4,4-三氟丁酸(4.15g)的二氯甲烷(50ml)溶液中加入草酰氯(2.55ml)和数滴N,N-二甲基甲酰胺。混合物在室温下搅拌1小时后,将溶剂蒸发。剩余物溶于二氯甲烷(100ml)中,然后0℃下将三氯化铝(3.89g)加入其中。混合物在0℃下搅拌30分钟后,加入异丁基苯(3.92g)。混合物在0℃下搅拌30分钟后,加入异丁基苯(3.92g)。混合物在0℃下搅拌1小时。然后倒入冰水中。分出有机层,用水、碳酸氢钠水溶液和盐水洗涤,硫酸镁干燥。蒸去溶剂,得4′-异丁基-4,4,4-三氟丁酰苯(6.80g),油状物。
NMR(CDCl3,δ):0.91(6H,d,J=7Hz),1.75-2.05(1H,m),2.45-2.7(4H,m),3.25(2H,t,J=8Hz),7.26(2H,d,J=8Hz),7.39(2H,d,J=8Hz)
制备69
按类似于制备11的方法,制得了下述化合物。
(1)(4-异丁基苯基)苯甲醇
NMR(CDCl3,δ):0.89(6H,d,J=7Hz),1.7-1.95(1H,m),2.19(1H,d,J=4Hz),2.45(2H,d,J=7Hz),5.33(1H,d,J=4Hz),7.11(2H,d,J=8Hz),7.15-7.45(7H,m)
(2)4,4,4-三氟-1-(4-异丁基苯基)丁醇
NMR(CDCl3,δ):0.90(6H,d,J=7Hz),1.75-2.4(6H,m),2.48(2H,d,J=7Hz),4.72(1H,t,J=6.5Hz),7.15(2H,d,J=8Hz),7.25(2H,d,J=8Hz)
制备70
按类似于制备12的方法,制得了下述化合物。
(4-异丁基苯基)苯甲基溴
NMR(CDCl3,δ):0.90(6H,d,J=7Hz),1.7-2.0(1H,m),2.47(2H,d,J=7Hz),6.29(1H,s),7.10(2H,d,J=8Hz),7.2-7.55(7H,m)
实施例1
室温下,向搅拌着的4-[1-(3-氨基苯甲酰基)中氮茚-3-基]丁酸乙酯(320mg)的二氯甲烷(10ml)溶液中加入二异丙基乙胺(0.22ml)、双(4-异丁基苯基)氯甲烷(340mg)的二氯甲烷(5ml)溶液。搅拌18小时后,将反应混合物蒸发,用乙醚提取。有机层用水和盐水洗涤,用硫酸钠二燥。蒸去溶剂后,剩余物用硅胶色谱分离(二氯甲烷∶乙酸乙酯=20∶1),得到4-[-[3-[双[4-异丁基苯基)甲基氨基]苯甲酰基]中氮茚-3-基]丁酸乙酯(279mg)。
NMR(CDCl3,δ):0.92(12H,d,J=7Hz),1.28(3H,t,J=7Hz),1.87(2H,m),2.08(2H,m),2.4-2.55(6H,m),2.88(2H,t,J=7Hz),4.25(2H,q,J=7Hz),5.56(1H,s),6.70(1H,m),6.86(1H,s),6.90(1H,dt,J=1Hz,7Hz),7.0-7.4(12H,m),8.02(1H,d,J=7Hz),8.50(1H,d,J=9Hz)
实施例2
按类似于实施例1的方法,制得了下述化合物。
(1)4-[1-[4-[双(4-异丁基苯基)甲基氨基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.89(12H,d,J=7Hz),1.24(3H,t,J=7Hz),1.85(2H,m),2.05(2H,m),2.35-2.5(6H,m),2.88(2H,t,J=7Hz),4.12(2H,q,J=7Hz),5.56(1H,s),6.59(2H,d,J=9Hz),6.82(1H,dt,J=1Hz,7Hz),6.92(1H,s),7.09(1H,m),7.12(4H,d,J=8Hz),7.25(4H,d,J=8Hz),7.72(2H,d,J=9Hz),7.96(1H,d,J=7Hz),8.42(1H,d,J=8Hz)
(2)4-[3-[3-[双(4-异丁基苯基)甲基氨基]苯甲酰基]中氮茚-1-基]丁酸乙酯
NMR(CDCl3,δ):0.87(12H,d,J=7Hz),1.22(3H,t,J=7Hz),1.7-2.05(4H,m),2.32(2H,t,J=7Hz),2.43(4H,d,J=7Hz),2.73(2H,t,J=7Hz),4.10(2H,q,J=7Hz),5.52(1H,s),6.68(1H,m),6.88(1H,dt,J=1Hz,7Hz),7.0-7.3(13H,m),7.52(1H,dt,J=8Hz,1Hz),9.92(1H,d,J=7Hz)
(3)4-[3-[4-[双(4-异丁基苯基)甲基氨基]苯甲酰基]中氮茚-1-基]丁酸乙酯
NMR(CDCl3,δ):0.89(12H,d,J=7Hz),1.22(3H,t,J=7Hz),1.7-2.1(4H,m),2.32(2H,t,J=7Hz),2.45(4H,d,J=7Hz),2.76(2H,t,J=7Hz),4.11(2H,q,J=7Hz),5.57(1H,s),6.59(2H,d,J=9Hz),6.83(1H,dt,J=1Hz,7Hz),7.0-7.35(10H,m),7.49(1H,d,J=9Hz),7.68(2H,d,J=9Hz),9.93(1H,d,J=7Hz)
实施例3
室温下,将4-[1-(4-羟基苯甲酰基)中氮茚-3-基]丁酸乙酯(334mg)、双(4-异丁基苯基)氯甲烷(599mg)、碳酸钾(394mg)和N,N-二甲基甲酰胺(5ml)的混合物搅拌20小时。反应混合物过滤,滤液倒入乙酸乙酯和0.5N盐酸的混合物中。分出有机层,用水和盐水洗涤。用硫酸镁干燥,蒸发。剩余物用硅胶色谱分离,用正己烷和乙酸乙酯(3∶1)洗脱,得到4-[1-[4-(双(4-异丁基苯基)甲氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯(95mg),油状物。
NMR(CDCl13,δ):0.89(12H,d,J=7Hz),1.26(3H,t,J=7Hz),1.74-2.15(4H,m),2.38-2.50(6H,m),2.88(2H,t,J=7Hz),4.13(2H,q,J=7Hz),6.28(1H,s),6.80-6.92(2H,m),6.98-7.20(7H,m),7.32(4H,d,J=8Hz),7.77(2H,d,J=9Hz),7.98(1H,d,J=8Hz),8.44(1H,d,J=9Hz)
实施例4
4-[1-(4-羟基苯甲酰基)中氮茚-3-基]丁酸乙酯(61mg)、1-溴-1-(4-异丁基苯基)丙烷(53mg)、碳酸钾(72mg)与N,N-二甲基甲酰胺(2ml)的混合物在室温下搅拌18小时。将反应混合物过滤,滤液倒入乙酸乙酯和0.5N盐酸的混合物中。分出有机层,用水和盐水洗涤。用硫酸镁干燥,蒸发。剩余物用硅胶色谱分离,用正己烷和乙酸乙酯(2∶1)洗脱,得到4-[1-[4-[1-(4-异丁基苯基)丙氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯(80mg),油状物。
TLC Rf∶0.48(正己烷∶乙酸乙酯=2∶1)
实施例5
按类似于实施例3的方法,制得下述化合物。
4-[1-[3-[双(4-异丁基苯基)甲氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.88(12H,d,J=7Hz),1.25(3H,t,J=7Hz),1.74-2.11(4H,m),2.33-2.49(6H,m),2.87(2H,t,J=7Hz),4.13(2H,q,J=7Hz),6.28(1H,s),6.76-7.47(15H,m),8.02(1H,d,J=9Hz),8.47(1H,d,J=9Hz)
实施6
按类似于实施例4的方法,制得了下述化合物。
4-[1-[3-[1-(4-异丁基苯基)丙氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.88(6H,d,J=7Hz),0.99(3H,t,J=7Hz),1.25(3H,t,J=7Hz),1.72-2.12(5H,m),2.42(2H,t,J=7Hz),2.87(2H,t,J=7Hz),4.13(2H,q,J=7Hz),5.08(1H,t,J=7Hz),6.73-7.37(1H,m),8.01(1H,d,J=7Hz),8.46(1H,d,J=9Hz)
实施例7
将4-[3-(4-羟基苯甲酰基]中氮茚-1-基]丁酸乙酯(400mg)、双(4-异丁基苯基)氯甲烷(430mg)、二异丙基乙胺(736mg)与二氯甲烷(20ml)的混合物回流14小时,然后蒸发。剩余物溶于乙酸乙酯中。溶液用水和盐水洗涤,用硫酸镁干燥,蒸发。剩余物用硅胶色谱分离,用正己烷和乙酸乙酯洗脱,得4-[3-[4-[双(4-异丁基苯基)甲氧基]苯甲酰基]中氮茚-1-基]丁酸乙酯(158mg),油状物。
NMR(CDCl3,δ):0.89(12H,d,J=7Hz),1.22(3H,t,J=7Hz),1.74-2.07(4H,m),2.33(2H,t,J=7Hz),2.46(4H,d,J=7Hz),2.77(2H,t,J=7Hz),4.11(2H,q,J=7Hz),6.27(1H,s),6.82-7.20(9H,m),7.33(1H,d,J=9Hz),7.52(1H,d,J=9Hz),7.72(1H,d,J=9Hz)
实施例8
按类似于实施例7的方法,制得下述化合物。
4-[3-[3-[双(4-异丁基苯基)甲氧基]苯甲酰基]中氮茚-1-基]丁酸乙酯
NMR(CDCl3,δ):0.88(12H,d,J=7Hz),1.23(3H,t,J=7Hz),1.73-2.06(4H,m),2.33(2H,t,J=7Hz),2.45(4H,d,J=7Hz),2.76(2H,t,J=7Hz),4.11(2H,q,J=7Hz),6.28(1H,s),6.86-6.96(1H,m),7.05-7.43(14H,m),7.55(1H,d,J=9Hz),9.93(1H,d,J=7Hz)
实施例9
向4-[1-[3-[双(4-异丁基苯基)甲基氨基]苯甲酰基]中氮茚-3-基]丁酸乙酯(279mg)的乙醇(10ml)溶液中加入4N氢氧化钠(0.44ml)。40℃下连续搅拌1小时。反应混合物真空蒸发,然后加入磷酸二氢钾(300mg)水溶液和1N盐酸(26ml),用乙酸乙酯提取。合并有机层,用硫酸钠干燥。蒸去溶剂后,剩余物用硅胶色层分离,用乙酸乙酯洗脱,得到4-[1-[3-[双(4-异丁基苯基)甲基氨基]苯甲酰基]中氮茚-3-基]丁酸(229mg)。
NMR(CDCl3,δ):0.87(12H,d,J=7Hz),1.83(2H,m),2.22(2H,m),2.4-2.5(6H,m),2.85(2H,t,J=7Hz),5.51(1H,s),6.69(1H,m),6.82(1H,s),6.84(1H,dt,J=1Hz,7Hz),7.0-7.3(12H,m),7.94(1H,d,J=7Hz),8.46(1H,d,J=9Hz)
实施例10
按类似于实施例9的方法,制得了下述化合物。
(1)4-[1-[4-[双(4-异丁基苯基)甲基氨基)苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.88(12H,d,J=7Hz),1.84(1H,m),2.06(2H,m),2.4-2.55(6H,m),2.88(2H,t,J=7Hz),5.56(1H,s),6.57(2H,d,J=9Hz),6.80(1H,dt,J=1Hz,7Hz),6.92(1H,s),7.08(1H,m),7.11(4H,d,J=8Hz),7.23(4H,d,J=8Hz),7.72(2H,d,J=9Hz),7.92(1H,d,J=7Hz),8.41(1H,d,J=8Hz)
(2)4-[3-[3-[双(4-异丁基苯基)甲基氨基)苯甲酰基]中氮茚-1-基]丁酸
NMR(CDCl3,δ):0.86(12H,d,J=7Hz),1.7-2.05(4H,m),2.38(2H,t,J=7Hz),2.43(4H,d,J=7Hz),2.76(2H,t,J=7Hz),5.52(1H,s),6.71(1H,m),6.88(1H,dt,J=1Hz,7Hz),7.0-7.3(13H,m),7.49(1H,dt,J=8Hz,1Hz),9.91(1H,d,J=7Hz)
(3)4-[3-[4-[双(4-异丁基苯基)甲基氨基)苯甲酰基]中氮茚-1-基]丁酸
NMR(CDCl3,δ):0.88(12H,d,J=7Hz),1.7-2.1(4H,m),2.39(2H,t,J=7Hz),2.45(4H,d,J=7Hz),2.79(2H,t,J=7Hz),5.57(1H,s),6.58(2H,d,J=9Hz),6.82(1H,dt,J=1Hz,7Hz),7.0-7.3(10H,m),7.49(1H,d,J=9Hz),7.68(2H,d,J=7Hz),9.93(1H,d,J=7Hz)
实施例11
向4-[1-[双(4-异丁基苯基)甲氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯(90mg)的乙醇(1ml)和1,4-二氧六环(1ml)溶液中,加入1N氢氧化钠(0.5ml)水溶液。混合物在室温下搅拌2小时,然后倒入乙酸乙酯和0.5N盐酸的混合物中。分出有机层,用水和盐水洗涤,用硫酸镁干燥,蒸发,得到4-[1-[4-[双(4-异丁基苯基)甲氧基]苯甲酰基]中氮茚-3-基]丁酸(79mg),粉末。
NMR(CDCl3,δ):0.89(12H,d,J=7Hz),1.73-1.97(2H,m),1.99-2.16(2H,m),2.40-2.55(6H,m),2.89(2H,m),6.27(1H,s),6.79-6.90(2H,m),6.98-7.18(7H,m),7.28-7.38(4H,m),7.75(2H,d,J=9Hz),7.96(1H,d,J=7Hz),8.43(1H,d,J=9Hz)
实施例12
按类似于实施例11的方法,制得了下述化合物。
(1)4-[1-[4-[1-(4-异丁基苯基)丙氧基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.88(6H,d,J=7Hz),1.01(3H,t,J=7Hz),1.72-2.17(5H,m),2.40-2.55(4H,m),2.88(2H,t,J=7Hz),5.08(1H,t,J=7Hz),6.79-6.98(4H,m),7.07-7.32(5H,m),7.73(2H,d,J=9Hz),7.94(1H,d,J=7Hz),8.42(1H,d,J=9Hz)
(2)4-[1-[3-[双(4-异丁基苯基)甲氧基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.88(12H,d,J=7Hz),1.76-1.92(2H,m),1.99-2.13(2H,m),2.40-2.55(6H,m),2.88(2H,t,J=7Hz),6.27(1H,s),6.76-7.46(15H,m),7.98(1H,d,J=7Hz),8.46(1H,d,J=9Hz)
(3)4-[1-[3-[1-(4-异丁基苯基)丙氧基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.88(6H,d,J=7Hz),0.99(3H,t,J=7Hz),1.70-2.14(5H,m),2.37-2.56(4H,m),2.88(2H,t,J=7Hz),5.08(1H,t,J=7Hz),6.76-7.38(11H,m),7.97(1H,d,J=7Hz),8.47(1H,d,J=9Hz)
(4)4-[3-[4-双(-(4-异丁基苯基)甲氧基]苯甲酰基]中氮茚-1-基]丁酸
NMR(CDCl3,δ):0.88(12H,d,J=7Hz),1.73-2.08(4H,m),2.35-2.50(6H,m),2.80(2H,t,J=7Hz),6.27(1H,s),6.81-7.22(9H,m),7.32(4H,d,J=8Hz),7.51(1H,d,J=9Hz),7.71(2H,d,J=9Hz)
(5)4-[3-[3-[双(4-异丁基苯基)甲氧基]苯甲酰基]中氮茚-1-基]丁酸
NMR(CDCl3,δ):0.88(12H,d,J=7Hz),1.72-2.05(4H,m),2.33-2.48(6H,m),2.78(2H,t,J=7Hz),6.27(1H,s),6.84-6.96(1H,m),7.04-7.42(14H,m)
实施例13
将4N-氯化氢的乙酸乙酯(0.5ml)溶液加入4-[1-[3-[双(4-异丁基苯基)甲基氨基]苯甲酰基]中氮茚-3-基]丁酸(0.60g)的乙酸乙酯(5ml)溶液中。溶液在冰箱中放置16小时后,过滤收集得到的晶体,得到4-[1-[3-[双(4-异丁基苯基)甲基氨基]苯甲酰基]中氮茚-3-基]丁酸盐酸盐,黄色粉末(0.62g)。
mp:136-138℃(dec.)
NMR(DMSO-d6,δ):8.40(1H,d,J=7Hz),8.30(1H,d,J=9Hz),7.35(2H,d,J=9Hz),7.10(2H,d,J=9Hz),6.9-7.4(6H,m),6.72(1H,s),5.67(1H,s),2.88(2H,t,J=7Hz),2.40(4H,d,J=7Hz),2.33(2H,t,J=7Hz),1.7-2.0(4H,m),0.82(12H,d,J=7Hz)
实施例14
向4-[1-[3-[双(4-异丁基苯基)甲基氨基]苯甲酰基]中氮茚-3-基]丁酸(244mg)的乙醇溶液中,加入1N氢氧化钠。除去溶剂后,剩余我党于苯中,用棉花滤器过滤,真空蒸发,得到4-[1-[3-[双(4-异丁基苯基)甲基氨基]苯甲酰基]中氮茚-3-基]丁酸钠(240mg)。
NMR(CD3OD,δ):0.88(12H,d,J=7Hz),1.82(2H,m),1.97(2H,m),2.31(2H,t,J=7Hz),2.44(4H,d,J=7Hz),2.88(2H,t,J=7Hz),5.56(1H,s),6.74(1H,s),6.81(1H,m),6.9-7.3(5H,m),7.08(4H,d,J=8Hz),7.28(1H,d,J=7Hz),8.25-8.35(2H,m)
实施例15
按类似于实施例1的方法,制得了下述化合物。
(1)4-[3-[4-[双(4-异丁基苯基)甲基氨基]苯甲酰基]-2-甲基中氮茚-1-基]丁酸乙酯
NMR(CDCl3,δ):0.88(12H,d,J=7Hz),1.23(3H,t,J=7Hz),1.75-2.0(4H,m),2.00(3H,s),2.32(2H,t,J=7Hz),2.46(4H,d,J=7Hz),2.72(2H,t,J=7Hz),4.11(2H,q,J=7Hz),5.57(1H,s),6.55(2H,d,J=8Hz),6.65(1H,dt,J=1Hz,7Hz),6.98(1H,m),7.11(4H,d,J=8Hz),7.24(1H,d,J=8Hz),7.38(1H,d,J=8Hz),7.49(2H,d,J=8Hz),9.30(1H,d,J=7Hz)
(2)4-[3-[3-[双(4-异丁基苯基)甲基氨基]苯甲酰基]-2-甲基中氮茚-1-基]丁酸乙酯
NMR(CDCl3,δ):0.88(12H,d,J=7Hz),1.23(3H,t,J=7Hz),1.76(3H,s),1.83(2H,m),2.31(2H,t,J=7Hz),2.42(4H,d,J=7Hz),2.68(2H,t,J=7Hz),4.12(2H,q,J=7Hz),5.51(1H,s),6.65-6.95(4H,m),7.08(4H,d,J=8Hz),7.0-7.3(2H,m),7.23(4H,d,J=8Hz),7.42(1H,d,J=9Hz),9.66(1H,d,J=7Hz)
(3)4-[1-[4-[双(4-异丁基苯基)甲基氨基]苯甲酰基]-2-甲基中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.88(12H,d,J=7Hz),1.25(3H,t,J=7Hz),1.87(4H,m),2.27(3H,s),2.38(2H,t,J=7Hz),2.45(4H,d,J=7Hz),2.92(2H,t,J=7Hz),4.14(2H,q,J=7Hz),5.56(1H,s),6.52(2H,d,J=9Hz),6.66(1H,dt,J=1Hz,7Hz),6.80(1H,m),7.10(4H,d,J=8Hz),7.22(4H,d,J=8Hz),7.46(1H,d,J=9Hz),7.59(2H,d,J=8Hz),7.93(1H,d,J=7Hz)
(4)4-[1-[3-[双(4-异丁基苯基)甲基氨基]苯甲酰基]-2-甲基中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.88(12H,d,J=7Hz),1.27(3H,t,J=7Hz),1.7-2.0(4H,m),2.20(3H,s),2.38(2H,t,J=7Hz),2.43(4H,d,J=7Hz),2.90(2H,t,J=7Hz),4.14(2H,q,J=7Hz),5.51(1H,s),6.63-6.78(2H,m),6.8-7.0(2H,m),7.05-7.3(10H,m),7.44(1H,d,J=8Hz),7.97(1H,d,J=7Hz)
实施例16
按类似于实施例4的方法,制得了下述化合物。
(1)4-[1-[4-[1-(4-异丁基苯基)己氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.80-0.95(9H,m),1.26-1.65(9H,m),1.70-2.15(4H,m),2.35-2.50(4H,m),2.87(2H,t,J=7Hz),4.13(2H,q,J=7Hz),5.15(1H,dd,J=2Hz,7Hz),6.80-6.97(4H,m),7.07-7.31(5H,m),7.72(2H,d,J=9Hz),7.98(1H,d,J=7Hz),8.43(1H,d,J=9Hz)
(2)4-[3-[4-[1-(4-异丁基苯基)己氧基]苯甲酰基]中氮茚-1-基]丁酸乙酯
NMR(CDCl3,δ):0.80-0.95(9H,m),1.17-1.63(9H,m),1.72-2.12(5H,m),2.32(2H,t,J=7Hz),2.46(2H,d,J=7Hz),2.76(2H,t,J=7Hz),4.10(2H,q,J=7Hz),5.14(1H,dd,J=1.5Hz,7Hz),6.81-6.98(3H,m),7.06-7.19(4H,m),7.27(2H,d,J=9Hz),7.51(1H,d,J=9Hz),7.68(2H,d,J=9Hz),9.87(1H,d,J=7Hz)
(3)4-[1-[4-[1-(4-异丁基苯基)庚氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.8-0.95(9H,m),1.15-1.65(13H,m),1.7-2.15(5H,m),2.35-2.5(4H,m),2.88(2H,t,J=7.5Hz),4.12(2H,q,J=7Hz),5.15(1H,dd,J=2Hz,7Hz),6.8-6.95(4H,m),7.05-7.3(5H,m),7.73(2H,d,J=9Hz),7.98(1H,d,J=7Hz),8.44(1H,d,J=9Hz)
(4)4-[1-[4-[1-(4-异丁基苯基)己氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.8-1.0(9H,m),1.2-1.65(11H,m),1.7-2.15(5H,m),2.35-2.5(4H,m),2.88(2H,t,J=7.5Hz),4.12(2H,q,J=7Hz),5.15(1H,dd,J=2Hz,7Hz),6.8-6.95(4H,m),7.05-7.3(5H,m),7.74(2H,d,J=9Hz),7.98(1H,d,J=7Hz),8.43(1H,d,J=9Hz)
(5)4-[1-[4-[1-(4-异丁基苯基)戊氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.8-1.0(9H,m),1.2-1.65(7H,m),1.7-2.15(5H,m),2.35-2.5(4H,m),2.88(2H,t,J=7.5Hz),4.12(2H,q,J=7Hz),5.15(1H,dd,J=2Hz,7Hz),6.8-6.95(4H,m),7.05-7.3(5H,m),7.73(2H,d,J=9Hz),7.99(1H,d,J=7Hz),8.44(2H,d,J=9Hz)
(6)4-[1-[4-[1-(4-异丁基苯基)丁氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.8-1.05(9H,m),1.24(3H,t,J=7Hz),1.3-1.65(2H,m),1.7-2.15(5H,m),2.35-2.5(4H,m),2.87(2H,t,J=7.5Hz),4.12(2H,q,J=7Hz),5.17(1H,dd,J=2Hz,7Hz),6.8-6.95(4H,m),7.05-7.3(5H,m),7.72(2H,d,J=9Hz),7.98(1H,d,J=7Hz),8.44(1H,d,J=9Hz)
实施例17
将4-[1-(3-氨基苯甲酰基)中氮茚-3-基]丁酸乙酯(175mg)、1-溴己基-4-异丁基苯(177mg)、二异丙基乙胺(194mg)与二氯甲烷(3ml)的混合物回流20小时。将反应混合物倒入乙酸乙酯和水的混合物中。分出有机层,用水和盐水洗涤,用硫酸镁干燥,蒸发。剩余物用硅胶柱色谱分离,用正己烷和乙酸乙酯(3∶1)洗脱,得到4-[1-[3-[1-(4-异丁基苯基)己基氨基]苯甲酰基]中氮茚-3-基]丁酸乙酯(170mg),油状物。
NMR(CDCl3,δ):0.80-0.95(9H,m),1.27-1.50(9H,m),1.68-2.12(5H,m),2.34-2.48(4H,m),2.85(2H,t,J=7.5Hz),4.12(2H,q,J=7Hz),4.33(1H,t,J=7Hz),6.63(1H,d,J=7.5Hz),6.80-6.91(2H,m),6.94-7.28(9H,m),7.98(1H,d,J=7Hz),8.46(1H,d,J=9Hz)
实施例18
按类似于实施例17的方法,制得了下述化合物。
(1)4-[3-[3-[1-(4-异丁基苯基)己基氨基]苯甲酰基]中氮茚-1-基]丁酸乙酯
NMR(CDCl3,δ):0.78-0.96(9H,m),1.20-1.50(9H,m),1.64-2.07(5H,m),2.25-2.48(4H,m),2.75(2H,t,J=7.5Hz),4.11(2H,q,J=7Hz),4.33(1H,t,J=7Hz),6.64(1H,d,J=7.5Hz),6.83-7.30(11H,m),7.52(1H,d,J=9Hz)
(2)4-[1-[3-[1-(4-异丁基苯基)丁基氨基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.8-1.0(9H,m),1.2-1.55(5H,m),1.7-2.15(5H,m),2.35-2.55(4H,m),2.87(2H,t,J=7.5Hz),4.13(2H,q,J=7Hz),4.36(1H,t,J=7Hz),6.64(1H,d,J=8Hz),6.8-6.95(2H,m),7.0-7.35(9H,m),7.98(1H,d,J=7Hz),8.45(1H,d,J=9Hz)
实施例19
按类似于实施例11的方法,制得了下述化合物。
(1)4-[3-[4-[1-(4-异丁基苯基)己氧基]苯甲酰基]中氮茚-1-基]丁酸
NMR(CDCl3,δ):0.81-0.96(9H,m),1.20-1.62(6H,m),1.72-2.15(5H,m),2.34-2.49(4H,m),2.79(2H,t,J=7Hz),5.14(1H,dd,J=1.5Hz,7Hz),6.80-6.97(3H,m),7.06-7.18(4H,m),7.26(2H,d,J=9Hz),7.50(1H,d,J=9Hz),7.68(2H,d,J=9Hz),9.87(1H,d,J=7Hz)
(2)4-[1-[4-[1-(4-异丁基苯基)己氧基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.82-0.95(9H,m),1.23-1.65(6H,m),1.70-2.15(5H,m),2.38-2.55(4H,m),2.88(2H,t,J=7Hz),5.14(1H,dd,J=2Hz,7Hz),6.78-6.97(4H,m),7.05-7.30(5H,m),7.72(2H,d,J=9Hz),7.94(1H,d,J=7Hz),8.43(1H,d,J=9Hz)
(3)4-[1-[4-[1-(4-异丁基苯基)辛氧基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.8-0.95(9H,m),1.15-1.65(10H,m),1.7-2.2(5H,m),2.4-2.55(4H,m),2.89(2H,t,J=7.5Hz),5.15(1H,dd,J=2Hz,7Hz),6.8-6.95(4H,m),7.05-7.3(5H,m),7.72(2H,d,J=9Hz),7.96(1H,d,J=7Hz),8.43(1H,d,J=9Hz)
(4)4-[1-[4-[1-(4-异丁基苯基)庚氧基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.8-1.0(9H,m),1.2-1.65(8H,m),1.7-2.15(5H,m),2.4-2.55(4H,m),2.89(2H,t,J=7.5Hz),5.15(1H,dd,J=2Hz,7Hz),6.8-6.95(4H,m),7.05-7.3(5H,m),7.73(2H,d,J=9Hz),7.95(1H,d,J=7Hz),8.43(1H,d,J=9Hz)
(5)4-[1-[4-[1-(4-异丁基苯基)戊氧基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.8-1.0(9H,m),1.25-1.6(4H,m),1.7-2.15(5H,m),2.4-2.55(4H,m),2.88(2H,t,J=7.5Hz),5.14(1H,dd,J=2Hz,7Hz),6.8-6.95(4H,m),7.05-7.3(5H,m),7.73(2H,d,J=9Hz),7.96(1H,d,J=7Hz),8.43(1H,d,J=9Hz)
(6)4-[1-[4-[1-(4-异丁基苯基)丁氧基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.8-1.05(9H,m),1.3-1.65(2H,m),1.7-2.15(5H,m),2.4-2.55(4H,m),2.88(2H,t,J=7.5Hz),5.16(1H,dd,J=7Hz),6.8-6.95(4H,m),7.05-7.3(5H,m),7.72(2H,d,J=9Hz),7.96(1H,d,J=7Hz),8.42(1H,d,J=9Hz)
实施例20
向4-[3-[3-[1-(4-异丁基苯基)己基氨基]苯甲酰基]中氮茚-1-基]丁酸乙酯(117mg)的乙醇(2ml)和1,4-二氧六环(2ml)溶液中,加入1N氢氧化钠水溶液(1ml)。混合物在室温下搅拌3小时,然后倒入乙酸乙酯和0.5N盐酸的混合物中。分出有机层,用水和盐水洗涤,硫酸镁干燥,蒸发,得到4-[3-[3-[1-(4-异丁基苯基)己基氨基]苯甲酰基]中氮茚-1-基]丁酸(98mg),粉末。
NMR(CDCl3,δ):0.78-0.96(9H,m),1.15-1.50(6H,m),1.68-2.07(5H,m),2.32-2.48(4H,m),2.77(2H,t,J=7.5Hz),4.32(1H,t,J=7Hz),6.64(1H,d,J=7.5Hz),6.82-7.28(11H,m),7.50(1H,d,J=9Hz)
实施例21
按类似于实施例20的方法,制得了下述化合物。
(1)4-[1-[3-[1-(4-异丁基苯基)己基氨基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.78-0.93(9H,m),1.15-1.50(6H,m),1.63-2.13(5H,m),2.37-2.53(4H,m),2.87(2H,t,J=7.5Hz),4.32(1H,t,J=7Hz),6.62(1H,d,J=7.5Hz),6.79-6.90(2H,m),6.94-7.27(9H,m),7.95(2H,d,J=7Hz),8.45(1H,d,J=9Hz)
(2)4-[1-[3-[1-(4-异丁基苯基)丁基氨基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.8-1.0(9H,m),1.2-1.5(2H,m),1.65-2.15(5H,m),2.35-2.5(4H,m),2.86(2H,t,J=7.5Hz),4.34(1H,t,J=7Hz),6.64(1H,d,J=8Hz),6.8-6.95(2H,m),7.0-7.3(9H,m),7.95(1H,d,J=7Hz),8.44(1H,d,J=9Hz)
实施例22
按类似于实施例9的方法,制得了下述化合物。
(1)4-[3-[4-[双(4-异丁基苯基)甲基氨基]苯甲酰基]-2-甲基中氮茚-1-基]丁酸
NMR(CDCl3,δ):0.88(12H,d,J=7Hz),1.7-2.0(4H,m),2.01(3H,s),2.39(2H,t,J=7Hz),2.46(4H,d,J=7Hz),2.74(2H,t,J=7Hz),5.57(1H,s),6.53(2H,d,J=8Hz),6.64(1H,dt,J=1Hz,7Hz),6.95(1H,m),7.11(4H,d,J=8Hz),7.22(4H,d,J=8Hz),7.37(1H,d,J=9Hz),7.50(2H,d,J=8Hz),9.30(1H,d,J=7Hz)
(2)4-[3-[3-[双(4-异丁基苯基)甲基氨基]苯甲酰基]-2-甲基中氮茚-1-基]丁酸
NMR(CDCl3,δ):0.88(12H,d,J=7Hz),1.74(3H,s),1.75-1.95(2H,m),2.37(2H,t,J=7Hz),2.42(4H,d,J=7Hz),2.69(2H,t,J=7Hz),5.51(1H,s),6.6-6.8(3H,m),6.88(1H,d,J=7Hz),7.07(4H,d,J=7Hz),7.0-7.3(2H,m),7.23(4H,d,J=7Hz),7.40(1H,d,J=8Hz),9.67(1H,d,J=7Hz)
(3)4-[1-[4-[双(4-异丁基苯基)甲基氨基]苯甲酰基]-2-甲基中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.88(12H,t,J=7Hz),1.7-2.0(4H,m),2.38(3H,s),2.42(2H,t,J=7Hz),2.44(4H,d,J=7Hz),2.93(2H,t,J=7Hz),5.56(1H,s),6.52(2H,d,J=9Hz),6.64(1H,dt,J=7Hz),6.81(1H,m),7.09(4H,d,J=8Hz),7.25(4H,d,J=7Hz),7.45(1H,d,J=8Hz),7.58(2H,d,J=9Hz),7.90(1H,d,J=7Hz)
(4)4-[1-[3-[双(4-异丁基苯基)甲基氨基]苯甲酰基]-2-甲基中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.88(12H,d,J=7Hz),1.7-2.0(4H,m),2.18(3H,s),2.42(4H,d,J=7Hz),2.45(2H,t,J=7Hz),2.91(2H,t,J=7Hz),5.50(1H,s),6.6-7.3(6H,m),7.06(4H,d,J=8Hz),7.22(4H,d,J=8Hz),7.45(1H,d,J=8Hz),7.92(1H,d,J=7Hz)
实施例23
在-20℃、氮气气氛下,向4-[1-(4-羟基苯甲酰基)中氮茚-3-基]丁酸乙酯(392mg)、(R)-1-(4-异丁基苯基)丁-11-醇(230mg)、三苯膦(292mg)与四氢呋喃(3ml)和甲苯(15ml)的混合物中,加入偶氮二甲酸二乙酯(0.178ml)。混合物在-20℃、氮气氛下搅拌2.5小时,加入乙酸(0.05ml),然后让混合物升温至室温。减压蒸去溶剂,剩余物倒入乙酸乙酯和水的混合物中。分出有机相,用水和盐水洗涤,硫酸镁干燥,蒸发。剩余物用硅胶柱色谱分离,用正己烷和乙酸乙酯(4∶1)的混合物洗脱,得4-[1-[4-[(S)-1-(4-异丁基苯基)丁氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯(295mg),油状物。
NMR(CDCl3,δ):0.8-1.05(9H,m),1.24(3H,t,J=7Hz),1.3-1.65(2H,m),1.7-2.15(5H,m),2.35-2.5(4H,m),2.87(2H,t,J=7.5Hz),4.12(2H,q,J=7Hz),5.17(1H,dd,J=2Hz,7Hz),6.8-6.95(4H,m),7.05-7.3(5H,m),7.72(2H,d,J=9Hz),7.98(1H,d,J=7Hz),8.44(1H,d,J=9Hz)
实施例24
向4-[1-[4-[(S)-1-(4-异丁基苯基)丁氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯(282mg)的乙醇(3ml)和1,4-二!烷(3ml)溶液中,加入1N氢氧化钠(2ml)水溶液。混合物在室温下搅拌2小时,然后倒入乙酸乙酯和0.5N盐酸的混合物中。分出有机层,用水和盐水洗涤,硫酸镁干燥,蒸发,得到4-[1-[4-[(S)-1-(4-异丁基苯基)丁氧基]苯甲酰基]中氮茚-3-基]丁酸(232mg),粉末。
NMR(CDCl3,δ):0.8-1.05(9H,m),1.3-1.65(2H,m),1.7-2.15(5H,m),2.4-2.55(4H,m),2.88(2H,t,J=7.5Hz),5.16(1H,dd,J=7Hz),6.8-6.95(4H,m),7.05-7.3(5H,m),7.72(2H,d,J=9Hz),7.96(1H,d,J=7Hz),8.42(1H,d,J=9Hz)
[α]25 D=-78.3°(C=0.5,CHCl3)
实施例25
按类似于实施例23的方法,制得了下述化合物。
4-[1-[4-[(R)-1-(4-异丁基苯基)丁氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.8-1.05(9H,m),1.24(3H,t,J=7Hz),1.3-1.65(2H,m),1.7-2.15(5H,m),2.35-2.5(4H,m),2.87(2H,t,J=7.5Hz),4.12(2H,q,J=7Hz),5.17(1H,dd,J=2Hz,7Hz),6.8-6.95(4H,m),7.05-7.3(5H,m),7.72(2H,d,J=9Hz),7.98(1H,d,J=7Hz),8.44(1H,d,J=9Hz)
实施例26
按类似于实施例24的方法,制得了下述化合物。
4-[1-[4-[(R)-1-(4-异丁基苯基)丁氧基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.8-1.05(9H,m),1.3-1.65(2H,m),1.7-2.15(5H,m),2.4-2.55(4H,m),2.88(2H,t,J=7.5Hz),5.16(1H,dd,J=7Hz),6.8-6.95(4H,m),7.05-7.3(5H,m),7.72(2H,d,J=9Hz),7.96(1H,d,J=7Hz),8.42(1H,d,J=9Hz)
[α]25 D=+79.8°(C=0.5,CHCl3)
实施例27
向4-[1-[3-[(1-羧基乙基)氨基]苯甲酰基]中氮茚-3-基]丁酸乙酯(60mg)、庚胺(16mg)和1-羟基苯并三唑(20mg)的二氯甲烷(3ml)溶液中,加入1-(3-二甲基氨基丙基)-3-乙基碳化二亚胺盐酸盐(30mg)。混合物在室温下搅拌3小时,蒸发,然后溶于乙酸乙酯(10ml)中。溶液用稀盐酸和水洗涤,用硫酸镁干燥。减压除去溶剂,得4-[1-[3-[1-(庚基氨基甲酰基)乙基]氨基]苯甲酰基]中氮茚-3-基]丁酸乙酯(70mg),黄色油状物。
NMR(CDCl3,δ):0.84(3H,m),1.1-1.4(11H,m),1.45(2H,m),1.54(3H,d,J=7Hz),2.05(2H,m),2.43(2H,t,J=7Hz),2.88(2H,t,J=7Hz),3.23(2H,q,J=7Hz),3.90(1H,q,J=7Hz),4.12(2H,q,J=7Hz),6.75(1H,m),6.88(1H,s),6.93(1H,m),7.1-7.3(3H,m),7.45(1H,m),7.7-7.9(1H,m),8.03(1H,d,J=7Hz),8.49(1H,d,J=9Hz)
实施例28
按类似于实施例27的方法,制得下述化合物。
(1)4-[1-[3-[(丁基氨基甲酰基)(4-异丁基苯基)甲基]氨基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.8-1.0(9H,m),1.1-1.3(5H,m),1.43(2H,m),1.82(1H,m),2.05(2H,m),2.3-2.6(4H,m),2.87(2H,t,J=7Hz),3.25(2H,m),4.11(2H,q,J=7Hz),4.88(1H,s),6.7-7.0(3H,m),7.1-7.4(8H,m),8.01(1H,d,J=7Hz),8.48(1H,d,J=9Hz)
(2)4-[1-[3-[(庚基氨基甲酰基)(4-异丁基苯基)甲基]氨基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.8-1.0(9H,m),1.1-1.3(11H,m),1.45(2H,m),1.85(1H,m),2.0-2.2(2H,m),2.4-2.6(4H,m),2.88(2H,t,J=7Hz),3.26(2H,m),4.12(2H,q,J=7Hz),4.70(1H,s),6.6-7.0(3H,m),7.1-7.3(6H,m),7.35(2H,d,J=9Hz),8.00(1H,d,J=7Hz),8.47(1H,d,J=9Hz)
(3)4-[1-[3-[[N-(4-异丁基苯基)氨基甲酰基]甲基氨基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.87(6H,d,J=7Hz),1.25(3H,t,J=7Hz),1.7-2.1(3H,m),2.3-2.5(4H,m),2.82(2H,t,J=7Hz),3.95(2H,s),4.11(2H,q,J=7Hz),6.7-7.0(3H,m),7.09(2H,d,J=9Hz),7.1-7.4(4H,m),7.45(2H,d,J=9Hz),8.02(1H,d,J=7Hz),8.50(1H,d,J=9Hz),8.58(1H,s)
(4)4-[1-[3-[[1-[N-(4-异丁基苯基)氨基甲酰基]乙基]氨基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.88(6H,d,J=7Hz),1.23(3H,t,J=7Hz),1.62(3H,d,J=7Hz),1.70(1H,m),1.9-2.1(2H,m),2.3-2.5(4H,m),2.80(2H,t,J=7Hz),3.96(1H,q,J=7Hz),4.12(2H,q,J=7Hz),6.7-7.0(3H,m),7.0-7.3(4H,m),7.4-7.5(3H,m),7.76(1H,m),8.03(1H,d,J=7Hz),8.50(1H,d,J=9Hz),8.83(1H,s)
实施例29
按类似于实施例1的方法,制得了下述化合物。
4-[1-[3-[(苄氧基羰基)(4-异丁基苯基)甲基]氨基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.88(6H,d,J=7Hz),1.25(3H,t,J=7Hz),1.83(1H,m),1.9-2.1(2H,m),2.3-2.5(4H,m),2.85(2H,t,J=7Hz),4.12(2H,q,J=7Hz),5.14(2H,s),5.19(1H,s),6.7-7.0(3H,m),7.0-7.3(11H,m),7.38(2H,d,J=9Hz),8.00(1H,d,J=7Hz),8.46(1H,d,J=9Hz)
实施例30
按类似于实施例9的方法,制得了下述化合物。
(1)4-[1-[3-[[(庚基氨基甲酰基)(4-异丁基苯基)甲基]氨基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.8-1.0(9H,m),1.1-1.3(11H,m),1.40(2H,m),1.85(1H,m),2.0-2.3(2H,m),2.4-2.6(4H,m),2.95(2H,t,J=7Hz),3.22(2H,m),4.93(1H,s),6.8-7.5(11H,m),7.96(1H,d,J=7Hz),8.54(1H,d,J=9Hz)
(2)4-[1-[3-[[1-(庚基氨基甲酰基)乙基]氨基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.8-1.0(5H,m),1.1-1.5(6H,m),1.56(3H,d,J=7Hz),2.0-2.4(4H,m),2.47(2H,t,J=7Hz),2.95(2H,t,J=7Hz),3.17(2H,m),3.95(1H,q,J=7Hz),6.8-7.1(3H,m),7.2-7.4(4H,m),7.96(1H,d,J=7Hz),8.55(1H,d,J=9Hz)
(3)4-[1-[3-[[1-[N-(4-异丁基苯基)氨基甲酰基]乙基]氨基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.85(6H,d,J=7Hz),1.62(3H,d,J=7Hz),1.78(1H,m),1.9-2.2(2H,m),2.3-2.5(4H,m),2.83(2H,t,J=7Hz),4.05(1H,m),6.83(1H,s),6.9-7.0(2H,m),7.05(2H,d,J=9Hz),7.1-7.5(6H,m),7.95(1H,d,J=7Hz),8.50(1H,d,J=9Hz),8.95(1H,s)
(4)4-[1-[3-[[(丁基氨基甲酰基)(4-异丁基苯基)甲基]氨基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.80(3H,t,J=7Hz),0.88(6H,d,J=7Hz),1.1-1.5(4H,m),1.34(1H,m),2.12(2H,m),2.4-2.6(4H,m),2.96(2H,t,J=7Hz),3.24(2H,m),4.99(1H,s),6.8-7.0(3H,m),7.0-7.4(8H,m),7.96(1H,d,J=7Hz),8.53(1H,d,J=9Hz)
(5)4-[1-[3-[[N-(4-异丁基苯基)氨基甲酰基甲基]氨基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.88(6H,d,J=7Hz),1.80(1H,m),2.02(2H,m),2.3-2.5(4H,m),2.84(2H,t,J=7Hz),3.94(2H,s),6.8-7.0(3H,m),7.08(2H,t,J=7Hz),7.1-7.4(4H,m),7.40(2H,d,J=9Hz),7.95(1H,d,J=7Hz),8.50(1H,d,J=9Hz),8.57(1H,s)
实例例31
按类似于实施例24的方法,制得了下述化合物。
(1)4-[1-[4-[(S)-1-(4-异丁基苯基)-2-乙氧基乙氧基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.88(6H,d,J=7Hz),1.22(3H,t,J=7Hz),1.7-2.15(3H,m),2.4-2.55(4H,m),2.88(2H,t,J=7.5Hz),3.5-3.75(3H,m),3.8-3.95(1H,m),5.41(1H,dd,J=4.5Hz,6Hz),6.8-6.9(2H,m),6.97(2H,d,J=9Hz),7.05-7.2(3H,m),7.25-7.35(2H,m),7.72(2H,d,J=9Hz),7.94(1H,d,J=7Hz),7.42(1H,d,J=9Hz)
(2)4-[1-[4-[(R)-1-(4-异丁基苯基)-2-乙氧基乙氧基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.88(6H,d,J=7Hz),1.22(3H,t,J=7Hz),1.7-2.15(3H,m),2.4-2.55(4H,m),2.88(2H,t,J=7.5Hz),3.5-3.75(3H,m),3.8-3.95(1H,m),5.41(1H,dd,J=4.5Hz,6Hz),6.8-6.9(2H,m),6.97(2H,d,J=9Hz),7.05-7.2(3H,m),7.25-7.35(2H,m),7.73(2H,d,J=9Hz),7.98(1H,d,J=7Hz),8.43(1H,d,J=9Hz)
实施例32
按类似于实施例23的方法,制得了下述化合物。
(1)4-[1-[4-[(S)-1-(4-异丁基苯基)-2-乙氧基乙氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.89(6H,d,J=7Hz),1.15-1.3(6H,m),1.7-2.15(3H,m),2.35-2.5(4H,m),2.88(2H,t,J=7.5Hz),3.5-3.75(3H,m),3.8-3.95(1H,m),4.13(2H,q,J=7Hz),5.41(1H,dd,J=4.5Hz,6Hz),6.8-6.9(2H,m),6.97(2H,d,J=9Hz),7.05-7.2(3H,m),7.25-7.35(2H,m),7.73(2H,d,J=9Hz),7.98(1H,d,J=7Hz),7.43(1H,d,J=9Hz)
(2)4-[1-[4-[(R)-1-(4-异丁基苯基)-2-乙氧基乙氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.89(6H,d,J=7Hz),1.15-1.3(6H,m),1.7-2.15(3H,m),2.35-2.5(4H,m),2.88(2H,t,J=7.5Hz),3.5-3.75(3H,m),3.8-3.95(1H,m),4.13(2H,q,J=7Hz),5.41(1H,dd,J=4.5Hz,6Hz),6.8-6.9(2H,m),6.97(2H,d,J=9Hz),7.05-7.2(3H,m),7.25-7.35(2H,m),7.73(2H,d,J=9Hz),7.98(1H,d,J=7Hz),8.43(1H,d,J=9Hz)
实施例33
按类似于实施例31的方法,制得了下述化合物。
4-[1-[3-[[(羧基)(4-异丁基苯基)甲基]氨基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.89(6H,d,J=7Hz),1.23(3H,t,J=7Hz),1.83(1H,m),1.9-2.2(2H,m),2.3-2.6(4H,m),2.82(2H,t,J=7Hz),4.13(2H,q,J=7Hz),5.08(1H,s),6.7-7.0(3H,m),7.0-7.4(6H,m),7.42(2H,d,J=9Hz),7.96(1H,d,J=7Hz),8.52(1H,d,J=9Hz)
实施例34
按类似于实施例23的方法,制得了下述化合物。
(1)4-[1-[4-[1-[(4-异丁基苯基)-2-丁炔氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.92(6H,d,J=7Hz),1.25(3H,t,J=7Hz),1.75-2.2(3H,m),1.92(3H,d,J=3Hz),2.4-2.55(4H,m),2.91(2H,t,J=7Hz),4.14(2H,q,J=7Hz),5.86(1H,m),6.88(1H,dt,J=2Hz,7Hz),6.93(1H,s),7.1-7.3(5H,m),7.52(2H,d,J=9Hz),7.85(2H,d,J=10Hz),8.01(1H,d,J=7Hz),8.48(1H,d,J=8Hz)
(2)4-[1-[4-[1-(4-异丁基苯基)-3-丁烯氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.88(6H,d,J=7Hz),1.25(3H,t,J=7Hz),1.84(1H,m),2.03(2H,m),2.35-2.5(4H,m),2.5-2.9(2H,m),2.87(2H,t,J=7Hz),4.12(2H,q,J=7Hz),5.05-5.3(3H,m),5.87(1H,m),6.8-6.97(4H,m),7.12(2H,d,J=8Hz),7.14(1H,m),7.28(2H,d,J=8Hz),7.74(2H,d,J=9Hz),7.98(1H,d,J=8Hz),8.43(1H,d,J=10Hz)
(3)4-[1-[4-[1-(4-异丁基苯基)-4-戊烯氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.88(6H,d,J=7Hz),1.25(3H,t,J=7Hz),1.7-2.35(7H,m),2.42(2H,t,J=7Hz),2.46(2H,d,J=7Hz),2.88(2H,t,J=7Hz),4.13(2H,q,J=7Hz),4.95-5.25(3H,m),5.87(1H,m),6.85(1H,m),6.87(1H,s),6.93(2H,d,J=9Hz),7.12(1H,d,J=8Hz),7.04(1H,m),7.28(2H,d,J=8Hz),7.73(2H,d,J=9Hz),7.98(1H,d,J=8Hz),8.43(1H,d,J=9Hz)
(4)4-[1-[4-[(S)-1-(4-异丁基苯基)-3-丁烯氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.88(6H,d,J=7Hz),1.25(3H,t,J=7Hz),1.7-2.15(3H,m),2.43(2H,t,J=7Hz),2.46(2H,d,J=7Hz),2.5-2.9(2H,m),2.87(2H,t,J=7Hz),4.12(2H,q,J=7Hz),5.05-5.3(3H,m),5.87(1H,m),6.8-6.97(4H,m),7.12(2H,d,J=8Hz),7.14(1H,m),7.28(2H,d,J=8Hz),7.74(2H,d,J=9Hz),7.98(1H,d,J=8Hz),8.43(1H,d,J=10Hz)
(5)4-[1-[4-[4,4,4-三氟-1-(4-异丁基苯基)丁氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.89(6H,d,J=7Hz),1.25(3H,t,J=7Hz),1.7-2.5(11H,m),2.88(2H,t,J=7.5Hz),4.12(2H,q,J=7Hz),5.24(1H,t,J=5.5Hz),6.8-6.95(4H,m),7.1-7.2(3H,m),7.27(2H,d,J=8Hz),7.73(2H,d,J=9Hz),7.99(1H,d,J=7Hz),8.44(1H,d,J=9Hz)
(6)4-[1-[4-[1-(4-异丁基苯基-2-甲氧基苯基)戊氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.8-1.0(9H,m),1.15-1.6(7H,m),1.7-2.2(5H,m),2.35-2.5(4H,m),2.87(2H,t,J=7.5Hz),3.91(3H,s),4.13(2H,q,J=7Hz),5.60(1H,dd,J=5Hz,8Hz),6.6-7.0(6H,m),7.05-7.35(2H,m),7.72(2H,d,J=9Hz),7.97(1H,d,J=7Hz),8.43(1H,d,J=9Hz)
(7)4-[1-[4-[1-(4-异丁基-3-甲氧基苯基)戊氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.8-1.0(9H,m),1.2-1.7(7H,m),1.75-2.15(5H,m),2.35-2.5(4H,m),2.88(2H,t,J=7.5Hz),3.79(3H,s),4.13(2H,q,J=7Hz),5.12(1H,dd,J=5Hz,8Hz),6.8-7.2(8H,m),7.74(2H,d,J=9Hz),7.98(1H,d,J=7Hz),8.44(1H,d,J=9Hz)
(8)4-[1-[4-[1-(3-氟-4-异丁基苯基)戊氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.85-1.0(9H,m),1.2-1.6(7H,m),1.75-2.15(5H,m),2.35-2.5(4H,m),2.88(2H,t,J=7.5Hz),4.13(2H,q,J=7Hz),5.14(1H,dd,J=5Hz,8Hz),6.8-7.2(8H,m),7.74(2H,d,J=9Hz),7.98(1H,d,J=7Hz),8.44(1H,d,J=9Hz)
(9)4-[1-[4-[1-[(4-(1-乙酰氧基-2-甲基丙基)-2-氟苯基)戊氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.75-1.0(9H,m),1.25(3H,t,J=7Hz),1.3-1.6(4H,m),1.75-2.15(8H,m),2.42(2H,t,J=7Hz),2.88(2H,t,J=7.5Hz),4.12(2H,q,J=7Hz),5.44(1H,q,J=7Hz),5.52(1H,dd,J=5Hz,8Hz),6.8-7.2(7H,m),7.3-7.4(1H,m),7.75(2H,d,J=9Hz),7.98(1H,d,J=7Hz),8.44(1H,d,J=9Hz)
(10)4-[1-[4-[1-[4-(环丙基甲基)苯基]-3-丁烯氧基]苄氧基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.45-0.6(2H,m),0.85-1.1(1H,m),1.25(3H,t,J=7Hz),1.95-2.15(2H,m),2.35-2.95(8H,m),4.12(2H,q,J=7Hz),5.05-5.3(3H,m),5.75-6.0(1H,m),6.8-7.0(4H,m),7.05-7.35(5H,m),7.73(2H,d,J=9Hz),7.98(1H,d,J=7Hz),8.44(1H,d,J=9Hz)
实施例35
近类似于实施例1的方法,制得了下述化合物。
4-[1-[3-[(4-异丁基苯基)(苯基)甲基氨基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.88(6H,d,J=7Hz),1.25(3H,t,J=7Hz),1.7-2.1(3H,m),2.3-2.5(4H,m),2.82(2H,t,J=7.5Hz),4.12(2H,q,J=7Hz),4.40(1H,br s),5.55(1H,s),6.6-6.95(3H,m),7.0-7.45(13H,m),7.99(1H,d,J=7Hz),8.48(1H,d,J=9Hz)
实施例36
向4-(3-中氮茚基)丁酸乙酯(0.20g)和3-反-[2-(4-异丁基苯基)乙烯基]苯甲酰氯(0.40g)的二氯甲烷(6ml)溶液中,加入二异丙基乙胺(0.23g)。混合物回流8小时,然后倒入冰和稀盐酸中,用乙酸乙酯(30ml)提取。有机层用水洗涤,用硫酸镁干燥,蒸发。剩余物用硅胶色谱分离,用正己烷和乙酸乙酯(3∶1)洗脱,得到4-[1-[3-反-[2-(4-异丁基苯基)乙烯基]苯甲酰基]中氮茚-3-基]丁酸乙酯(0.29g),黄色油状物。
NMR(CDCl3,δ):0.91(6H,d,J=7Hz),1.24(3H,t,J=7Hz),1.88(1H,m),2.05(2H,m),2.45(2H,t,J=7Hz),2.50(2H,d,J=7Hz),2.90(2H,t,J=7Hz),4.13(2H,q,J=7Hz),6.90(1H,s),7.14(2H,d,J=8Hz),7.16(2H,s),7.23(1H,m),7.45(2H,d,J=8Hz),7.5(1H,m),7.65(2H,m),7.95(1H,s),8.04(1H,d,J=7Hz),
8.52(1H,d,J=9Hz)
实施例37
按类似于实施例36的方法,制得下述化合物。
(1)4-[1-[4-反-[2-(4-异丁基苯基)乙烯基]苯甲酰基]中氮茚-3-基]丁酸乙酯
mp:94-95℃
NMR(CDCl3,δ):0.92(6H,d,J=7Hz),1.36(3H,t,J=7Hz),1.88(1H,m),2.0-2.2(2H,m),2.4-2.6(4H,m),2.90(2H,t,J=7Hz),4.13(2H,q,J=7Hz),6.8-7.0(2H,m),7.1-7.3(5H,m),7.47(2H,d,J=9Hz),7.62(2H,d,J=9Hz),7.85(2H,d,J=9Hz),8.02(1H,d,J=7Hz),8.51(1H,d,J=9Hz)
(2)4-[1-[4-顺-[2-(4-异丁基苯基)乙烯基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.90(6H,d,J=7Hz),1.25(3H,t,J=7Hz),1.85(1H,m),2.0-2.2(2H,m),2.4-2.5(4H,m),2.89(2H,t,J=7Hz),4.13(2H,q,J=7Hz),6.60(1H,d,J=11Hz),6.68(1H,d,J=11Hz),6.85-7.0(2H,m),7.02(2H,d,J=9Hz),7.15-7.3(3H,m),7.39(2H,d,J=9Hz),7.71(2H,d,J=9Hz),8.02(1H,d,J=7Hz),8.50(1H,d,J=9Hz)
(3)4-[1-[3-顺-[2-(4-异丁基苯基)乙烯基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.85(6H,d,J=7Hz),1.28(3H,t,J=7Hz),1.80(1H,m),2.05(2H,m),2.40(2H,d,J=7Hz),2.42(2H,t,J=7Hz),2.85(2H,t,J=7Hz),4.13(2H,q,J=7Hz),6.62(2H,s),6.79(1H,s),6.89(1H,t,J=7Hz),7.00(2H,d,J=8Hz),7.18(2H,d,J=8Hz),7.1-7.2(1H,m),7.3-7.5(2H,m),7.65(1H,d,J=8Hz),7.71(1H,s),8.02(1H,d,J=7Hz),8.48(1H,d,J=9Hz)
实施例38
按类似于实施例9的方法,制得下述化合物。
(1)4-[1-[4-[1-(4-异丁基苯基)-2-丁炔氧基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.92(6H,d,J=7Hz),1.87(1H,m),1.90(3H,d,J=3Hz),2.08(2H,m),2.49(2H,d,J=7Hz),2.50(2H,t,J=7Hz),2.91(2H,t,J=7Hz),5.86(1H,m),6.87(1H,dt,J=2Hz,7Hz),6.92(1H,s),7.1-7.25(5H,m),7.52(2H,d,J=9Hz),7.84(2H,d,J=10Hz),7.97(1H,d,J=7Hz),8.46(1H,d,J=8Hz)
(2)4-[1-[4-[1-(4-异丁基苯基)-3-丁烯氧基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.88(6H,d,J=7Hz),1.84(1H,m),2.05(2H,m),2.44(2H,d,J=7Hz),2.48(2H,t,J=7Hz),2.5-2.9(2H,m),2.88(2H,t,J=7Hz),5.03-5.27(3H,m),5.87(1H,m),6.84(1H,m),6.87(1H,s),6.92(2H,d,J=10Hz),7.11(2H,d,J=8Hz),7.13(1H,m),7.27(2H,d,J=8Hz),7.72(2H,d,J=10Hz),7.94(1H,d,J=7Hz),8.42(1H,d,J=9Hz)
(3)4-[1-[4-[1-(4-异丁基苯基)-4-戊烯氧基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.88(6H,d,J=7Hz),1.7-2.35(7H,m),2.43(2H,d,J=7Hz),2.49(2H,t,J=7Hz),2.89(2H,t,J=7Hz),4.95-5.1(2H,m),5.18(1H,m),5.86(1H,m),6.84(1H,m),6.88(1H,s),6.92(2H,d,J=9Hz),7.11(2H,d,J=8Hz),7.13(1H,m),7.27(2H,d,J=8Hz),7.73(2H,d,J=9Hz),7.94(1H,d,J=7Hz),8.43(1H,d,J=9Hz)
(4)4-[1-[4-[(S)-1-(4-异丁基苯基)-3-丁烯氧基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.88(6H,d,J=7Hz),1.84(1H,m),2.05(2H,m),2.44(2H,d,J=7Hz),2.48(2H,t,J=7Hz),2.5-2.9(2H,m),2.88(2H,t,J=7Hz),5.03-5.27(3H,m),5.87(1H,m),6.84(1H,m),6.87(1H,s),6.92(2H,d,J=10Hz),7.11(2H,d,J=8Hz),7.13(1H,m),7.27(2H,d,J=8Hz),7.72(2H,d,J=10Hz),7.94(1H,d,J=7Hz),8.42(1H,d,J=9Hz)
实施例39
按类似于实例11的方法,制得了下述化合物。
(1)4-[1-[4-[4,4,4-三氟-1-(4-异丁基苯基)丁氧基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.88(6H,d,J=7Hz),1.7-2.55(11H,m),2.39(2H,t,J=7.5Hz),5.25(1H,t,J=5.5Hz),6.8-7.0(4H,m),7.1-7.2(3H,m),7.27(2H,d,J=8Hz),7.75(2H,d,J=9Hz),8.97(1H,d,J=7Hz),8.46(1H,d,J=9Hz)
(2)4-[1-[3-[(4-异丁基苯基)(苯基)甲基氨基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.88(6H,d,J=7Hz),1.7-2.1(3H,m),2.35-2.55(4H,m),2.85(2H,t,J=7.5Hz),5.55(1H,s),6.6-6.9(3H,m),6.95-7.45(13H,m),7.95(1H,d,J=7Hz),8.47(1H,d,J=9Hz)
(3)4-[1-[4-[1-(4-异丁基-2-甲氧基苯基)戊氧基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.8-1.0(9H,m),1.2-1.65(4H,m),1.7-2.2(5H,m),2.4-2.55(4H,m),2.89(2H,t,J=7.5Hz),3.90(3H,s),5.59(1H,dd,J=5Hz,8Hz),6.78(2H,d,J=7Hz),6.8-6.95(4H,m),7.05-7.3(2H,m),7.72(2H,d,J=9Hz),7.94(1H,d,J=7Hz),8.42(1H,d,J=9Hz)
(4)4-[1-[4-[1-(4-异丁基-3-甲氧基苯基)戊氧基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.8-1.0(9H,m),1.25-1.6(4H,m),1.75-2.15(5H,m),2.4-2.55(4H,m),2.89(2H,t,J=7.5Hz),3.78(3H,s),5.12(1H,dd,J=5Hz,8Hz),6.75-7.2(8H,m),7.73(2H,d,J=9Hz),7.95(1H,d,J=7Hz),8.43(1H,d,J=9Hz)
(5)4-[1-[4-[1-(3-氟-4-异丁基苯基)戊氧基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.8-1.0(9H,m),1.2-1.6(4H,m),1.75-2.15(5H,m),2.4-2.55(4H,m),2.88(2H,t,J=7.5Hz),5.13(1H,dd,J=5Hz,8Hz),6.8-7.2(8H,m),7.74(2H,d,J=9Hz),7.95(1H,d,J=7Hz),8.44(1H,d,J=9Hz)
(6)4-[1-[4-[1-[4-(环丙基甲基)苯基]-3-丁烯氧基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.45-0.6(2H,m),0.85-1.1(1H,m),1.95-2.15(2H,m),2.4-3.0(8H,m),5.0-5.3(3H,m),5.75-6.0(1H,m),6.8-7.0(4H,m),7.05-7.4(5H,m),7.72(2H,d,J=9Hz),7.95(1H,d,J=7Hz),8.43(1H,d,J=9Hz)
实施例40
向4-[1-3-反-[2-(4-异丁基苯基)乙烯基]苯甲酰基]中氮茚-3-基]丁酸乙酯(0.24g)的二噁烷(5ml)溶液中,加入1N氢氧化钠水溶液(1ml)。混合物在40℃下搅拌4小时,然后倒入冰和稀盐酸中。有机层用乙酸乙酯(15ml)提取,用水洗涤,硫酸镁干燥,蒸发。剩余物用硅胶(20g)色谱分离,用氯仿和甲醇(50∶1)的混合物洗脱,得到4-[1-[3-反-[2-(4-异丁基苯基)乙烯基]苯甲酰基]中氮茚-3-基]丁酸(0.20g),黄色粉末。
NMR(CDCl3,δ):0.90(6H,d,J=7Hz),1.85(1H,m),2.0-2.2(2H,m),2.4-2.6(4H,m),2.90(2H,t,J=7Hz),6.8-7.0(2H,m),7.1-7.3(5H,m),7.4-7.5(3H,m),7.6-7.7(2H,m),7.93(1H,s),7.99(1H,d,J=7Hz),8.51(1H,d,J=9Hz)
实施例41
按类似于实施例40的方法,制得了下述化合物。
(1)4-[1-[4-反-[2-(4-异丁基苯基)乙基]苯甲酰基]中氮茚-3-基]丁酸
mp:175-176℃
NMR(CDCl3,δ):0.92(6H,d,J=7Hz),1.90(1H,m),2.0-2.2(2H,m),2.4-2.6(4H,m),2.90(2H,t,J=7Hz),6.8-7.0(2H,m),7.0-7.2(5H,m),7.47(2H,d,J=9Hz),7.60(2H,d,J=9Hz),7.82(2H,d,J=9Hz),7.97(1H,d,J=7Hz),8.51(1H,d,J=9Hz)
(2)4-[1-(4-顺-[2-(4-异丁基苯基)乙烯基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.88(6H,d,J=7Hz),1.83(1H,m),2.0-2.2(2H,m),2.4-2.6(4H,m),2.92(2H,t,J=7Hz),6.58(1H,d,J=11Hz),6.68(1H,d,J=11Hz),6.85-6.95(2H,m),7.00(2H,d,J=9Hz),7.1-7.2(1H,m),7.20(2H,d,J=9Hz),7.38(2H,d,J=9Hz),7.70(2H,d,J=9Hz),7.98(1H,d,J=7Hz),8.49(1H,d,J=9Hz)
(3)4-[1-[3-顺-[2-(4-异丁基苯基)乙烯基]苯甲酰基]中氮茚-3-基]丁酸
NMR(CDCl3,δ):0.83(6H,d,J=7Hz),1.80(1H,m),1.9-2.15(2H,m),2.40(2H,d,J=7Hz),2.46(2H,t,J=7Hz),2.87(2H,t,J=7Hz),6.62(2H,s),6.79(1H,s),6.88(1H,t,J=7Hz),7.00(2H,d,J=9Hz),7.1-7.3(3H,m),7.3-7.5(2H,m),7.65(1H,d,J=7Hz),7.70(1H,s),7.96(1H,d,J=7Hz),8.48(1H,d,J=9Hz)
实施例42
向4-[1-[4-[1-[4-(1-乙酰氧基-2-甲基丙基)-2-氟苯基]戊氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯(300mg)的乙醇(3ml)和1,4-二氧六环(3ml)溶液中,加入1N氢氧化钠水溶液(1.5ml)。混合物在室温下搅拌1小时,然后倒入乙酸乙酯和0.5N盐酸的混合物中。分出有机层,用水和盐水洗涤,用硫酸镁干燥,浓缩。剩余物用硅胶柱色谱分离,用氯仿和甲醇(25∶1)的混合物洗脱,得4-[1-[4-[1-[2-氟-4-(1-羟基-2-甲基丙基)苯基]戊氧基]苯甲酰基]中氮茚-3-基]丁酸(151mg),粉末。
NMR(CDCl3,δ):0.75-1.05(9H,m),1.2-1.65(4H,m),1.75-2.15(5H,m),2.45(2H,t,J=7Hz),2.84(2H,t,J=7Hz),4.35(1H,d,J=6.5Hz),5.53(1H,dd,J=5Hz,7.5Hz),6.75-7.2(7H,m),7.25-7.4(1H,m),7.70(2H,d,J=9Hz),7.91(1H,d,J=7Hz),8.42(1H,d,J=9Hz)
实施例43
按类似于实施36的方法,制得下述化合物。
(1)4-[1-[4-[1-(4-异丁基苯基)丁氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.8-1.05(9H,m),1.24(3H,t,J=7Hz),1.3-1.65(2H,m),1.7-2.15(5H,m),2.35-2.5(4H,m),2.87(2H,t,J=7.5Hz),4.12(2H,q,J=7Hz),5.17(1H,dd,J=2Hz,7Hz),6.8-6.95(4H,m),7.05-7.3(5H,m),7.72(2H,d,J=9Hz),7.98(1H,d,J=7Hz),8.44(1H,d,J=9Hz)
(2)4-[1-[4-[(S)-1-(4-异丁基苯基)丁氧基]苯甲酰基]中氮茚-3-基]丁酸乙酯
NMR(CDCl3,δ):0.8-1.05(9H,m),1.24(3H,t,J=7Hz),1.3-1.65(2H,m),1.7-2.15(5H,m),2.35-2.5(4H,m),2.87(2H,t,J=7.5Hz),4.12(2H,q,J=7Hz),5.17(1H,dd,J=2Hz,7Hz),6.8-6.95(4H,m),7.05-7.3(5H,m),7.72(2H,d,J=9Hz),7.98(1H,d,J=7Hz),8.44(1H,d,J=9Hz)
Claims (16)
2、权利要求1的化合物,其中
R1是羧基或酯化的羧基,
R3是可被低级烷基取代的芳基,可被一个或多个选自下述基团的取代基取代的芳(低级)烷基:低级烷基、囟素、氰基、羧基、酯化的羧基、酰胺化的羧基、低级烷氧基、羟基(低级)烷基、保护的羟基(低级)烷基、环(低级)烷基(低级)烷基、低级链烯基和低级链炔基,氨基甲酰基(低级)烷基,其中氨基甲酰基部分被一个基两个选自下述基团的取代基取代:低级烷基和低级烷基芳基,5或6员脂肪族杂单环羰基或不饱和稠杂单环基,和
R6是氢、低级烷基、可被低级烷取代的芳(低级)烷基,或酰基。
3、权利要求2的化合物,其中
R1是羧基、低级烷氧基羰基或一或二或三苯基(低级)烷氧基羰基,
R3是低级烷基取代的苯基,可被1-4个选自下述取代基取代的一或二或三苯基(低级)烷基:低级烷基、囟素、氰基、羧基、一或二或三苯基(低级)烷氧基羰基、一或二(低级)烷基氨基甲酰基、苯基氨基甲酰基、低级烷基苯基氨基甲酰基、低级烷氧基、羟基(低级)烷基、低级烷酰氧基(低级)烷基、环(低级)烷基(低级)烷基、低级链烯基和低级链炔基,低级烷基氨基甲酰基(低级)烷基,低级烷基苯基氨基甲酰基(低级)烷基,哌啶基羰基,吩!嗪基,10,11-二氢-5H-苯并[b,f]吖庚因基,
R6是氢,低级烷基,可被低级烷基或低级烷氧基羰基取代的一或二或三苯基(低级)烷基。
5、权利要求4的化合物,其中
R3是异丁基苯基、异丁基苯基丙基、异丁基苯基丁基、异丁基苯基戊基、异丁基苯基己基、异丁基苯基庚基、异丁基苯基辛基、双(异丁基苯基)甲基、(羧基)(异丁基苯基)甲基、(苄氧基羰基)(异丁基苯基)甲基、(丁基氨基甲酰基)(异丁基苯基(甲基、(庚基氨基甲酰基)(异丁基苯基)甲基、(乙氧基)(异丁基苯基)乙基、(异丁基苯基)(三氟)丁基、(苯基)(异丁基苯基)甲基、[(异丁基)(甲氧基)苯基]戊基、[(氟)(异丁基)苯基]戊基、[(氟)(羟基异丁基)苯基]戊基、[(氟)(乙酰氧基异丁基)苯基]戊基、(环丙基甲基苯基)丁烯基、(异丁基苯基)丁炔基、(异丁基苯基)丁烯基、(异丁基苯基)戊烯基、庚基氨基甲酰基乙基、异丁基苯基氨基甲酰基甲基或异丁基苯基氨基甲酰基乙基,
R11是氢或甲基,
A 是亚丙基,和
Z 是亚乙烯基、-O-或-NH-。
6、权利要求5的化合物,它们选自下述各化合物:
4[1-[4-[双(4-异丁基苯基)甲基氨基]苯甲酰基]中氮茚-3-基]丁酸,
4[1-[4-[1-(4-异丁基苯基)丙氧基]苯甲酰基]中氮茚-3-基]丁酸,
4[1-[4-[1-(4-异丁基苯基)丁氧基]苯甲酰基]中氮茚-3-基]丁酸,和
4[1-[4-[1-(4-异丁基苯基)戊氧基]苯甲酰基]中氮茚-3-基]丁酸。
7、权利要求6的化合物,是选自下述化合物的R或S构型化合物:
4[1-[4-[1-(4-异丁基苯基)丙氧基]苯甲酰基]中氮茚-3-基]丁酸,
4[1-[4-[1-(4-异丁基苯基)丁氧基]苯甲酰基]中氮茚-3-基]丁酸,和
4[1-[4-[1-(4-异丁基苯基)戊氧基]苯甲酰基]中氮茚-3-基]丁酸。
8、权利要求3的化合物,用下式表示
其中
R3是可被一至两个选自下述基团的取代基取代的一或二苯基(低级)烷基:低级烷基、囟素、氰基、羧基、苯基(低级)烷氧基羰、一或二(低级)烷基氨基甲酰基、苯基氨基甲酰基和低级烷基苯基氨基甲酰基,
R11是氢或低级烷基,
A 是低级亚烷基,和
Z是低级亚烷基、-0-或
,其中R6是氢、低级烷基或苯基(低级)烷基。
9、权利要求8的化合物,其中
R3是异丁基苯基己基或双(异丁基苯基)甲基,
R11是氢或甲基,
A 是亚丙基,和
Z 是-0-或-NH-。
10、权利要求9的化合物,它选自下述化合物:
4-[3-[3-[双(4-异丁基苯基)甲基氨基]苯甲酰基]中氮茚-1-基]丁酸,和
4-[3-[3-[双(4-异丁基苯基)甲氧基]苯甲酰基]中氮茚-1-基]丁酸。
11、下式化合物或其盐制备方法:
式中R1是羧基或保护的羧基,
R2是氢、低级烷基或囟素,
R11是氢或低级烷基,
A 是低级亚烷基,它可以被氧或低级亚烯基取代,
Q 是羰或或低级亚烷基,
X是
其中R4是氢或低级烷基、R5是氢、低级烷基或Y-Z-R3,
Y是单键或低级亚烷基
(1)下式化合物或其盐:
其中R1、R2、R11、A、Q、X和Y的定义同前,和
Z是-0-或
其中R6 a是氢、低级烷基或氨基保护基,
与下式化合物或其盐
反应,得到下式化合物或其盐,
其中R1、R2、R3 a、R11、A、Q、X、Y和Z的定义同前,或者(2)将下式化合物或其盐
式中R1、R2、R11、A、Q和X的定义分别同上,
W2是酸残基,和
Y1是低级亚烷基,
与下式化合物或其盐反应
式中R1、R2、R3、R11、A、Q、X、Y1和Z2的定义同前;或者
(3)将下式化合物或其盐
式中R1、R2、R6 a、R11、A、Q、X和Y的定义同上,
与下式化合物或其盐反应,
式中R3 a的定义同上,W1 a是酸残基,
得到下式化合物或其盐
式中R1、R2、R3 a、R6 a、R11、A、Q、X和Y的定义同前;或者
(4)将下式化合物或其盐
式中R2、R3、R11、R、A、Q、X、Y和Z的定义同前,R1 a是保护的羧基,经受羧基保护基的消除反应,得到下式化合物或其盐
式中R2、R3、R11、R、A、Q、X、Y和Z的定义同前;或者
(5)将下式化合物或其盐
式中R1、R2、R11、A、Q、X、Y和Z的定义同上,R7是可具有适宜取代基的芳基,R8是羧基保护基,经受羧基保护基的消去反应,得到下式化合物或其盐
式中R1、R2、R7、R11、A、Q、X、Y和Z的定义同上;或者
(6)将下式化合物或其羧基活性衍生物或其盐
式中R1、R2、R7、R11、A、Q、X、Y和Z的定义同上;
与下式化合物或其氨基活性衍生物或其盐反应,
式中R9是可带有取代基的氨基,
得到下式化合物或其盐:
式中R1、R2、R7、R9、R11、A、Q、X、Y和Z的定义同上;或者
(7)将下式化合物或其盐
式中R1、R2、R3、R11、A、Q、X、Y和Z的定义同上;R6 b是氨基保护基,
经受氨基保护基的消去反应,得到下式化合物或其盐:
式中R1、R2、R3、R11、A、Q、X和Y的定义同上;或者
(8)将下式化合物或其盐
式中R1、R2、R3、R11、A、Q、X和Y的定义同上,
与下式化合物或其盐反应,
式中R6 c是低级烷基,可带有适宜取代基的芳(低级)烷基或氨基保护基,W3是酸残基,得到下式化合物或其盐:
式中R1、R2、R3、R6、R11、A、Q、X和Y的定义同上;或者
(9)将下式化合物或其盐
式中R2、R3、R11、A、Q、X、Y和Z的定义同上,
经受羧基保护基的引入反应,得到下式化合物或其盐,
式中R1 a、R2、R3、R11、A、Q、X、Y和Z的定义同上;或者
(10)将下式化合物或其盐
式中R1、R2、R11和A的定义同上,
与下式化合物或其盐反应,
式中R3、Q、X、Y和Z的定义同上,W10是酸残基,
得到下式化合物或其盐
式中R1、R2、R3、R11、A、Q、X、Y和Z的定义同前。
12、一种药用组合物,它包括权利要求1化合物或其药学上可接受盐,及药学上可接受的基本无毒的载体或赋形剂。
13、治疗或预防睾酮5α-还原酶有关的疾病的方法,该方法包括将权利要求1化合物或其药学上可接受的盐给予人或动物。
14、权利要求1化合物或其药学上可接受的盐用作药物。
15、权利要求1化合物或其药学上可接受的盐用作睾酮5α-还原酶抑制剂。
16、制备药用组合物的方法,它包括将权利要求1化合物或其药学可接受的盐与药学上可接受、基本无毒的载体或赋形剂混合。
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919113027A GB9113027D0 (en) | 1991-06-17 | 1991-06-17 | Indolizine derivatives |
| GB9113027.8 | 1991-06-17 | ||
| GB9120764.7 | 1991-09-30 | ||
| GB919120764A GB9120764D0 (en) | 1991-09-30 | 1991-09-30 | Heterocyclic derivatives |
| GB9124345.1 | 1991-11-15 | ||
| GB919124345A GB9124345D0 (en) | 1991-11-15 | 1991-11-15 | Heterocyclic derivatives |
| GB929203809A GB9203809D0 (en) | 1992-02-21 | 1992-02-21 | Heterocyclic derivatives |
| GB9203809.0 | 1992-02-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1067893A true CN1067893A (zh) | 1993-01-13 |
| CN1042226C CN1042226C (zh) | 1999-02-24 |
Family
ID=27450702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN92104790A Expired - Fee Related CN1042226C (zh) | 1991-02-21 | 1992-06-16 | 中氮茚衍生物或其盐的制备方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5334716A (zh) |
| EP (1) | EP0519353B1 (zh) |
| JP (1) | JP2663794B2 (zh) |
| KR (1) | KR100244879B1 (zh) |
| CN (1) | CN1042226C (zh) |
| AT (1) | ATE195521T1 (zh) |
| AU (1) | AU656197B2 (zh) |
| CA (1) | CA2071375C (zh) |
| DE (1) | DE69231350T2 (zh) |
| DK (1) | DK0519353T3 (zh) |
| ES (1) | ES2149160T3 (zh) |
| GR (1) | GR3034429T3 (zh) |
| HU (2) | HUT61544A (zh) |
| IE (1) | IE921805A1 (zh) |
| MX (1) | MX9202901A (zh) |
| PT (1) | PT519353E (zh) |
| TW (1) | TW203050B (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1043992C (zh) * | 1993-09-10 | 1999-07-07 | 藤泽药品工业株式会社 | 制备中氮茚衍生物的新方法 |
| CN101486710B (zh) * | 2009-02-11 | 2011-04-06 | 中国科学院上海有机化学研究所 | 一种合成3-卤代中氮茚类化合物的方法 |
| CN101312973B (zh) * | 2005-11-23 | 2011-12-28 | 赛诺菲-安万特 | 新的中氮茚衍生物,它们的制备方法和含有它们的药物组合物 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214876B1 (en) | 1994-07-21 | 2001-04-10 | Eli Lilly And Company | Indene-1-acetamide sPLA2 inhibitors |
| US5543417A (en) * | 1994-10-21 | 1996-08-06 | Merck & Co., Inc. | Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents |
| WO2003020311A1 (fr) * | 2001-08-28 | 2003-03-13 | Fujisawa Pharmaceutical Co., Ltd. | Remedes contre les maladies de la peau |
| CN1678314A (zh) * | 2002-08-27 | 2005-10-05 | 默克专利有限公司 | 作为raf-激酶抑制剂的甘氨酸酰胺衍生物 |
| EP1543875A1 (en) * | 2003-12-04 | 2005-06-22 | Boehringer Ingelheim Pharma GmbH & Co. KG | Novel metathesis ruthenium catalyst |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1268424A (en) * | 1969-10-04 | 1972-03-29 | Beecham Group Ltd | Indolizine derivatives |
| US3806513A (en) * | 1969-10-04 | 1974-04-23 | Beecham Group Ltd | Alpha-substituted indolizine propionic acid and its salts |
| US4205074A (en) * | 1977-05-16 | 1980-05-27 | Hokuriku Pharmaceutical Co., Ltd. | Anti-spasmodic substituted quinolizidine and indolizidine compounds |
| US4935240A (en) * | 1987-06-04 | 1990-06-19 | Ono Pharmaceutical Co., Ltd. | Benzoylaminophenoxybutanoic acid derivatives |
| GB9011335D0 (en) * | 1990-05-21 | 1990-07-11 | Fujisawa Pharmaceutical Co | Indolebutyric acid derivatives and process for preparation thereof |
-
1992
- 1992-06-02 US US07/892,453 patent/US5334716A/en not_active Expired - Fee Related
- 1992-06-12 TW TW081104603A patent/TW203050B/zh active
- 1992-06-13 ES ES92109968T patent/ES2149160T3/es not_active Expired - Lifetime
- 1992-06-13 EP EP92109968A patent/EP0519353B1/en not_active Expired - Lifetime
- 1992-06-13 AT AT92109968T patent/ATE195521T1/de not_active IP Right Cessation
- 1992-06-13 DE DE69231350T patent/DE69231350T2/de not_active Expired - Fee Related
- 1992-06-13 PT PT92109968T patent/PT519353E/pt unknown
- 1992-06-13 DK DK92109968T patent/DK0519353T3/da active
- 1992-06-15 HU HU929201993A patent/HUT61544A/hu unknown
- 1992-06-15 KR KR1019920010367A patent/KR100244879B1/ko not_active Expired - Fee Related
- 1992-06-16 CA CA002071375A patent/CA2071375C/en not_active Expired - Fee Related
- 1992-06-16 JP JP4157074A patent/JP2663794B2/ja not_active Expired - Fee Related
- 1992-06-16 CN CN92104790A patent/CN1042226C/zh not_active Expired - Fee Related
- 1992-06-16 MX MX9202901A patent/MX9202901A/es not_active IP Right Cessation
- 1992-06-16 AU AU18270/92A patent/AU656197B2/en not_active Ceased
- 1992-07-01 IE IE180592A patent/IE921805A1/en not_active Application Discontinuation
-
1995
- 1995-06-22 HU HU95P/P00394P patent/HU211621A9/hu unknown
-
2000
- 2000-09-18 GR GR20000402118T patent/GR3034429T3/el not_active IP Right Cessation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1043992C (zh) * | 1993-09-10 | 1999-07-07 | 藤泽药品工业株式会社 | 制备中氮茚衍生物的新方法 |
| CN101312973B (zh) * | 2005-11-23 | 2011-12-28 | 赛诺菲-安万特 | 新的中氮茚衍生物,它们的制备方法和含有它们的药物组合物 |
| CN101486710B (zh) * | 2009-02-11 | 2011-04-06 | 中国科学院上海有机化学研究所 | 一种合成3-卤代中氮茚类化合物的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU656197B2 (en) | 1995-01-27 |
| EP0519353A3 (en) | 1993-04-14 |
| EP0519353A2 (en) | 1992-12-23 |
| CN1042226C (zh) | 1999-02-24 |
| JP2663794B2 (ja) | 1997-10-15 |
| CA2071375A1 (en) | 1992-12-18 |
| DE69231350T2 (de) | 2001-01-04 |
| MX9202901A (es) | 1993-05-01 |
| PT519353E (pt) | 2000-12-29 |
| CA2071375C (en) | 2003-02-11 |
| DK0519353T3 (da) | 2000-09-18 |
| HU211621A9 (en) | 1995-12-28 |
| US5334716A (en) | 1994-08-02 |
| DE69231350D1 (de) | 2000-09-21 |
| EP0519353B1 (en) | 2000-08-16 |
| JPH05178856A (ja) | 1993-07-20 |
| HU9201993D0 (en) | 1992-09-28 |
| HUT61544A (en) | 1993-01-28 |
| TW203050B (zh) | 1993-04-01 |
| KR930000513A (ko) | 1993-01-15 |
| KR100244879B1 (ko) | 2000-03-02 |
| IE921805A1 (en) | 1992-12-30 |
| AU1827092A (en) | 1992-12-24 |
| GR3034429T3 (en) | 2000-12-29 |
| ATE195521T1 (de) | 2000-09-15 |
| ES2149160T3 (es) | 2000-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1032203C (zh) | 制备取代2-吡啶酮和吡啶-2-硫酮的方法 | |
| CN1057522C (zh) | 作为前列腺素i2激动剂的萘衍生物 | |
| CN1183111C (zh) | 环烷并吲哚和环烷并氮杂吲哚衍生物,其制备方法和含有它们的药物组合物 | |
| CN1114596C (zh) | 联苯基衍生物 | |
| CN1024547C (zh) | 一类环胺化合物的制备方法 | |
| CN1020093C (zh) | 1-苯基-3-萘氧基丙胺的制备方法 | |
| CN1153771C (zh) | 苯并呋喃并[3,4-f]喹啉衍生物、含有其的药物组合物及其应用 | |
| CN86102738A (zh) | 新的含硫5-取代苯并咪唑衍生物的制备方法 | |
| CN1203587A (zh) | 新的杂环衍生物及其医药用途 | |
| CN86100090A (zh) | 萘衍生物的制备方法 | |
| CN1056685A (zh) | 吲哚衍生物及其制备方法 | |
| CN86107947A (zh) | 新的头孢烯化合物及其制备方法 | |
| CN1084846A (zh) | 乙醇胺衍生物 | |
| CN1058208A (zh) | 药物化合物 | |
| CN1017707B (zh) | 新的噻唑化合物的制备方法 | |
| CN1068328A (zh) | 吡咯并吡嗪 | |
| CN1021733C (zh) | 制备新的吲哚基哌啶类化合物的方法 | |
| CN1042226C (zh) | 中氮茚衍生物或其盐的制备方法 | |
| CN1033991A (zh) | 取代羟胺类 | |
| CN1100425A (zh) | 噻唑并嘧啶衍生物 | |
| CN1599717A (zh) | 具有稠环基团的环二胺化合物 | |
| CN1043706A (zh) | 4,5,6,7-四氢化苯并咪唑衍生物制备方法 | |
| CN1112924A (zh) | 新的噻嗪或硫代吗啉衍生物 | |
| CN1177353A (zh) | 具有三环式稠合杂环的新颖的奎宁环衍生物 | |
| CN1025674C (zh) | 取代的联苯 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C15 | Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993) | ||
| OR01 | Other related matters | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |